{
 "cells": [
  {
   "cell_type": "markdown",
   "id": "784a93ca-60b3-4f58-9858-b0364dea8788",
   "metadata": {},
   "source": [
    "# In-Context Learning for AbstRCT dataset with LlaMA 3"
   ]
  },
  {
   "cell_type": "raw",
   "id": "92f1f194-601e-4e45-8d32-a8d705d8b2e6",
   "metadata": {},
   "source": [
    "- In-Context Learning with AbstRCT dataset.\n",
    "- Using: LlaMA-3-8B, LlaMA-3-70B.\n",
    "- Using BioBERT for title embeddings.\n",
    "- All in One Predictions strategy\n",
    "- K=5, N=1"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "2537d6cb-6d1c-4da1-abf1-ee5d2de44f32",
   "metadata": {},
   "source": [
    "## Libraries"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 1,
   "id": "0debac83-2e8a-4275-b5fd-09955716a9a9",
   "metadata": {},
   "outputs": [],
   "source": [
    "import ast\n",
    "import torch\n",
    "import random\n",
    "import numpy as np\n",
    "import pandas as pd\n",
    "import torch.nn.functional as F\n",
    "\n",
    "\n",
    "from tqdm import tqdm\n",
    "from operator import itemgetter\n",
    "from sklearn.metrics import classification_report\n",
    "from transformers import AutoTokenizer, AutoModel, AutoModelForCausalLM"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "54183905-9932-4205-a4b0-429ea8631c48",
   "metadata": {},
   "source": [
    "## Tokenizers and Models"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "id": "df587783-b14e-4d68-954f-ebb7238bb0fd",
   "metadata": {},
   "outputs": [],
   "source": [
    "embedding_tokenizer = AutoTokenizer.from_pretrained(\"dmis-lab/biobert-v1.1\")\n",
    "embedding_model = AutoModel.from_pretrained(\"dmis-lab/biobert-v1.1\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "id": "1eb931f7-0cef-4521-8950-0fc6bc3a2f14",
   "metadata": {},
   "outputs": [],
   "source": [
    "model_id = \"unsloth/llama-3-70b-Instruct-bnb-4bit\""
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "id": "73057574-c355-4140-bb8e-6f67beb59eb3",
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "Special tokens have been added in the vocabulary, make sure the associated word embeddings are fine-tuned or trained.\n"
     ]
    }
   ],
   "source": [
    "inference_tokenizer = AutoTokenizer.from_pretrained(model_id, padding='left', padding_side='left')\n",
    "inference_tokenizer.pad_token = inference_tokenizer.eos_token\n",
    "terminators = [\n",
    "    inference_tokenizer.eos_token_id,\n",
    "    inference_tokenizer.convert_tokens_to_ids(\"<|eot_id|>\")\n",
    "]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "id": "88d46bbb-e215-4015-8b8c-7e4e7148d4b3",
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "Unused kwargs: ['_load_in_4bit', '_load_in_8bit', 'quant_method']. These kwargs are not used in <class 'transformers.utils.quantization_config.BitsAndBytesConfig'>.\n"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "f81f6151df6e47819e5193a4ea229832",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Loading checkpoint shards:   0%|          | 0/6 [00:00<?, ?it/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "generation_model = AutoModelForCausalLM.from_pretrained(\n",
    "    model_id,\n",
    "    cache_dir = '/home/umushtaq/scratch/am_work/in_context_learning/model_downloads',\n",
    "    torch_dtype=torch.bfloat16,\n",
    "    device_map=\"auto\",\n",
    ")"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "790eeebc-3379-4347-ba86-e7f79beae0e6",
   "metadata": {},
   "source": [
    "## Dataset"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "id": "2e26e061-1fca-4a67-9e96-55e09149a096",
   "metadata": {},
   "outputs": [],
   "source": [
    "neo_train_df = pd.read_csv(\"dataset/neo/train.csv\")\n",
    "neo_test_df = pd.read_csv(\"dataset/neo/test.csv\")\n",
    "gla_test_df = pd.read_csv(\"dataset/gla/test.csv\")\n",
    "mix_test_df = pd.read_csv(\"dataset/mix/test.csv\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 7,
   "id": "8a2eee29-e2ba-4bff-a4e3-e96d10ee1f75",
   "metadata": {},
   "outputs": [],
   "source": [
    "def get_title_line(x, df):\n",
    "\n",
    "    doc_id = x.doc_id\n",
    "    df_doc = df[df[\"doc_id\"] == doc_id].reset_index()\n",
    "    \n",
    "    for index, row in df_doc.iterrows():\n",
    "        \n",
    "        if pd.notna(row['text']):\n",
    "            title_line = row['text'].split(\".\")[0]\n",
    "            break\n",
    "\n",
    "    return title_line"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 8,
   "id": "e8e8fc2e-879a-45ed-a76d-0f13ed7d0579",
   "metadata": {},
   "outputs": [],
   "source": [
    "neo_train_df[\"abstract_title\"] = neo_train_df.apply(lambda x: get_title_line(x, neo_train_df), axis=1)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 9,
   "id": "2cee210a-f615-49ae-b749-fd1d26ddb223",
   "metadata": {},
   "outputs": [],
   "source": [
    "neo_test_df[\"abstract_title\"] = neo_test_df.apply(lambda x: get_title_line(x, neo_test_df), axis=1)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 10,
   "id": "f9e3b6d5-7bcc-424f-aff2-90c1e56b237a",
   "metadata": {},
   "outputs": [],
   "source": [
    "gla_test_df[\"abstract_title\"] = gla_test_df.apply(lambda x: get_title_line(x, gla_test_df), axis=1)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 11,
   "id": "50d87b26-711d-4359-bc83-ecf0b2b85fbf",
   "metadata": {},
   "outputs": [],
   "source": [
    "mix_test_df[\"abstract_title\"] = mix_test_df.apply(lambda x: get_title_line(x, mix_test_df), axis=1)"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "f119cf67-e9a5-407c-80cb-3b649da65132",
   "metadata": {},
   "source": [
    "## Get title embeddings using BioBERT"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 12,
   "id": "72a2cc49-075f-4675-ab63-f4f208e7d193",
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "100%|██████████| 350/350 [00:32<00:00, 10.80it/s]\n"
     ]
    }
   ],
   "source": [
    "title_embed_d = {}\n",
    "for title in tqdm(neo_train_df.abstract_title.unique()):\n",
    "    # print(title)\n",
    "    while True:\n",
    "        try:\n",
    "            inputs = embedding_tokenizer(title, return_tensors=\"pt\")\n",
    "            output = embedding_model(**inputs)\n",
    "            embedding = output[1][0].squeeze()\n",
    "            title_embed_d[title] = embedding.detach().numpy()\n",
    "            break\n",
    "        except Exception as e:\n",
    "            print(e)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 13,
   "id": "487b9cda-69b6-42aa-8710-281486a810e8",
   "metadata": {},
   "outputs": [],
   "source": [
    "neo_train_df['title_embedding'] = neo_train_df.abstract_title.apply(lambda x: title_embed_d[x])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 14,
   "id": "75ad74f5-41f8-4ed8-9eb9-7490861dc6e9",
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "100%|██████████| 99/99 [00:09<00:00, 10.43it/s]\n"
     ]
    }
   ],
   "source": [
    "title_embed_d = {}\n",
    "for title in tqdm(neo_test_df.abstract_title.unique()):\n",
    "    # print(title)\n",
    "    while True:\n",
    "        try:\n",
    "            inputs = embedding_tokenizer(title, return_tensors=\"pt\")\n",
    "            output = embedding_model(**inputs)\n",
    "            embedding = output[1][0].squeeze()\n",
    "            title_embed_d[title] = embedding.detach().numpy()\n",
    "            break\n",
    "        except Exception as e:\n",
    "            print(e)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 15,
   "id": "01bc990b-4a39-4aee-8d7c-75dd00d44257",
   "metadata": {},
   "outputs": [],
   "source": [
    "neo_test_df['title_embedding'] = neo_test_df.abstract_title.apply(lambda x: title_embed_d[x])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 16,
   "id": "1e3e903c-c3e6-48b1-806e-1d825dc4d9c6",
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "100%|██████████| 98/98 [00:08<00:00, 10.99it/s]\n"
     ]
    }
   ],
   "source": [
    "title_embed_d = {}\n",
    "for title in tqdm(gla_test_df.abstract_title.unique()):\n",
    "    # print(title)\n",
    "    while True:\n",
    "        try:\n",
    "            inputs = embedding_tokenizer(title, return_tensors=\"pt\")\n",
    "            output = embedding_model(**inputs)\n",
    "            embedding = output[1][0].squeeze()\n",
    "            title_embed_d[title] = embedding.detach().numpy()\n",
    "            break\n",
    "        except Exception as e:\n",
    "            print(e)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 17,
   "id": "d6e47383-fd00-4b77-b9b1-3a790b90d80c",
   "metadata": {},
   "outputs": [],
   "source": [
    "gla_test_df['title_embedding'] = gla_test_df.abstract_title.apply(lambda x: title_embed_d[x])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 18,
   "id": "80f6a1ef-ef93-4699-9442-89fc300ca1d6",
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "100%|██████████| 100/100 [00:09<00:00, 10.81it/s]\n"
     ]
    }
   ],
   "source": [
    "title_embed_d = {}\n",
    "for title in tqdm(mix_test_df.abstract_title.unique()):\n",
    "    # print(title)\n",
    "    while True:\n",
    "        try:\n",
    "            inputs = embedding_tokenizer(title, return_tensors=\"pt\")\n",
    "            output = embedding_model(**inputs)\n",
    "            embedding = output[1][0].squeeze()\n",
    "            title_embed_d[title] = embedding.detach().numpy()\n",
    "            break\n",
    "        except Exception as e:\n",
    "            print(e)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 19,
   "id": "d547eff8-aaf8-4040-970b-dc7d8c0f5ad1",
   "metadata": {},
   "outputs": [],
   "source": [
    "mix_test_df['title_embedding'] = mix_test_df.abstract_title.apply(lambda x: title_embed_d[x])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 20,
   "id": "c575b23a-2528-4121-b89f-1e994c88d85a",
   "metadata": {},
   "outputs": [],
   "source": [
    "def get_abstract_texts(df):\n",
    "\n",
    "    concatenated_text = df.fillna('').groupby('doc_id')['text'].agg(' '.join).reset_index()\n",
    "    concatenated_text['text'] = concatenated_text['text'].str.strip()\n",
    "    df = df.merge(concatenated_text, on='doc_id', suffixes=('', '_concatenated'))\n",
    "    df = df.rename(columns={'text_concatenated': 'abstract_text'})\n",
    "\n",
    "    return df"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 21,
   "id": "5ed9778d-0f96-4964-93da-8a74a168200b",
   "metadata": {},
   "outputs": [],
   "source": [
    "neo_train_df = get_abstract_texts(neo_train_df)\n",
    "neo_test_df = get_abstract_texts(neo_test_df)\n",
    "gla_test_df = get_abstract_texts(gla_test_df)\n",
    "mix_test_df = get_abstract_texts(mix_test_df)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 22,
   "id": "fbe0f84f-5550-47af-a376-db874fb508d0",
   "metadata": {},
   "outputs": [],
   "source": [
    "def process_majorclaims(x):\n",
    "\n",
    "    aty = x.aty\n",
    "    if aty == 'MajorClaim':\n",
    "        aty = 'Claim'\n",
    "\n",
    "    return aty"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 23,
   "id": "6d312b59-f56e-4319-9bad-2548854e78b8",
   "metadata": {},
   "outputs": [],
   "source": [
    "neo_train_df['aty'] = neo_train_df.apply(lambda x: process_majorclaims(x), axis=1)\n",
    "neo_test_df['aty'] = neo_test_df.apply(lambda x: process_majorclaims(x), axis=1)\n",
    "gla_test_df['aty'] = gla_test_df.apply(lambda x: process_majorclaims(x), axis=1)\n",
    "mix_test_df['aty'] = mix_test_df.apply(lambda x: process_majorclaims(x), axis=1)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 24,
   "id": "43294d67-5e1d-4b5c-a7f3-74d64a4e249a",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "aty\n",
       "Premise    0.680052\n",
       "Claim      0.319948\n",
       "Name: proportion, dtype: float64"
      ]
     },
     "execution_count": 24,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "neo_train_df[neo_train_df.aty != 'none'].aty.value_counts(normalize=True)"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "ee72f2fb-f89c-4f44-b52a-e3735c570452",
   "metadata": {},
   "source": [
    "## Get K neighbours"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 25,
   "id": "af5e4bd3-0fb2-43bf-b1c0-423bc64cf869",
   "metadata": {},
   "outputs": [],
   "source": [
    "def get_k_neighbours(k, title, test_df, train_df=neo_train_df):\n",
    "\n",
    "    test_title_embedding = test_df[test_df.abstract_title == title][\"title_embedding\"].values[0]\n",
    "\n",
    "    title_embed_d = {}\n",
    "    for e in train_df.iterrows():\n",
    "        if e[1].abstract_title not in title_embed_d:\n",
    "            title_embed_d[e[1].abstract_title] = e[1].title_embedding\n",
    "\n",
    "    # train_titles = set(df[df.split == 'TRAIN'].title.unique())\n",
    "    train_titles = set(train_df.abstract_title.unique())\n",
    "\n",
    "    dist_l = []\n",
    "    for t, v in title_embed_d.items():\n",
    "        if t in train_titles:\n",
    "            # d = cos_sim(title_embed_d[title], v)\n",
    "            d = F.cosine_similarity(torch.tensor(test_title_embedding), torch.tensor(v), dim=0)\n",
    "            dist_l.append((t, d.item()))\n",
    "\n",
    "    sorted_dist_l = sorted(dist_l, key=itemgetter(1), reverse=True)\n",
    "    \n",
    "    return sorted_dist_l[0: k]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 26,
   "id": "80b2cd04-08d5-488a-95d2-cb1ece514ce4",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[(' Research has shown that self-directed stress management training improves mental well-being in patients undergoing chemotherapy',\n",
       "  0.9953505992889404),\n",
       " (' Numerous studies have examined the comorbidity of depression with cancer, and some have indicated that depression may be associated with cancer progression or survival',\n",
       "  0.994724452495575),\n",
       " (' Behavioral symptoms are common in breast cancer survivors, including disturbances in energy, sleep, and mood, though few risk factors for these negative outcomes have been identified',\n",
       "  0.9935887455940247),\n",
       " (' Lymphoma patients commonly experience declines in physical functioning and quality of life (QoL) that may be reversed with exercise training',\n",
       "  0.9935306310653687),\n",
       " (' Few intervention studies have been conducted to help couples manage the effects of prostate cancer and maintain their quality of life',\n",
       "  0.992271900177002)]"
      ]
     },
     "execution_count": 26,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "get_k_neighbours(5, neo_test_df.iloc[100][\"abstract_title\"], neo_test_df)"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "835b1354-2302-4d83-b7ae-c6c3373b868b",
   "metadata": {},
   "source": [
    "## Prepare Prompts"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 27,
   "id": "552c1b97-e8e0-4425-900e-59d77baf447e",
   "metadata": {},
   "outputs": [],
   "source": [
    "def prepare_similar_example_prompts(title, df, k=5, seed=33):\n",
    "    \"\"\"\n",
    "    Create a part of prompt made of k examples in the train set, whose topic is most similar to a given title.\n",
    "    \"\"\"\n",
    "\n",
    "    random.seed(seed)\n",
    "\n",
    "    neighbours_l = get_k_neighbours(2*k, title, df) # Fetch the 2*k closest neighbors\n",
    "    # print(neighbours_l)\n",
    "    sampled_neighbours_l = random.sample(neighbours_l, k) # Only keep k of them\n",
    "    # bprint(sampled_neighbours_l)\n",
    "\n",
    "    prompt = ''\n",
    "    cnt = 0\n",
    "    for i, (title, dist) in enumerate(sampled_neighbours_l):\n",
    "        prompt += f'## Example {i+1}\\n'\n",
    "\n",
    "        example_df = neo_train_df[neo_train_df.abstract_title == title]\n",
    "        example_df = example_df[example_df.aty != 'none'].reset_index()\n",
    "        \n",
    "        class_l = []\n",
    "        for k in example_df.iterrows():\n",
    "            \n",
    "            if k[0] == 0:\n",
    "\n",
    "                prompt += f'# Abstract:\\n{example_df.iloc[0].abstract_text}\\n\\n# Arguments:\\n'\n",
    "                cnt = 0\n",
    "                \n",
    "            # prompt += f'Argument {cnt + 1}={k[1].text} - Class={k[1].aty}\\n'\n",
    "            prompt += f'Argument {cnt + 1}={k[1].text}\\n'\n",
    "            class_l.append(k[1].aty)\n",
    "            cnt += 1\n",
    "            \n",
    "        prompt += '\\n# Result:\\n'\n",
    "        prompt += '{' + ', '.join([f'\"Argument {i + 1}\": \"{class_l[i]}\"' for i in range(len(class_l))]) + '}'\n",
    "        prompt += '\\n\\n'\n",
    "\n",
    "    return prompt"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 28,
   "id": "808aaf63-3b10-4366-a13f-c2eee4b1ba95",
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "## Example 1\n",
      "# Abstract:\n",
      "A single-item linear analogue self-assessment scale for mood was compared with a 28-item adjective checklist for emotional well-being. To confirm its concurrent validity and responsiveness to treatment and recurrence in patients with breast cancer, emotional well-being was assessed every 3 months for 2 years and at 1 and 6 months after recurrence in 1,169 patients who were premenopausal and 960 patients who were postmenopausal. These patients were enrolled in two International Breast Cancer Study Group randomized clinical trials in operable breast cancer conducted from 1986 to 1993. To assess concurrent validity, Pearson's correlation between the linear analogue self-assessment scale and the adjective checklist were calculated for each time-point within each treatment group and for the two assessments after recurrence. Responsiveness to treatment and recurrence were analyzed using paired t tests and the squared ratio of these t tests, an estimate of relative efficiency. Concurrent validity of the mood linear analogue self-assessment was consistently confirmed across four language groups. Both measures were responsive; out of 24 changes over time, 19 were in the expected direction for the linear analogue self-assessment scale (p < or = 0.05 for 9 of 19) and 17 for the adjective checklist (p < or = 0.05 for 10 of 17). The linear analogue self-assessment scale was less but significantly efficient for detection of treatment effects, with relative efficiency estimates ranging from 0.16 to 2.45 and a median of 0.66 among the comparisons with relatively stable estimates (/t/ > or = 1.0) and more efficient for recurrence than the adjective checklist. The mood linear analogue self-assessment scale is a valid indicator of emotional well-being in patients with breast cancer in large multicenter, multicultural trials in which comprehensive scales are less feasible. This investigation supports the clinical relevance of linear analogue self-assessment scales as indicators of components of quality of life in cancer clinical trials.\n",
      "\n",
      "# Arguments:\n",
      "Argument 1=Both measures were responsive;\n",
      "Argument 2=out of 24 changes over time, 19 were in the expected direction for the linear analogue self-assessment scale (p < or = 0.05 for 9 of 19) and 17 for the adjective checklist (p < or = 0.05 for 10 of 17).\n",
      "Argument 3=The linear analogue self-assessment scale was less but significantly efficient for detection of treatment effects, with relative efficiency estimates ranging from 0.16 to 2.45 and a median of 0.66 among the comparisons with relatively stable estimates (/t/ > or = 1.0) and more efficient for recurrence than the adjective checklist.\n",
      "Argument 4=The mood linear analogue self-assessment scale is a valid indicator of emotional well-being in patients with breast cancer in large multicenter, multicultural trials in which comprehensive scales are less feasible.\n",
      "Argument 5=This investigation supports the clinical relevance of linear analogue self-assessment scales as indicators of components of quality of life in cancer clinical trials.\n",
      "\n",
      "# Result:\n",
      "{\"Argument 1\": \"Claim\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Claim\", \"Argument 5\": \"Claim\"}\n",
      "\n",
      "## Example 2\n",
      "# Abstract:\n",
      "It is not clear whether the administration of radioiodine provides any benefit to patients with low-risk thyroid cancer after a complete surgical resection. The administration of the smallest possible amount of radioiodine would improve care. In our randomized, phase 3 trial, we compared two thyrotropin-stimulation methods (thyroid hormone withdrawal and use of recombinant human thyrotropin) and two radioiodine ((131)I) doses (i.e., administered activities) (1.1 GBq and 3.7 GBq) in a 2-by-2 design. Inclusion criteria were an age of 18 years or older; total thyroidectomy for differentiated thyroid carcinoma; tumor-node-metastasis (TNM) stage, ascertained on pathological examination (p) of a surgical specimen, of pT1 (with tumor diameter ≤1 cm) and N1 or Nx, pT1 (with tumor diameter >1 to 2 cm) and any N stage, or pT2N0; absence of distant metastasis; and no iodine contamination. Thyroid ablation was assessed 8 months after radioiodine administration by neck ultrasonography and measurement of recombinant human thyrotropin-stimulated thyroglobulin. Comparisons were based on an equivalence framework. There were 752 patients enrolled between 2007 and 2010; 92% had papillary cancer. There were no unexpected serious adverse events. In the 684 patients with data that could be evaluated, ultrasonography of the neck was normal in 652 (95%), and the stimulated thyroglobulin level was 1.0 ng per milliliter or less in 621 of the 652 patients (95%) without detectable thyroglobulin antibodies. Thyroid ablation was complete in 631 of the 684 patients (92%). The ablation rate was equivalent between the (131)I doses and between the thyrotropin-stimulation methods. The use of recombinant human thyrotropin and low-dose (1.1 GBq) postoperative radioiodine ablation may be sufficient for the management of low-risk thyroid cancer.\n",
      "\n",
      "# Arguments:\n",
      "Argument 1=There were no unexpected serious adverse events.\n",
      "Argument 2=In the 684 patients with data that could be evaluated, ultrasonography of the neck was normal in 652 (95%), and the stimulated thyroglobulin level was 1.0 ng per milliliter or less in 621 of the 652 patients (95%) without detectable thyroglobulin antibodies.\n",
      "Argument 3=Thyroid ablation was complete in 631 of the 684 patients (92%).\n",
      "Argument 4=The ablation rate was equivalent between the (131)I doses and between the thyrotropin-stimulation methods.\n",
      "Argument 5=The use of recombinant human thyrotropin and low-dose (1.1 GBq) postoperative radioiodine ablation may be sufficient for the management of low-risk thyroid cancer.\n",
      "\n",
      "# Result:\n",
      "{\"Argument 1\": \"Premise\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Premise\", \"Argument 5\": \"Claim\"}\n",
      "\n",
      "## Example 3\n",
      "# Abstract:\n",
      "The aim of the study is to demonstrate that intrapatient dose escalation of carboplatin would improve the outcome in ovarian cancer compared with flat dosing. Patients with untreated stage IC-IV ovarian cancer received six cycles of carboplatin area under the curve 6 (AUC 6) 3 weekly either with no dose modification except for toxicity (Arm A) or with dose escalations in cycles 2-6 based on nadir neutrophil and platelet counts (Arm B). The primary end-point was progression-free survival (PFS). Nine hundred and sixty-four patients were recruited from 71 centers. Dose escalation was achieved in 77% of patients who had ≥1 cycle. The median AUCs (cycle 2-6) received were 6.0 (Arm A) and 7.2 (Arm B) (P < 0.001). Grade 3/4 non-hematological toxicity was higher in Arm B (31% versus 22% P = 0.001). The median PFS was 12.1 months in Arm A and B [hazard ratio (HR) 0.99; 95% confidence interval (CI) 0.85-1.15; P = 0.93]. The median overall survival (OS) was 34.1 and 30.7 months in Arms A and B, respectively (HR 0.98; 95% CI 0.81-1.18, P = 0.82). In multivariate analysis, baseline neutrophil (P < 0.001), baseline platelet counts (P < 0.001) and the difference between white blood cell (WBC) and neutrophil count (P = 0.009) had a significant adverse prognostic value. Intrapatient dose escalation of carboplatin based on nadir blood counts is feasible and safe. However, it provided no improvement in PFS or OS compared with flat dosing. Baseline neutrophils over-ride nadir counts in prognostic significance. These data may have wider implications particularly in respect of the management of chemotherapy-induced neutropenia.\n",
      "\n",
      "# Arguments:\n",
      "Argument 1=The median AUCs (cycle 2-6) received were 6.0 (Arm A) and 7.2 (Arm B) (P < 0.001).\n",
      "Argument 2=Grade 3/4 non-hematological toxicity was higher in Arm B (31% versus 22% P = 0.001).\n",
      "Argument 3=The median PFS was 12.1 months in Arm A and B [hazard ratio (HR) 0.99; 95% confidence interval (CI) 0.85-1.15; P = 0.93].\n",
      "Argument 4=The median overall survival (OS) was 34.1 and 30.7 months in Arms A and B, respectively (HR 0.98; 95% CI 0.81-1.18, P = 0.82).\n",
      "Argument 5=In multivariate analysis, baseline neutrophil (P < 0.001), baseline platelet counts (P < 0.001) and the difference between white blood cell (WBC) and neutrophil count (P = 0.009) had a significant adverse prognostic value.\n",
      "Argument 6=Intrapatient dose escalation of carboplatin based on nadir blood counts is feasible and safe.\n",
      "Argument 7=However, it provided no improvement in PFS or OS compared with flat dosing.\n",
      "\n",
      "# Result:\n",
      "{\"Argument 1\": \"Premise\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Premise\", \"Argument 5\": \"Premise\", \"Argument 6\": \"Claim\", \"Argument 7\": \"Claim\"}\n",
      "\n",
      "## Example 4\n",
      "# Abstract:\n",
      "Hormonal breast cancer treatment increases menopausal symptoms in women. This study investigated differences between the symptoms associated with either adjuvant tamoxifen or exemestane. Ten common symptoms were assessed by self-report questionnaire administered to 1,614 consecutive patients at baseline and every 3 months during the first year of a double-blind, randomized trial of postmenopausal women with early hormone receptor-positive breast cancer. Symptoms were categorized as none, mild, moderate, or severe. A hot flash score was calculated at each time point. Symptoms were analyzed by repeated-measures analysis of variance. Each time period was tested repeatedly against the baseline; an overall P value was assigned for each reported symptom. Compliance was excellent, with 7,286 questionnaires analyzed. Baseline symptom prevalence ranged from 2% (vaginal bleeding) to 60% to 70% (bone/muscle aches and low energy). There were no significant differences in vaginal bleeding, mood alteration, or low energy. Patients receiving tamoxifen had significantly more vaginal discharge (P < .0001). Exemestane patients reported more bone/muscle aches (P < .0001), vaginal dryness (P = .0004), and difficulty sleeping (P = .03). In both groups, the hot flash score peaked at 3 months and decreased thereafter. At 12 months, patients receiving tamoxifen had a significantly higher mean hot flash score (P = .03), with daily hot flashes increasing from baseline by 33% compared with a 7% increase from baseline with exemestane. At 12 months, exemestane was associated with fewer hot flashes and less vaginal discharge than tamoxifen, but with more vaginal dryness, bone/muscle aches, and difficulty sleeping. Symptoms were common in both groups.\n",
      "\n",
      "# Arguments:\n",
      "Argument 1=Hormonal breast cancer treatment increases menopausal symptoms in women.\n",
      "Argument 2=There were no significant differences in vaginal bleeding, mood alteration, or low energy.\n",
      "Argument 3=Patients receiving tamoxifen had significantly more vaginal discharge (P < .0001).\n",
      "Argument 4=Exemestane patients reported more bone/muscle aches (P < .0001), vaginal dryness (P = .0004), and difficulty sleeping (P = .03).\n",
      "Argument 5=In both groups, the hot flash score peaked at 3 months and decreased thereafter.\n",
      "Argument 6=At 12 months, patients receiving tamoxifen had a significantly higher mean hot flash score (P = .03), with daily hot flashes increasing from baseline by 33% compared with a 7% increase from baseline with exemestane.\n",
      "Argument 7=At 12 months, exemestane was associated with fewer hot flashes and less vaginal discharge than tamoxifen, but with more vaginal dryness, bone/muscle aches, and difficulty sleeping.\n",
      "Argument 8=Symptoms were common in both groups.\n",
      "\n",
      "# Result:\n",
      "{\"Argument 1\": \"Claim\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Premise\", \"Argument 5\": \"Premise\", \"Argument 6\": \"Premise\", \"Argument 7\": \"Premise\", \"Argument 8\": \"Claim\"}\n",
      "\n",
      "## Example 5\n",
      "# Abstract:\n",
      "Facial hirsutism is one of the characteristic features of polycystic ovary syndrome (PCOS), and this can lead to high levels of depression and anxiety. To evaluate the impact of laser treatment on the severity of facial hirsutism and on psychological morbidity in women with PCOS. A randomized controlled trial of five high-fluence treatments (intervention) vs. five low-fluence treatments (control) was performed over 6 months in a National Health Service teaching hospital. Subjects were 88 women with facial hirsutism due to PCOS recruited from hospital outpatient clinics and a patient support group in 2001-2002. The main outcomes were self-reported severity of facial hair (measured on a scale of 1-10), depression, anxiety (measured on the Hospital Anxiety and Depression Scale) and quality of life (measured on the WHOQOL-BREF). Self-reported severity of facial hair in the intervention group (n = 51) fell from 7.3 to 3.6 over the 6-month study period; for the control group (n = 37) the corresponding scores were 7.1 and 6.1. The change was significantly greater in the intervention group [ancova F((1,83)) = 24.5, P < 0.05]. Self-reported time spent on hair removal declined from 112 to 21 min per week in the intervention group and from 92 to 56 min in the control group [F((1,80)) = 10.2, P </= 0.05]. Mean depression scores fell from 6.7 to 3.6 in the intervention group, compared with 6.1 to 5.4 in the control group [F((1,83)) = 14.7, P < 0.05]. A similar change was seen for mean anxiety scores: intervention 11.1 to 8.2, control 9.6 to 9.3 [F((1,84)) = 17.8, P < 0.05]. Psychological quality of life also improved more in the intervention group, from 49.6 to 61.2 vs. 50.1 to 51.5 in the control group [F((1,84)) = 10.9, P < 0.05]. Laser treatment appeared to reduce the severity of facial hair and time spent on hair removal as well as alleviating depression and anxiety in women with PCOS. These findings suggest that ways of making this method of hair removal more widely available to women with facial hirsutism should be considered.\n",
      "\n",
      "# Arguments:\n",
      "Argument 1=Facial hirsutism is one of the characteristic features of polycystic ovary syndrome (PCOS), and this can lead to high levels of depression and anxiety.\n",
      "Argument 2=Self-reported severity of facial hair in the intervention group (n = 51) fell from 7.3 to 3.6 over the 6-month study period; for the control group (n = 37) the corresponding scores were 7.1 and 6.1.\n",
      "Argument 3=The change was significantly greater in the intervention group [ancova F((1,83)) = 24.5, P < 0.05].\n",
      "Argument 4=Self-reported time spent on hair removal declined from 112 to 21 min per week in the intervention group and from 92 to 56 min in the control group [F((1,80)) = 10.2, P </= 0.05].\n",
      "Argument 5=Mean depression scores fell from 6.7 to 3.6 in the intervention group, compared with 6.1 to 5.4 in the control group [F((1,83)) = 14.7, P < 0.05].\n",
      "Argument 6=A similar change was seen for mean anxiety scores: intervention 11.1 to 8.2, control 9.6 to 9.3 [F((1,84)) = 17.8, P < 0.05].\n",
      "Argument 7=Psychological quality of life also improved more in the intervention group, from 49.6 to 61.2 vs. 50.1 to 51.5 in the control group [F((1,84)) = 10.9, P < 0.05].\n",
      "Argument 8=Laser treatment appeared to reduce the severity of facial hair and time spent on hair removal as well as alleviating depression and anxiety in women with PCOS.\n",
      "Argument 9=These findings suggest that ways of making this method of hair removal more widely available to women with facial hirsutism should be considered.\n",
      "\n",
      "# Result:\n",
      "{\"Argument 1\": \"Claim\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Premise\", \"Argument 5\": \"Premise\", \"Argument 6\": \"Premise\", \"Argument 7\": \"Premise\", \"Argument 8\": \"Claim\", \"Argument 9\": \"Claim\"}\n",
      "\n",
      "\n"
     ]
    }
   ],
   "source": [
    "print(prepare_similar_example_prompts(neo_test_df.iloc[14][\"abstract_title\"], neo_test_df, k=5))"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "ac26cf7a-b9a9-43ec-aa97-1d399c5acb3f",
   "metadata": {},
   "source": [
    "## Prepare Test Set Prompts"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 29,
   "id": "74d1d550-d451-47d2-8791-0a4879a4abb7",
   "metadata": {},
   "outputs": [],
   "source": [
    "claim_fulldesc = \"A claim in the abstract of an RCT is a statement or conclusion about the findings of the study.\""
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 30,
   "id": "9113d8e4-e75c-4bbe-a690-b3069ba838dc",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "'A claim in the abstract of an RCT is a statement or conclusion about the findings of the study.'"
      ]
     },
     "execution_count": 30,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "claim_fulldesc"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 31,
   "id": "50e826fc-5d8c-4479-88ba-b223dd452512",
   "metadata": {},
   "outputs": [],
   "source": [
    "premise_fulldesc = \"A premise in the abstract of an RCT is a statement that provides an evidence or proof for a claim.\""
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 32,
   "id": "598963db-b3fc-4f56-8024-45fa1423fba3",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "'A premise in the abstract of an RCT is a statement that provides an evidence or proof for a claim.'"
      ]
     },
     "execution_count": 32,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "premise_fulldesc"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 33,
   "id": "a9a35223-8e73-416f-86e1-0f26ab7d3120",
   "metadata": {},
   "outputs": [],
   "source": [
    "proportion_desc = \"68.0052% of examples are of type Premise and 31.9948% of type Claim.\""
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 34,
   "id": "c0803ab3-d136-439f-90b1-a3e412ad2370",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "'68.0052% of examples are of type Premise and 31.9948% of type Claim.'"
      ]
     },
     "execution_count": 34,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "proportion_desc"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "11e65615-7cfc-4eb6-ae7d-615386f17853",
   "metadata": {},
   "source": [
    "### Neo_test"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 35,
   "id": "d2bacc91-8288-4d64-a605-50c9cb20c5cf",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "CPU times: user 25 s, sys: 18.4 ms, total: 25 s\n",
      "Wall time: 25.1 s\n"
     ]
    }
   ],
   "source": [
    "%%time\n",
    "\n",
    "#experiment_df = df[df.split == 'TEST']\n",
    "experiment_df = neo_test_df\n",
    "# experiment_df = gla_test_df\n",
    "# experiment_df = mix_test_df\n",
    "\n",
    "target_l = []\n",
    "\n",
    "# Pre-prepare all examples from each document\n",
    "title_l = []\n",
    "essay_l = []\n",
    "example_l = []\n",
    "buffer_l = []\n",
    "label_l = []\n",
    "for e in experiment_df.iterrows():\n",
    "\n",
    "    if e[1].span_pos == 1:\n",
    "    #if e[0] == 0:\n",
    "        essay_l.append(e[1].abstract_text)\n",
    "        title_l.append(e[1].abstract_title)\n",
    "    \n",
    "    if e[1].span_pos == 1 and len(buffer_l) > 0:\n",
    "    #if e[0] == 0 and len(buffer_l) > 0:\n",
    "        example_l.append(buffer_l)\n",
    "        target_l.append(label_l)\n",
    "        buffer_l = []\n",
    "        label_l = []\n",
    "    if e[1].aty != 'none':\n",
    "        buffer_l.append(e[1].text)\n",
    "        label_l.append(e[1].aty)\n",
    "\n",
    "# Flush the buffers\n",
    "example_l.append(buffer_l)\n",
    "target_l.append(label_l)\n",
    "\n",
    "\n",
    "sys_msg_l_by_seed_d = {}\n",
    "task_msg_l = []\n",
    "\n",
    "for i in range(len(example_l)):\n",
    "\n",
    "    # Prepare numbered list of ACs in this example\n",
    "    other_acs_prompt = ''\n",
    "    for j, s in enumerate(example_l[i]):\n",
    "        # other_acs_prompt += f'Argument {j + 1}={s}\\n'\n",
    "        other_acs_prompt += f'Argument {j + 1}={s}\\n'\n",
    "\n",
    "    for seed in [33, 34, 35, 36, 37]:\n",
    "        sys_msg = {\"role\":\"system\", \"content\": \"### Task description: You are an expert biomedical assistant that takes 1) an abstract text, 2) the list of all arguments from this abstract text, and must classify all arguments into one of two classes: Claim or Premise. \" + proportion_desc + \" You must absolutely not generate any text or explanation other than the following JSON format {\\\"Argument 1\\\": <predicted class for Argument 1 (str)>, ..., \\\"Argument n\\\": <predicted class for Argument n (str)>}\\n\\n### Class definitions:\" + \" Claim = \" + claim_fulldesc + \" Premise = \" + premise_fulldesc + \"\\n\\n### Examples:\\n\\n\" + prepare_similar_example_prompts(title_l[i], experiment_df, k=5, seed=seed)}  # Sample by similar title\n",
    "\n",
    "        try:\n",
    "            sys_msg_l_by_seed_d[seed].append(sys_msg)\n",
    "        except KeyError:\n",
    "            sys_msg_l_by_seed_d[seed] = [sys_msg]\n",
    "\n",
    "    task_msg = {\"role\":\"user\", \"content\": f\"# Abstract:\\n{essay_l[i]}\\n\\n# Arguments:\\n{other_acs_prompt}\\n\\n# Result:\\n\"}\n",
    "    \n",
    "    task_msg_l.append(task_msg)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 36,
   "id": "bab5f946-2558-487c-9242-dd26c53ecf38",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "100"
      ]
     },
     "execution_count": 36,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "len(sys_msg_l_by_seed_d[33])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 37,
   "id": "5bc622e9-738a-4f72-a57c-7297d1c84f3b",
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "### Task description: You are an expert biomedical assistant that takes 1) an abstract text, 2) the list of all arguments from this abstract text, and must classify all arguments into one of two classes: Claim or Premise. 68.0052% of examples are of type Premise and 31.9948% of type Claim. You must absolutely not generate any text or explanation other than the following JSON format {\"Argument 1\": <predicted class for Argument 1 (str)>, ..., \"Argument n\": <predicted class for Argument n (str)>}\n",
      "\n",
      "### Class definitions: Claim = A claim in the abstract of an RCT is a statement or conclusion about the findings of the study. Premise = A premise in the abstract of an RCT is a statement that provides an evidence or proof for a claim.\n",
      "\n",
      "### Examples:\n",
      "\n",
      "## Example 1\n",
      "# Abstract:\n",
      "The aim of this study was to compare the 2-year functional performance and quality of life in patients with operable squamous cell carcinoma of the esophagus, who have received either surgery or definitive chemoradiation (CRT). The functional outcomes and quality of life in patients receiving esophagectomy or definitive CRT is uncertain. Data were extracted from the database of a prospective randomized controlled trial that included patients with resectable mid or lower thoracic esophageal cancers. The patients were randomized to either standard esophagectomy or definitive CRT. Quality of life assessments were performed using the EORTC QLQ-C30 and QLQ-OES24 modules. Other functional assessments included pulmonary and eating functions. From July 2000 to December 2004, a total of 81 patients were enrolled into the study. No significant longitudinal changes were detected in the global health status in both groups upon available follow-up. Surgery was associated with worsened physical functioning and fatigue symptoms up to 6 months after treatment (P < 0.001 and P = 0.021, respectively) and these scales improved at 2 years. In terms of pulmonary function, dyspnoic and coughing symptoms were significantly worsened 3 months after surgery (P = 0.024 and P = 0.036, respectively) whereas symptoms in the CRT group progressively deteriorated over time. In terms of pulmonary function, dyspnoic and coughing symptoms were significantly worsened 3 months after surgery (P = 0.024 and P = 0.036, respectively) whereas symptoms in the CRT group progressively deteriorated over time. Concerning the eating function, both groups had improvements in dysphagia but there were frequent need for endoscopic intervention. Neither surgery nor definitive CRT significantly impaired the global health status of patients. Surgery was associated with a short-term negative impact in some aspects of health related quality of life assessments but these changes became insignificant 2 years after treatment. However, CRT was associated with progressive deteriorations in pulmonary function in the longer term.\n",
      "\n",
      "# Arguments:\n",
      "Argument 1=No significant longitudinal changes were detected in the global health status in both groups upon available follow-up.\n",
      "Argument 2=Surgery was associated with worsened physical functioning and fatigue symptoms up to 6 months after treatment (P < 0.001 and P = 0.021, respectively) and these scales improved at 2 years.\n",
      "Argument 3=In terms of pulmonary function, dyspnoic and coughing symptoms were significantly worsened 3 months after surgery (P = 0.024 and P = 0.036, respectively) whereas symptoms in the CRT group progressively deteriorated over time.\n",
      "Argument 4=In terms of pulmonary function, dyspnoic and coughing symptoms were significantly worsened 3 months after surgery (P = 0.024 and P = 0.036, respectively) whereas symptoms in the CRT group progressively deteriorated over time.\n",
      "Argument 5=Concerning the eating function, both groups had improvements in dysphagia but there were frequent need for endoscopic intervention.\n",
      "Argument 6=Neither surgery nor definitive CRT significantly impaired the global health status of patients.\n",
      "Argument 7=Surgery was associated with a short-term negative impact in some aspects of health related quality of life assessments\n",
      "Argument 8=but these changes became insignificant 2 years after treatment.\n",
      "Argument 9=CRT was associated with progressive deteriorations in pulmonary function in the longer term.\n",
      "\n",
      "# Result:\n",
      "{\"Argument 1\": \"Premise\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Premise\", \"Argument 5\": \"Premise\", \"Argument 6\": \"Premise\", \"Argument 7\": \"Claim\", \"Argument 8\": \"Claim\", \"Argument 9\": \"Claim\"}\n",
      "\n",
      "## Example 2\n",
      "# Abstract:\n",
      "To report 5-year contrast-enhanced magnetic resonance imaging findings of the REST trial recruits who underwent either uterine artery embolization (UAE) or myomectomy. A total of 157 patients were randomized to UAE or surgery (hysterectomy or myomectomy). Ninety-nine patients who had UAE and eight patients who had myomectomy were analyzed. MRI scans at baseline, 6 months, and 5 years were independently interpreted by two radiologists. Dominant fibroid diameter, uterine volume, total fibroid infarction (complete 100 %, almost complete 90-99 %, partial <90 %), and new fibroid formation were the main parameters assessed and related to the need for reintervention. In the UAE group, mean ± standard deviation uterine volume was 670 ± 503, 422 ± 353, and 292 ± 287 mL at baseline, 6 months, and 5 years, respectively. Mean dominant fibroid diameter was 7.6 ± 3.0, 5.8 ± 2.9, and 5 ± 2.9 cm at baseline, 6 months, and 5 years. Fibroid infarction at 6 months was complete in 35 % of women, almost complete in 29 %, and partial in 36 %. Need for reintervention was 19, 10, and 33 % in these groups, respectively (p = 0.123). No myomectomy cases had further intervention. At 5 years, the prevalence of new fibroid was 60 % in the myomectomy group and 7 % in the UAE group (p = 0.008). There is a further significant reduction in both uterine volume and dominant fibroid diameter between 6 months and 5 years after UAE. Complete fibroid infarction does not translate into total freedom from a subsequent reintervention. New fibroid formation is significantly higher after myomectomy.\n",
      "\n",
      "# Arguments:\n",
      "Argument 1=In the UAE group, mean ± standard deviation uterine volume was 670 ± 503, 422 ± 353, and 292 ± 287 mL at baseline, 6 months, and 5 years, respectively.\n",
      "Argument 2=Mean dominant fibroid diameter was 7.6 ± 3.0, 5.8 ± 2.9, and 5 ± 2.9 cm at baseline, 6 months, and 5 years.\n",
      "Argument 3=Fibroid infarction at 6 months was complete in 35 % of women, almost complete in 29 %, and partial in 36 %.\n",
      "Argument 4=Need for reintervention was 19, 10, and 33 % in these groups, respectively (p = 0.123).\n",
      "Argument 5=No myomectomy cases had further intervention.\n",
      "Argument 6=At 5 years, the prevalence of new fibroid was 60 % in the myomectomy group and 7 % in the UAE group (p = 0.008).\n",
      "Argument 7=There is a further significant reduction in both uterine volume and dominant fibroid diameter between 6 months and 5 years after UAE.\n",
      "Argument 8=Complete fibroid infarction does not translate into total freedom from a subsequent reintervention.\n",
      "Argument 9=New fibroid formation is significantly higher after myomectomy.\n",
      "\n",
      "# Result:\n",
      "{\"Argument 1\": \"Premise\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Premise\", \"Argument 5\": \"Premise\", \"Argument 6\": \"Premise\", \"Argument 7\": \"Premise\", \"Argument 8\": \"Claim\", \"Argument 9\": \"Claim\"}\n",
      "\n",
      "## Example 3\n",
      "# Abstract:\n",
      "This randomized phase II study compared two treatment schedules of gemcitabine in patients with non-small-cell lung cancer (NSCLC) and impaired Karnofsky performance status (KP). Primary objectives were to record changes from baseline KP and to assess symptom palliation. Secondary objectives were overall survival, tumor response, and toxicity. Patients with stage IIIb and IV NSCLC and KP </= 70 were randomly assigned to receive gemcitabine 1,000 mg/m(2) on days 1, 8, and 15 of each 28-day cycle (3w4) or gemcitabine 1,500 mg/m(2) on days 1 and 8 of each 21-day cycle (2w3), both for up to six cycles. KP, toxicity, and SS14 lung cancer specific questions were recorded before each cycle of treatment. Response was evaluated 4 weeks after the last cycle. One hundred seventy-four patients were enrolled. There was significant early attrition due to disease progression; only 61.5% of patients were alive at 2 months. There was a significant improvement in KP from baseline to pre-cycle 3 in both arms, with a trend in favor of the 3w4 regimen for duration and faster onset of improvement. Eight of the 17 quality-of-life (QOL) variables assessed showed an improvement of more than 10% between baseline and the start of the third cycle of treatment. Response rate, survival, and duration were similar in both arms. There was no significant difference between the two schedules examined in terms of improvement in KP or QOL, but there seemed to be a trend in favor of the 3w4 schedule.\n",
      "\n",
      "# Arguments:\n",
      "Argument 1=There was significant early attrition due to disease progression; only 61.5% of patients were alive at 2 months.\n",
      "Argument 2=There was a significant improvement in KP from baseline to pre-cycle 3 in both arms, with a trend in favor of the 3w4 regimen for duration and faster onset of improvement.\n",
      "Argument 3=Eight of the 17 quality-of-life (QOL) variables assessed showed an improvement of more than 10% between baseline and the start of the third cycle of treatment.\n",
      "Argument 4=Response rate, survival, and duration were similar in both arms.\n",
      "Argument 5=There was no significant difference between the two schedules examined in terms of improvement in KP or QOL, but there seemed to be a trend in favor of the 3w4 schedule.\n",
      "\n",
      "# Result:\n",
      "{\"Argument 1\": \"Premise\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Premise\", \"Argument 5\": \"Claim\"}\n",
      "\n",
      "## Example 4\n",
      "# Abstract:\n",
      "The aim of the present trial was to evaluate the effects of chemotherapy on the quality of life and survival of patients with advanced non-small cell lung cancer (NSCLC) (stage IIIB or IV). In a controlled multicentre trial, patients were randomised to receive supportive care only or supportive care plus chemotherapy. Chemotherapy consisted of intravenous (i.v.) carboplatin 300 mg/m2 on day 1 and etoposide 120 mg/m2 orally on days 1-5 every 4 weeks for a maximum of eight courses. Quality of life was measured at randomisation and prior to each treatment course and at corresponding 4-week intervals in the control arm, using the EORTC QLQ-C30 + LC13 questionnaire. 48 patients were randomised (supportive care 26, chemotherapy 22), being eligible for comparative analyses. Another 102 patients, 97 of which received chemotherapy, were subsequently included in the study on an individual treatment preference basis. Data from these patients were used for confirmative purposes. Patients in the chemotherapy group reported better overall physical functioning and symptom control compared with the supportive care group. Group differences were smaller within the psychosocial domain, although trends were seen in favour of the chemotherapy group. No significant differences were seen in favour of the supportive care group, except for hair loss. Median survival times were 29 weeks in the chemotherapy group versus 11 weeks in the supportive care group, and 1-year survival rates were 28% versus 8%. Quality of life and survival outcomes were similar in the randomised and non-randomised patients receiving chemotherapy. No treatment-related deaths occurred. In conclusion, treatment with carboplatin and etoposide can improve both the quality of life and the survival of patients with advanced NSCLC.\n",
      "\n",
      "# Arguments:\n",
      "Argument 1=Patients in the chemotherapy group reported better overall physical functioning and symptom control compared with the supportive care group.\n",
      "Argument 2=Group differences were smaller within the psychosocial domain,\n",
      "Argument 3=although trends were seen in favour of the chemotherapy group.\n",
      "Argument 4=No significant differences were seen in favour of the supportive care group,\n",
      "Argument 5=except for hair loss.\n",
      "Argument 6=Median survival times were 29 weeks in the chemotherapy group versus 11 weeks in the supportive care group, and 1-year survival rates were 28% versus 8%.\n",
      "Argument 7=Quality of life and survival outcomes were similar in the randomised and non-randomised patients receiving chemotherapy.\n",
      "Argument 8=No treatment-related deaths occurred.\n",
      "Argument 9=In conclusion, treatment with carboplatin and etoposide can improve both the quality of life and the survival of patients with advanced NSCLC.\n",
      "\n",
      "# Result:\n",
      "{\"Argument 1\": \"Premise\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Premise\", \"Argument 5\": \"Premise\", \"Argument 6\": \"Premise\", \"Argument 7\": \"Premise\", \"Argument 8\": \"Premise\", \"Argument 9\": \"Claim\"}\n",
      "\n",
      "## Example 5\n",
      "# Abstract:\n",
      "The aim of this prospective controlled study was to assess the efficacy of two different combination treatment modalities of lymphedema (LE). Manual lymphatic drainage (MLD) and compression bandage combination (complex decongestive therapy) have been compared with intermittent pneumatic compression (IPC) plus self-lymphatic drainage (SLD). Both MLD with compression bandage (complex decongestive therapy) group (Group I, n=15) and IPC with SLD group (Group II, n=15) received treatment for LE 3 days in a week and every other day for 6 weeks. Arm circumferences were measured before and the 1st, 3rd, and 6th weeks of the treatment. EORTC-QLQ and ASES-tests were performed to assess the quality of life before and after 6 week-treatment. Patients in both groups had similar demographic and clinical characteristics. Even though both treatment modalities resulted in significant decrease in the total arm volume (12.2% decrease in Group II and 14.9% decrease in Group I) (p<0.001), no significant difference (p=0.582) was found between those two groups. Similarly, ASES scores were significantly (p=0.001) improved in both Group I and II without any significant difference between the groups. While emotional functioning, fatigue, and pain scores were significantly improved in both groups, global health status, functional and cognitive functioning scores appeared to be improved only in patients of group I. Different treatment modalities consisting of MLD and compression bandage(complex decongestive therapy) or IPC and SLD appear to be effective in the treatment of LE with similar therapeutic efficacy in patients with breast cancer. However, combination modalities including IPC and SLD may be the preferred choices for their applicability at home.\n",
      "\n",
      "# Arguments:\n",
      "Argument 1=both treatment modalities resulted in significant decrease in the total arm volume (12.2% decrease in Group II and 14.9% decrease in Group I) (p<0.001),\n",
      "Argument 2=no significant difference (p=0.582) was found between those two groups.\n",
      "Argument 3=Similarly, ASES scores were significantly (p=0.001) improved in both Group I and II without any significant difference between the groups.\n",
      "Argument 4=While emotional functioning, fatigue, and pain scores were significantly improved in both groups, global health status, functional and cognitive functioning scores appeared to be improved only in patients of group I.\n",
      "Argument 5=Different treatment modalities consisting of MLD and compression bandage(complex decongestive therapy) or IPC and SLD appear to be effective in the treatment of LE with similar therapeutic efficacy in patients with breast cancer.\n",
      "Argument 6=However, combination modalities including IPC and SLD may be the preferred choices for their applicability at home.\n",
      "\n",
      "# Result:\n",
      "{\"Argument 1\": \"Premise\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Premise\", \"Argument 5\": \"Claim\", \"Argument 6\": \"Claim\"}\n",
      "\n",
      "\n"
     ]
    }
   ],
   "source": [
    "print(sys_msg_l_by_seed_d[33][0]['content'])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 38,
   "id": "6c231a43-6c8e-44e3-a844-28c84091194a",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "100"
      ]
     },
     "execution_count": 38,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "len(task_msg_l)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 39,
   "id": "6421a3d0-4d0d-4344-ad1b-2f79c87a9d1f",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "# Abstract:\n",
      "To determine the safety and efficacy of oral bexarotene (Targretin capsules; Ligand Pharmaceuticals Incorporated, San Diego, Calif). The effects of 2 randomized doses of 6.5 mg/m(2) per day (with crossover for progression) vs 650 mg/m(2) per day (later modified to 300 mg/m(2) per day) were evaluated in an open-label, multicenter, phase 2 and 3 study conducted between February 1997 and November 1998. Eighteen international cutaneous T-cell lymphoma clinics at academic referral centers. Fifty-eight patients with biopsy-proven stage IA through IIA cutaneous T-cell lymphoma that was refractory to (or patients were intolerant of) treatment or had reached at least a 6-month response plateau under at least 2 forms of prior therapy (median of 3.5 prior therapies). Bexarotene (Targretin capsules) administered once daily with meal for 16 weeks or longer. Primary end point classification of overall response rate of complete and partial remissions determined by either the Physician's Global Assessment of Clinical Condition or the objective Composite Assessment of Index Lesion Severity. Body surface area, time to response, duration of disease control, time to disease progression, individual index lesion signs and symptoms, and quality of life parameters were secondary outcomes. Responses (> or = 50% improvement) were seen in 3 (20%) of 15 patients with an initial dose at 6.5 mg/m(2) per day (95% confidence interval [CI], 0%-40%), 15 (54%) of 28 patients at 300 mg/m(2) per day (95% CI, 35%-72%), and 10 (67%) of 15 patients at above 300 mg/m(2) per day (95% CI, 43%-91%). The rate of progressive disease was 47%, 21%, and 13% at the same dose levels, respectively. Eight (73%) of 11 patients crossing over from 6.5 mg/m(2) per day to higher doses subsequently responded. The median duration of response from start of therapy could not be estimated for the 15 patients at 300 mg/m(2) per day owing to low relapse rates in 2 patients (13%); at higher doses it was 516 days. The following drug-related adverse effects were reversible and treatable: hypertriglyceridemia (46 patients [79%]), hypercholesterolemia (28 patients [48%]), headache (27 patients [47%]), central hypothyroidism (23 patients [40%]), asthenia (21 patients [36%]), and leukopenia (16 patients [28%]). No cases of drug-related neutropenic fever, sepsis, or death occurred. Pancreatitis occurred in 3 patients with triglyceride levels higher than 14.69 mmol/L (1300 mg/dL), all of whom were taking 300 mg/m(2) or more of oral bexarotene per day. Bexarotene (Targretin capsules) (the first retinoid X receptor-selective rexinoid) was well tolerated and effective as an oral treatment for 15 (54%) of 28 patients with refractory or persistent early-stage cutaneous T-cell lymphoma at doses of 300 mg/m(2) per day. Hypertriglyceridemia and hypothyroidism require monitoring but are reversible and manageable with concomitant medication.\n",
      "\n",
      "# Arguments:\n",
      "Argument 1=Responses (> or = 50% improvement) were seen in 3 (20%) of 15 patients with an initial dose at 6.5 mg/m(2) per day (95% confidence interval [CI], 0%-40%), 15 (54%) of 28 patients at 300 mg/m(2) per day (95% CI, 35%-72%), and 10 (67%) of 15 patients at above 300 mg/m(2) per day (95% CI, 43%-91%).\n",
      "Argument 2=The rate of progressive disease was 47%, 21%, and 13% at the same dose levels, respectively.\n",
      "Argument 3=Eight (73%) of 11 patients crossing over from 6.5 mg/m(2) per day to higher doses subsequently responded.\n",
      "Argument 4=The median duration of response from start of therapy could not be estimated for the 15 patients at 300 mg/m(2) per day owing to low relapse rates in 2 patients (13%); at higher doses it was 516 days.\n",
      "Argument 5=The following drug-related adverse effects were reversible and treatable: hypertriglyceridemia (46 patients [79%]), hypercholesterolemia (28 patients [48%]), headache (27 patients [47%]), central hypothyroidism (23 patients [40%]), asthenia (21 patients [36%]), and leukopenia (16 patients [28%]).\n",
      "Argument 6=No cases of drug-related neutropenic fever, sepsis, or death occurred.\n",
      "Argument 7=Pancreatitis occurred in 3 patients with triglyceride levels higher than 14.69 mmol/L (1300 mg/dL), all of whom were taking 300 mg/m(2) or more of oral bexarotene per day.\n",
      "Argument 8=Bexarotene (Targretin capsules) (the first retinoid X receptor-selective rexinoid) was well tolerated and effective as an oral treatment for 15 (54%) of 28 patients with refractory or persistent early-stage cutaneous T-cell lymphoma at doses of 300 mg/m(2) per day.\n",
      "Argument 9=Hypertriglyceridemia and hypothyroidism require monitoring but are reversible and manageable with concomitant medication.\n",
      "\n",
      "\n",
      "# Result:\n",
      "\n"
     ]
    }
   ],
   "source": [
    "print(task_msg_l[0]['content'])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 40,
   "id": "c42dfc53-2fa9-4c21-bfa8-284d6442e935",
   "metadata": {},
   "outputs": [],
   "source": [
    "prepared_sys_task_msg_l = []\n",
    "\n",
    "for i in range(len(sys_msg_l_by_seed_d[33])):\n",
    "    prepared_sys_task_msg_l.append([sys_msg_l_by_seed_d[33][i], task_msg_l[i]])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 41,
   "id": "b50a3f80-0c05-48c1-b3d2-ec22966d9cec",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "100"
      ]
     },
     "execution_count": 41,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "len(prepared_sys_task_msg_l)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 42,
   "id": "b2d6ca65-b456-4b45-ace2-2f923701c84f",
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "[{'role': 'system', 'content': '### Task description: You are an expert biomedical assistant that takes 1) an abstract text, 2) the list of all arguments from this abstract text, and must classify all arguments into one of two classes: Claim or Premise. 68.0052% of examples are of type Premise and 31.9948% of type Claim. You must absolutely not generate any text or explanation other than the following JSON format {\"Argument 1\": <predicted class for Argument 1 (str)>, ..., \"Argument n\": <predicted class for Argument n (str)>}\\n\\n### Class definitions: Claim = A claim in the abstract of an RCT is a statement or conclusion about the findings of the study. Premise = A premise in the abstract of an RCT is a statement that provides an evidence or proof for a claim.\\n\\n### Examples:\\n\\n## Example 1\\n# Abstract:\\nThe aim of this study was to compare the 2-year functional performance and quality of life in patients with operable squamous cell carcinoma of the esophagus, who have received either surgery or definitive chemoradiation (CRT). The functional outcomes and quality of life in patients receiving esophagectomy or definitive CRT is uncertain. Data were extracted from the database of a prospective randomized controlled trial that included patients with resectable mid or lower thoracic esophageal cancers. The patients were randomized to either standard esophagectomy or definitive CRT. Quality of life assessments were performed using the EORTC QLQ-C30 and QLQ-OES24 modules. Other functional assessments included pulmonary and eating functions. From July 2000 to December 2004, a total of 81 patients were enrolled into the study. No significant longitudinal changes were detected in the global health status in both groups upon available follow-up. Surgery was associated with worsened physical functioning and fatigue symptoms up to 6 months after treatment (P < 0.001 and P = 0.021, respectively) and these scales improved at 2 years. In terms of pulmonary function, dyspnoic and coughing symptoms were significantly worsened 3 months after surgery (P = 0.024 and P = 0.036, respectively) whereas symptoms in the CRT group progressively deteriorated over time. In terms of pulmonary function, dyspnoic and coughing symptoms were significantly worsened 3 months after surgery (P = 0.024 and P = 0.036, respectively) whereas symptoms in the CRT group progressively deteriorated over time. Concerning the eating function, both groups had improvements in dysphagia but there were frequent need for endoscopic intervention. Neither surgery nor definitive CRT significantly impaired the global health status of patients. Surgery was associated with a short-term negative impact in some aspects of health related quality of life assessments but these changes became insignificant 2 years after treatment. However, CRT was associated with progressive deteriorations in pulmonary function in the longer term.\\n\\n# Arguments:\\nArgument 1=No significant longitudinal changes were detected in the global health status in both groups upon available follow-up.\\nArgument 2=Surgery was associated with worsened physical functioning and fatigue symptoms up to 6 months after treatment (P < 0.001 and P = 0.021, respectively) and these scales improved at 2 years.\\nArgument 3=In terms of pulmonary function, dyspnoic and coughing symptoms were significantly worsened 3 months after surgery (P = 0.024 and P = 0.036, respectively) whereas symptoms in the CRT group progressively deteriorated over time.\\nArgument 4=In terms of pulmonary function, dyspnoic and coughing symptoms were significantly worsened 3 months after surgery (P = 0.024 and P = 0.036, respectively) whereas symptoms in the CRT group progressively deteriorated over time.\\nArgument 5=Concerning the eating function, both groups had improvements in dysphagia but there were frequent need for endoscopic intervention.\\nArgument 6=Neither surgery nor definitive CRT significantly impaired the global health status of patients.\\nArgument 7=Surgery was associated with a short-term negative impact in some aspects of health related quality of life assessments\\nArgument 8=but these changes became insignificant 2 years after treatment.\\nArgument 9=CRT was associated with progressive deteriorations in pulmonary function in the longer term.\\n\\n# Result:\\n{\"Argument 1\": \"Premise\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Premise\", \"Argument 5\": \"Premise\", \"Argument 6\": \"Premise\", \"Argument 7\": \"Claim\", \"Argument 8\": \"Claim\", \"Argument 9\": \"Claim\"}\\n\\n## Example 2\\n# Abstract:\\nTo report 5-year contrast-enhanced magnetic resonance imaging findings of the REST trial recruits who underwent either uterine artery embolization (UAE) or myomectomy. A total of 157 patients were randomized to UAE or surgery (hysterectomy or myomectomy). Ninety-nine patients who had UAE and eight patients who had myomectomy were analyzed. MRI scans at baseline, 6 months, and 5 years were independently interpreted by two radiologists. Dominant fibroid diameter, uterine volume, total fibroid infarction (complete 100 %, almost complete 90-99 %, partial <90 %), and new fibroid formation were the main parameters assessed and related to the need for reintervention. In the UAE group, mean ± standard deviation uterine volume was 670 ± 503, 422 ± 353, and 292 ± 287 mL at baseline, 6 months, and 5 years, respectively. Mean dominant fibroid diameter was 7.6 ± 3.0, 5.8 ± 2.9, and 5 ± 2.9 cm at baseline, 6 months, and 5 years. Fibroid infarction at 6 months was complete in 35 % of women, almost complete in 29 %, and partial in 36 %. Need for reintervention was 19, 10, and 33 % in these groups, respectively (p = 0.123). No myomectomy cases had further intervention. At 5 years, the prevalence of new fibroid was 60 % in the myomectomy group and 7 % in the UAE group (p = 0.008). There is a further significant reduction in both uterine volume and dominant fibroid diameter between 6 months and 5 years after UAE. Complete fibroid infarction does not translate into total freedom from a subsequent reintervention. New fibroid formation is significantly higher after myomectomy.\\n\\n# Arguments:\\nArgument 1=In the UAE group, mean ± standard deviation uterine volume was 670 ± 503, 422 ± 353, and 292 ± 287 mL at baseline, 6 months, and 5 years, respectively.\\nArgument 2=Mean dominant fibroid diameter was 7.6 ± 3.0, 5.8 ± 2.9, and 5 ± 2.9 cm at baseline, 6 months, and 5 years.\\nArgument 3=Fibroid infarction at 6 months was complete in 35 % of women, almost complete in 29 %, and partial in 36 %.\\nArgument 4=Need for reintervention was 19, 10, and 33 % in these groups, respectively (p = 0.123).\\nArgument 5=No myomectomy cases had further intervention.\\nArgument 6=At 5 years, the prevalence of new fibroid was 60 % in the myomectomy group and 7 % in the UAE group (p = 0.008).\\nArgument 7=There is a further significant reduction in both uterine volume and dominant fibroid diameter between 6 months and 5 years after UAE.\\nArgument 8=Complete fibroid infarction does not translate into total freedom from a subsequent reintervention.\\nArgument 9=New fibroid formation is significantly higher after myomectomy.\\n\\n# Result:\\n{\"Argument 1\": \"Premise\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Premise\", \"Argument 5\": \"Premise\", \"Argument 6\": \"Premise\", \"Argument 7\": \"Premise\", \"Argument 8\": \"Claim\", \"Argument 9\": \"Claim\"}\\n\\n## Example 3\\n# Abstract:\\nThis randomized phase II study compared two treatment schedules of gemcitabine in patients with non-small-cell lung cancer (NSCLC) and impaired Karnofsky performance status (KP). Primary objectives were to record changes from baseline KP and to assess symptom palliation. Secondary objectives were overall survival, tumor response, and toxicity. Patients with stage IIIb and IV NSCLC and KP </= 70 were randomly assigned to receive gemcitabine 1,000 mg/m(2) on days 1, 8, and 15 of each 28-day cycle (3w4) or gemcitabine 1,500 mg/m(2) on days 1 and 8 of each 21-day cycle (2w3), both for up to six cycles. KP, toxicity, and SS14 lung cancer specific questions were recorded before each cycle of treatment. Response was evaluated 4 weeks after the last cycle. One hundred seventy-four patients were enrolled. There was significant early attrition due to disease progression; only 61.5% of patients were alive at 2 months. There was a significant improvement in KP from baseline to pre-cycle 3 in both arms, with a trend in favor of the 3w4 regimen for duration and faster onset of improvement. Eight of the 17 quality-of-life (QOL) variables assessed showed an improvement of more than 10% between baseline and the start of the third cycle of treatment. Response rate, survival, and duration were similar in both arms. There was no significant difference between the two schedules examined in terms of improvement in KP or QOL, but there seemed to be a trend in favor of the 3w4 schedule.\\n\\n# Arguments:\\nArgument 1=There was significant early attrition due to disease progression; only 61.5% of patients were alive at 2 months.\\nArgument 2=There was a significant improvement in KP from baseline to pre-cycle 3 in both arms, with a trend in favor of the 3w4 regimen for duration and faster onset of improvement.\\nArgument 3=Eight of the 17 quality-of-life (QOL) variables assessed showed an improvement of more than 10% between baseline and the start of the third cycle of treatment.\\nArgument 4=Response rate, survival, and duration were similar in both arms.\\nArgument 5=There was no significant difference between the two schedules examined in terms of improvement in KP or QOL, but there seemed to be a trend in favor of the 3w4 schedule.\\n\\n# Result:\\n{\"Argument 1\": \"Premise\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Premise\", \"Argument 5\": \"Claim\"}\\n\\n## Example 4\\n# Abstract:\\nThe aim of the present trial was to evaluate the effects of chemotherapy on the quality of life and survival of patients with advanced non-small cell lung cancer (NSCLC) (stage IIIB or IV). In a controlled multicentre trial, patients were randomised to receive supportive care only or supportive care plus chemotherapy. Chemotherapy consisted of intravenous (i.v.) carboplatin 300 mg/m2 on day 1 and etoposide 120 mg/m2 orally on days 1-5 every 4 weeks for a maximum of eight courses. Quality of life was measured at randomisation and prior to each treatment course and at corresponding 4-week intervals in the control arm, using the EORTC QLQ-C30 + LC13 questionnaire. 48 patients were randomised (supportive care 26, chemotherapy 22), being eligible for comparative analyses. Another 102 patients, 97 of which received chemotherapy, were subsequently included in the study on an individual treatment preference basis. Data from these patients were used for confirmative purposes. Patients in the chemotherapy group reported better overall physical functioning and symptom control compared with the supportive care group. Group differences were smaller within the psychosocial domain, although trends were seen in favour of the chemotherapy group. No significant differences were seen in favour of the supportive care group, except for hair loss. Median survival times were 29 weeks in the chemotherapy group versus 11 weeks in the supportive care group, and 1-year survival rates were 28% versus 8%. Quality of life and survival outcomes were similar in the randomised and non-randomised patients receiving chemotherapy. No treatment-related deaths occurred. In conclusion, treatment with carboplatin and etoposide can improve both the quality of life and the survival of patients with advanced NSCLC.\\n\\n# Arguments:\\nArgument 1=Patients in the chemotherapy group reported better overall physical functioning and symptom control compared with the supportive care group.\\nArgument 2=Group differences were smaller within the psychosocial domain,\\nArgument 3=although trends were seen in favour of the chemotherapy group.\\nArgument 4=No significant differences were seen in favour of the supportive care group,\\nArgument 5=except for hair loss.\\nArgument 6=Median survival times were 29 weeks in the chemotherapy group versus 11 weeks in the supportive care group, and 1-year survival rates were 28% versus 8%.\\nArgument 7=Quality of life and survival outcomes were similar in the randomised and non-randomised patients receiving chemotherapy.\\nArgument 8=No treatment-related deaths occurred.\\nArgument 9=In conclusion, treatment with carboplatin and etoposide can improve both the quality of life and the survival of patients with advanced NSCLC.\\n\\n# Result:\\n{\"Argument 1\": \"Premise\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Premise\", \"Argument 5\": \"Premise\", \"Argument 6\": \"Premise\", \"Argument 7\": \"Premise\", \"Argument 8\": \"Premise\", \"Argument 9\": \"Claim\"}\\n\\n## Example 5\\n# Abstract:\\nThe aim of this prospective controlled study was to assess the efficacy of two different combination treatment modalities of lymphedema (LE). Manual lymphatic drainage (MLD) and compression bandage combination (complex decongestive therapy) have been compared with intermittent pneumatic compression (IPC) plus self-lymphatic drainage (SLD). Both MLD with compression bandage (complex decongestive therapy) group (Group I, n=15) and IPC with SLD group (Group II, n=15) received treatment for LE 3 days in a week and every other day for 6 weeks. Arm circumferences were measured before and the 1st, 3rd, and 6th weeks of the treatment. EORTC-QLQ and ASES-tests were performed to assess the quality of life before and after 6 week-treatment. Patients in both groups had similar demographic and clinical characteristics. Even though both treatment modalities resulted in significant decrease in the total arm volume (12.2% decrease in Group II and 14.9% decrease in Group I) (p<0.001), no significant difference (p=0.582) was found between those two groups. Similarly, ASES scores were significantly (p=0.001) improved in both Group I and II without any significant difference between the groups. While emotional functioning, fatigue, and pain scores were significantly improved in both groups, global health status, functional and cognitive functioning scores appeared to be improved only in patients of group I. Different treatment modalities consisting of MLD and compression bandage(complex decongestive therapy) or IPC and SLD appear to be effective in the treatment of LE with similar therapeutic efficacy in patients with breast cancer. However, combination modalities including IPC and SLD may be the preferred choices for their applicability at home.\\n\\n# Arguments:\\nArgument 1=both treatment modalities resulted in significant decrease in the total arm volume (12.2% decrease in Group II and 14.9% decrease in Group I) (p<0.001),\\nArgument 2=no significant difference (p=0.582) was found between those two groups.\\nArgument 3=Similarly, ASES scores were significantly (p=0.001) improved in both Group I and II without any significant difference between the groups.\\nArgument 4=While emotional functioning, fatigue, and pain scores were significantly improved in both groups, global health status, functional and cognitive functioning scores appeared to be improved only in patients of group I.\\nArgument 5=Different treatment modalities consisting of MLD and compression bandage(complex decongestive therapy) or IPC and SLD appear to be effective in the treatment of LE with similar therapeutic efficacy in patients with breast cancer.\\nArgument 6=However, combination modalities including IPC and SLD may be the preferred choices for their applicability at home.\\n\\n# Result:\\n{\"Argument 1\": \"Premise\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Premise\", \"Argument 5\": \"Claim\", \"Argument 6\": \"Claim\"}\\n\\n'}, {'role': 'user', 'content': \"# Abstract:\\nTo determine the safety and efficacy of oral bexarotene (Targretin capsules; Ligand Pharmaceuticals Incorporated, San Diego, Calif). The effects of 2 randomized doses of 6.5 mg/m(2) per day (with crossover for progression) vs 650 mg/m(2) per day (later modified to 300 mg/m(2) per day) were evaluated in an open-label, multicenter, phase 2 and 3 study conducted between February 1997 and November 1998. Eighteen international cutaneous T-cell lymphoma clinics at academic referral centers. Fifty-eight patients with biopsy-proven stage IA through IIA cutaneous T-cell lymphoma that was refractory to (or patients were intolerant of) treatment or had reached at least a 6-month response plateau under at least 2 forms of prior therapy (median of 3.5 prior therapies). Bexarotene (Targretin capsules) administered once daily with meal for 16 weeks or longer. Primary end point classification of overall response rate of complete and partial remissions determined by either the Physician's Global Assessment of Clinical Condition or the objective Composite Assessment of Index Lesion Severity. Body surface area, time to response, duration of disease control, time to disease progression, individual index lesion signs and symptoms, and quality of life parameters were secondary outcomes. Responses (> or = 50% improvement) were seen in 3 (20%) of 15 patients with an initial dose at 6.5 mg/m(2) per day (95% confidence interval [CI], 0%-40%), 15 (54%) of 28 patients at 300 mg/m(2) per day (95% CI, 35%-72%), and 10 (67%) of 15 patients at above 300 mg/m(2) per day (95% CI, 43%-91%). The rate of progressive disease was 47%, 21%, and 13% at the same dose levels, respectively. Eight (73%) of 11 patients crossing over from 6.5 mg/m(2) per day to higher doses subsequently responded. The median duration of response from start of therapy could not be estimated for the 15 patients at 300 mg/m(2) per day owing to low relapse rates in 2 patients (13%); at higher doses it was 516 days. The following drug-related adverse effects were reversible and treatable: hypertriglyceridemia (46 patients [79%]), hypercholesterolemia (28 patients [48%]), headache (27 patients [47%]), central hypothyroidism (23 patients [40%]), asthenia (21 patients [36%]), and leukopenia (16 patients [28%]). No cases of drug-related neutropenic fever, sepsis, or death occurred. Pancreatitis occurred in 3 patients with triglyceride levels higher than 14.69 mmol/L (1300 mg/dL), all of whom were taking 300 mg/m(2) or more of oral bexarotene per day. Bexarotene (Targretin capsules) (the first retinoid X receptor-selective rexinoid) was well tolerated and effective as an oral treatment for 15 (54%) of 28 patients with refractory or persistent early-stage cutaneous T-cell lymphoma at doses of 300 mg/m(2) per day. Hypertriglyceridemia and hypothyroidism require monitoring but are reversible and manageable with concomitant medication.\\n\\n# Arguments:\\nArgument 1=Responses (> or = 50% improvement) were seen in 3 (20%) of 15 patients with an initial dose at 6.5 mg/m(2) per day (95% confidence interval [CI], 0%-40%), 15 (54%) of 28 patients at 300 mg/m(2) per day (95% CI, 35%-72%), and 10 (67%) of 15 patients at above 300 mg/m(2) per day (95% CI, 43%-91%).\\nArgument 2=The rate of progressive disease was 47%, 21%, and 13% at the same dose levels, respectively.\\nArgument 3=Eight (73%) of 11 patients crossing over from 6.5 mg/m(2) per day to higher doses subsequently responded.\\nArgument 4=The median duration of response from start of therapy could not be estimated for the 15 patients at 300 mg/m(2) per day owing to low relapse rates in 2 patients (13%); at higher doses it was 516 days.\\nArgument 5=The following drug-related adverse effects were reversible and treatable: hypertriglyceridemia (46 patients [79%]), hypercholesterolemia (28 patients [48%]), headache (27 patients [47%]), central hypothyroidism (23 patients [40%]), asthenia (21 patients [36%]), and leukopenia (16 patients [28%]).\\nArgument 6=No cases of drug-related neutropenic fever, sepsis, or death occurred.\\nArgument 7=Pancreatitis occurred in 3 patients with triglyceride levels higher than 14.69 mmol/L (1300 mg/dL), all of whom were taking 300 mg/m(2) or more of oral bexarotene per day.\\nArgument 8=Bexarotene (Targretin capsules) (the first retinoid X receptor-selective rexinoid) was well tolerated and effective as an oral treatment for 15 (54%) of 28 patients with refractory or persistent early-stage cutaneous T-cell lymphoma at doses of 300 mg/m(2) per day.\\nArgument 9=Hypertriglyceridemia and hypothyroidism require monitoring but are reversible and manageable with concomitant medication.\\n\\n\\n# Result:\\n\"}]\n"
     ]
    }
   ],
   "source": [
    "print(prepared_sys_task_msg_l[0])"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "7ecf1b59-b3ce-4cd4-a6bc-9888a4600aac",
   "metadata": {},
   "source": [
    "## Generate Predictions"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 43,
   "id": "58ec6f7d-3838-4be8-b4b8-71b58f146b75",
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "  0%|          | 0/100 [00:00<?, ?it/s]Asking to truncate to max_length but no maximum length is provided and the model has no predefined maximum length. Default to no truncation.\n",
      "The attention mask is not set and cannot be inferred from input because pad token is same as eos token.As a consequence, you may observe unexpected behavior. Please pass your input's `attention_mask` to obtain reliable results.\n",
      "100%|██████████| 100/100 [14:13<00:00,  8.53s/it]\n"
     ]
    }
   ],
   "source": [
    "outputs_l = []\n",
    "\n",
    "for i in tqdm(range(len(prepared_sys_task_msg_l))):\n",
    "\n",
    "    messages = prepared_sys_task_msg_l[i]\n",
    "\n",
    "    input_ids = inference_tokenizer.apply_chat_template(\n",
    "    messages,\n",
    "    add_generation_prompt=True,\n",
    "    tokenize=True,\n",
    "    padding=True,\n",
    "    truncation=True,\n",
    "    return_tensors=\"pt\"\n",
    ").to(generation_model.device)\n",
    "\n",
    "    outputs = generation_model.generate(\n",
    "    input_ids = input_ids,\n",
    "    max_new_tokens=1024,\n",
    "    pad_token_id=inference_tokenizer.eos_token_id,\n",
    "    eos_token_id=terminators,\n",
    "    do_sample=True,\n",
    "    temperature=0.1,\n",
    "    top_p=0.9,\n",
    "    )\n",
    "    # inference_tokenizer.decode(outputs[0][input_ids.shape[-1]:], skip_special_tokens=True)\n",
    "    outputs_l.append(inference_tokenizer.decode(outputs[0][input_ids.shape[-1]:], skip_special_tokens=True))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 44,
   "id": "c6b68d0e-88c9-43d4-ae30-b97f4a849756",
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "['{\"Argument 1\": \"Premise\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Premise\", \"Argument 5\": \"Premise\", \"Argument 6\": \"Premise\", \"Argument 7\": \"Premise\", \"Argument 8\": \"Claim\", \"Argument 9\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Claim\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Premise\", \"Argument 5\": \"Premise\", \"Argument 6\": \"Premise\", \"Argument 7\": \"Claim\", \"Argument 8\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Premise\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Premise\", \"Argument 5\": \"Premise\", \"Argument 6\": \"Premise\", \"Argument 7\": \"Claim\", \"Argument 8\": \"Premise\", \"Argument 9\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Claim\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Premise\", \"Argument 5\": \"Premise\", \"Argument 6\": \"Claim\", \"Argument 7\": \"Premise\"}',\n",
       " '{\"Argument 1\": \"Claim\", \"Argument 2\": \"Claim\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Premise\", \"Argument 5\": \"Premise\", \"Argument 6\": \"Claim\", \"Argument 7\": \"Claim\", \"Argument 8\": \"Premise\", \"Argument 9\": \"Premise\", \"Argument 10\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Premise\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Premise\", \"Argument 5\": \"Premise\", \"Argument 6\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Premise\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Premise\", \"Argument 5\": \"Claim\", \"Argument 6\": \"Claim\", \"Argument 7\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Premise\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Premise\", \"Argument 5\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Premise\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Premise\", \"Argument 5\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Premise\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Premise\", \"Argument 5\": \"Premise\", \"Argument 6\": \"Claim\", \"Argument 7\": \"Claim\", \"Argument 8\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Claim\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Premise\", \"Argument 5\": \"Premise\", \"Argument 6\": \"Premise\", \"Argument 7\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Premise\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Claim\", \"Argument 4\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Premise\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Premise\", \"Argument 5\": \"Premise\", \"Argument 6\": \"Premise\", \"Argument 7\": \"Claim\", \"Argument 8\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Claim\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Premise\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Claim\", \"Argument 4\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Premise\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Claim\", \"Argument 5\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Premise\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Premise\", \"Argument 5\": \"Claim\", \"Argument 6\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Premise\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Premise\", \"Argument 5\": \"Premise\", \"Argument 6\": \"Premise\", \"Argument 7\": \"Claim\", \"Argument 8\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Claim\", \"Argument 2\": \"Claim\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Premise\", \"Argument 5\": \"Premise\", \"Argument 6\": \"Premise\", \"Argument 7\": \"Premise\", \"Argument 8\": \"Claim\", \"Argument 9\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Premise\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Premise\", \"Argument 5\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Premise\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Claim\", \"Argument 5\": \"Premise\", \"Argument 6\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Premise\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Premise\", \"Argument 5\": \"Claim\", \"Argument 6\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Premise\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Premise\", \"Argument 5\": \"Premise\", \"Argument 6\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Premise\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Premise\", \"Argument 5\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Premise\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Claim\", \"Argument 5\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Claim\", \"Argument 2\": \"Claim\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Premise\", \"Argument 5\": \"Premise\", \"Argument 6\": \"Premise\", \"Argument 7\": \"Premise\", \"Argument 8\": \"Claim\", \"Argument 9\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Premise\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Premise\", \"Argument 5\": \"Claim\", \"Argument 6\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Premise\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Premise\", \"Argument 5\": \"Premise\", \"Argument 6\": \"Premise\", \"Argument 7\": \"Claim\", \"Argument 8\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Premise\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Premise\", \"Argument 5\": \"Premise\", \"Argument 6\": \"Premise\", \"Argument 7\": \"Claim\", \"Argument 8\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Premise\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Premise\", \"Argument 5\": \"Premise\", \"Argument 6\": \"Premise\", \"Argument 7\": \"Premise\", \"Argument 8\": \"Premise\", \"Argument 9\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Claim\", \"Argument 2\": \"Claim\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Premise\", \"Argument 5\": \"Premise\", \"Argument 6\": \"Premise\", \"Argument 7\": \"Claim\", \"Argument 8\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Claim\", \"Argument 2\": \"Claim\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Premise\", \"Argument 5\": \"Premise\", \"Argument 6\": \"Premise\", \"Argument 7\": \"Premise\", \"Argument 8\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Claim\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Premise\", \"Argument 5\": \"Premise\", \"Argument 6\": \"Premise\", \"Argument 7\": \"Claim\", \"Argument 8\": \"Claim\", \"Argument 9\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Premise\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Claim\", \"Argument 2\": \"Claim\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Premise\", \"Argument 5\": \"Premise\", \"Argument 6\": \"Premise\", \"Argument 7\": \"Premise\", \"Argument 8\": \"Claim\", \"Argument 9\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Premise\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Premise\", \"Argument 5\": \"Premise\", \"Argument 6\": \"Premise\", \"Argument 7\": \"Premise\", \"Argument 8\": \"Premise\", \"Argument 9\": \"Claim\", \"Argument 10\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Premise\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Premise\", \"Argument 5\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Premise\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Premise\", \"Argument 5\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Premise\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Premise\", \"Argument 5\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Premise\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Premise\", \"Argument 5\": \"Claim\", \"Argument 6\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Premise\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Premise\", \"Argument 5\": \"Premise\", \"Argument 6\": \"Premise\", \"Argument 7\": \"Claim\", \"Argument 8\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Premise\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Premise\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Claim\", \"Argument 4\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Premise\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Claim\", \"Argument 5\": \"Premise\", \"Argument 6\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Premise\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Premise\", \"Argument 5\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Premise\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Premise\", \"Argument 5\": \"Premise\", \"Argument 6\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Premise\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Premise\", \"Argument 5\": \"Premise\", \"Argument 6\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Premise\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Claim\", \"Argument 5\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Premise\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Premise\", \"Argument 5\": \"Premise\", \"Argument 6\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Premise\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Premise\", \"Argument 5\": \"Premise\", \"Argument 6\": \"Premise\", \"Argument 7\": \"Premise\", \"Argument 8\": \"Claim\", \"Argument 9\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Premise\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Claim\", \"Argument 5\": \"Premise\", \"Argument 6\": \"Premise\", \"Argument 7\": \"Claim\", \"Argument 8\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Premise\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Premise\", \"Argument 5\": \"Premise\", \"Argument 6\": \"Premise\", \"Argument 7\": \"Premise\", \"Argument 8\": \"Claim\", \"Argument 9\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Premise\", \"Argument 2\": \"Claim\", \"Argument 3\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Premise\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Premise\", \"Argument 5\": \"Premise\", \"Argument 6\": \"Premise\", \"Argument 7\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Premise\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Premise\", \"Argument 5\": \"Claim\", \"Argument 6\": \"Premise\", \"Argument 7\": \"Premise\", \"Argument 8\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Premise\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Premise\", \"Argument 5\": \"Premise\", \"Argument 6\": \"Premise\", \"Argument 7\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Premise\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Premise\", \"Argument 5\": \"Claim\", \"Argument 6\": \"Claim\", \"Argument 7\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Claim\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Claim\", \"Argument 5\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Claim\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Premise\", \"Argument 5\": \"Premise\", \"Argument 6\": \"Claim\", \"Argument 7\": \"Claim\", \"Argument 8\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Premise\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Premise\", \"Argument 5\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Premise\", \"Argument 2\": \"Claim\", \"Argument 3\": \"Claim\", \"Argument 4\": \"Premise\", \"Argument 5\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Premise\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Premise\", \"Argument 5\": \"Premise\", \"Argument 6\": \"Premise\", \"Argument 7\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Premise\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Claim\", \"Argument 5\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Premise\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Premise\", \"Argument 5\": \"Premise\", \"Argument 6\": \"Claim\", \"Argument 7\": \"Claim\", \"Argument 8\": \"Claim\", \"Argument 9\": \"Claim\", \"Argument 10\": \"Claim\", \"Argument 11\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Claim\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Premise\", \"Argument 5\": \"Claim\", \"Argument 6\": \"Premise\", \"Argument 7\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Claim\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Premise\", \"Argument 5\": \"Premise\", \"Argument 6\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Premise\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Claim\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Premise\", \"Argument 5\": \"Premise\", \"Argument 6\": \"Claim\", \"Argument 7\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Premise\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Premise\", \"Argument 5\": \"Premise\", \"Argument 6\": \"Premise\", \"Argument 7\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Premise\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Premise\", \"Argument 5\": \"Premise\", \"Argument 6\": \"Premise\", \"Argument 7\": \"Premise\", \"Argument 8\": \"Claim\", \"Argument 9\": \"Claim\", \"Argument 10\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Premise\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Premise\", \"Argument 5\": \"Premise\", \"Argument 6\": \"Premise\", \"Argument 7\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Premise\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Premise\", \"Argument 5\": \"Premise\", \"Argument 6\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Premise\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Premise\", \"Argument 5\": \"Premise\", \"Argument 6\": \"Premise\", \"Argument 7\": \"Claim\", \"Argument 8\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Premise\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Premise\", \"Argument 5\": \"Premise\", \"Argument 6\": \"Premise\", \"Argument 7\": \"Premise\", \"Argument 8\": \"Premise\", \"Argument 9\": \"Claim\", \"Argument 10\": \"Premise\", \"Argument 11\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Premise\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Premise\", \"Argument 5\": \"Premise\", \"Argument 6\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Premise\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Premise\", \"Argument 5\": \"Premise\", \"Argument 6\": \"Premise\", \"Argument 7\": \"Premise\", \"Argument 8\": \"Claim\", \"Argument 9\": \"Claim\", \"Argument 10\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Premise\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Premise\", \"Argument 5\": \"Premise\", \"Argument 6\": \"Premise\", \"Argument 7\": \"Premise\", \"Argument 8\": \"Premise\", \"Argument 9\": \"Claim\", \"Argument 10\": \"Claim\", \"Argument 11\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Claim\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Premise\", \"Argument 5\": \"Premise\", \"Argument 6\": \"Claim\", \"Argument 7\": \"Claim\", \"Argument 8\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Premise\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Premise\", \"Argument 5\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Premise\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Premise\", \"Argument 5\": \"Premise\", \"Argument 6\": \"Claim\", \"Argument 7\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Claim\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Premise\", \"Argument 5\": \"Premise\", \"Argument 6\": \"Premise\", \"Argument 7\": \"Premise\", \"Argument 8\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Premise\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Premise\", \"Argument 5\": \"Premise\", \"Argument 6\": \"Premise\", \"Argument 7\": \"Premise\", \"Argument 8\": \"Premise\", \"Argument 9\": \"Claim\", \"Argument 10\": \"Claim\", \"Argument 11\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Claim\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Premise\", \"Argument 5\": \"Claim\", \"Argument 6\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Claim\", \"Argument 2\": \"Claim\", \"Argument 3\": \"Claim\", \"Argument 4\": \"Premise\", \"Argument 5\": \"Premise\", \"Argument 6\": \"Premise\", \"Argument 7\": \"Claim\", \"Argument 8\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Claim\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Premise\", \"Argument 5\": \"Premise\", \"Argument 6\": \"Premise\", \"Argument 7\": \"Premise\", \"Argument 8\": \"Premise\", \"Argument 9\": \"Claim\", \"Argument 10\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Premise\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Premise\", \"Argument 5\": \"Premise\", \"Argument 6\": \"Claim\", \"Argument 7\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Premise\", \"Argument 2\": \"Claim\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Premise\", \"Argument 5\": \"Premise\", \"Argument 6\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Premise\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Premise\", \"Argument 5\": \"Premise\", \"Argument 6\": \"Premise\", \"Argument 7\": \"Premise\", \"Argument 8\": \"Claim\", \"Argument 9\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Claim\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Premise\", \"Argument 5\": \"Premise\", \"Argument 6\": \"Premise\", \"Argument 7\": \"Premise\", \"Argument 8\": \"Claim\", \"Argument 9\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Claim\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Premise\", \"Argument 5\": \"Premise\", \"Argument 6\": \"Premise\", \"Argument 7\": \"Premise\", \"Argument 8\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Premise\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Premise\", \"Argument 5\": \"Claim\", \"Argument 6\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Claim\", \"Argument 2\": \"Claim\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Premise\", \"Argument 5\": \"Premise\", \"Argument 6\": \"Premise\", \"Argument 7\": \"Premise\", \"Argument 8\": \"Claim\", \"Argument 9\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Premise\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Claim\", \"Argument 5\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Premise\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Premise\", \"Argument 5\": \"Claim\", \"Argument 6\": \"Claim\", \"Argument 7\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Claim\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Premise\", \"Argument 5\": \"Premise\", \"Argument 6\": \"Claim\", \"Argument 7\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Premise\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Premise\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Premise\", \"Argument 5\": \"Claim\", \"Argument 6\": \"Claim\", \"Argument 7\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Premise\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Premise\", \"Argument 5\": \"Premise\", \"Argument 6\": \"Claim\", \"Argument 7\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Premise\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Premise\", \"Argument 5\": \"Premise\", \"Argument 6\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Premise\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Premise\", \"Argument 5\": \"Premise\", \"Argument 6\": \"Premise\", \"Argument 7\": \"Claim\", \"Argument 8\": \"Claim\"}']"
      ]
     },
     "execution_count": 44,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "outputs_l"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 45,
   "id": "d29a8016-c734-4531-91db-f5dfaec7f120",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "100"
      ]
     },
     "execution_count": 45,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "len(outputs_l)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 46,
   "id": "fd51f0c3-4067-4c10-8fde-111f8d2b95d0",
   "metadata": {},
   "outputs": [],
   "source": [
    "preds_l = [list(ast.literal_eval(output).values()) for output in outputs_l]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 47,
   "id": "b8fb4f97-ae13-4448-9e2a-c5d7bbdc5f01",
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[['Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Claim',\n",
       "  'Claim'],\n",
       " ['Claim',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Claim',\n",
       "  'Claim'],\n",
       " ['Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Claim',\n",
       "  'Premise',\n",
       "  'Claim'],\n",
       " ['Claim', 'Premise', 'Premise', 'Premise', 'Premise', 'Claim', 'Premise'],\n",
       " ['Claim',\n",
       "  'Claim',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Claim',\n",
       "  'Claim',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Premise', 'Premise', 'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Premise', 'Claim', 'Claim', 'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Premise', 'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Premise', 'Claim'],\n",
       " ['Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Claim',\n",
       "  'Claim',\n",
       "  'Claim'],\n",
       " ['Claim', 'Premise', 'Premise', 'Premise', 'Premise', 'Premise', 'Claim'],\n",
       " ['Premise', 'Premise', 'Claim', 'Claim'],\n",
       " ['Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Claim',\n",
       "  'Claim'],\n",
       " ['Claim', 'Premise', 'Claim'],\n",
       " ['Premise', 'Premise', 'Claim', 'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Claim', 'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Premise', 'Claim', 'Claim'],\n",
       " ['Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Claim',\n",
       "  'Claim'],\n",
       " ['Claim',\n",
       "  'Claim',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Claim',\n",
       "  'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Premise', 'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Claim', 'Premise', 'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Premise', 'Claim', 'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Premise', 'Premise', 'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Premise', 'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Claim', 'Claim'],\n",
       " ['Claim',\n",
       "  'Claim',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Claim',\n",
       "  'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Premise', 'Claim', 'Claim'],\n",
       " ['Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Claim',\n",
       "  'Claim'],\n",
       " ['Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Claim',\n",
       "  'Claim'],\n",
       " ['Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Claim'],\n",
       " ['Claim',\n",
       "  'Claim',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Claim',\n",
       "  'Claim'],\n",
       " ['Claim',\n",
       "  'Claim',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Claim'],\n",
       " ['Claim',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Claim',\n",
       "  'Claim',\n",
       "  'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Claim'],\n",
       " ['Claim',\n",
       "  'Claim',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Claim',\n",
       "  'Claim'],\n",
       " ['Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Claim',\n",
       "  'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Premise', 'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Premise', 'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Premise', 'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Premise', 'Claim', 'Claim'],\n",
       " ['Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Claim',\n",
       "  'Claim'],\n",
       " ['Premise', 'Premise', 'Claim'],\n",
       " ['Premise', 'Premise', 'Claim', 'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Claim', 'Premise', 'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Premise', 'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Premise', 'Premise', 'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Premise', 'Premise', 'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Claim', 'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Premise', 'Premise', 'Claim'],\n",
       " ['Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Claim',\n",
       "  'Claim'],\n",
       " ['Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Claim',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Claim',\n",
       "  'Claim'],\n",
       " ['Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Claim',\n",
       "  'Claim'],\n",
       " ['Premise', 'Claim', 'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Premise', 'Premise', 'Premise', 'Claim'],\n",
       " ['Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Claim',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Premise', 'Premise', 'Premise', 'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Premise', 'Claim', 'Claim', 'Claim'],\n",
       " ['Claim', 'Premise', 'Premise', 'Claim', 'Claim'],\n",
       " ['Claim',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Claim',\n",
       "  'Claim',\n",
       "  'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Premise', 'Claim'],\n",
       " ['Premise', 'Claim', 'Claim', 'Premise', 'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Premise', 'Premise', 'Premise', 'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Claim', 'Claim'],\n",
       " ['Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Claim',\n",
       "  'Claim',\n",
       "  'Claim',\n",
       "  'Claim',\n",
       "  'Claim',\n",
       "  'Claim'],\n",
       " ['Claim', 'Premise', 'Premise', 'Premise', 'Claim', 'Premise', 'Claim'],\n",
       " ['Claim', 'Premise', 'Premise', 'Premise', 'Premise', 'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Claim'],\n",
       " ['Claim', 'Premise', 'Premise', 'Premise', 'Premise', 'Claim', 'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Premise', 'Premise', 'Premise', 'Claim'],\n",
       " ['Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Claim',\n",
       "  'Claim',\n",
       "  'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Premise', 'Premise', 'Premise', 'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Premise', 'Premise', 'Claim'],\n",
       " ['Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Claim',\n",
       "  'Claim'],\n",
       " ['Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Claim',\n",
       "  'Premise',\n",
       "  'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Premise', 'Premise', 'Claim'],\n",
       " ['Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Claim',\n",
       "  'Claim',\n",
       "  'Claim'],\n",
       " ['Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Claim',\n",
       "  'Claim',\n",
       "  'Claim'],\n",
       " ['Claim',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Claim',\n",
       "  'Claim',\n",
       "  'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Premise', 'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Premise', 'Premise', 'Claim', 'Claim'],\n",
       " ['Claim',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Claim'],\n",
       " ['Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Claim',\n",
       "  'Claim',\n",
       "  'Claim'],\n",
       " ['Claim', 'Premise', 'Premise', 'Premise', 'Claim', 'Claim'],\n",
       " ['Claim',\n",
       "  'Claim',\n",
       "  'Claim',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Claim',\n",
       "  'Claim'],\n",
       " ['Claim',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Claim',\n",
       "  'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Premise', 'Premise', 'Claim', 'Claim'],\n",
       " ['Premise', 'Claim', 'Premise', 'Premise', 'Premise', 'Claim'],\n",
       " ['Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Claim',\n",
       "  'Claim'],\n",
       " ['Claim',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Claim',\n",
       "  'Claim'],\n",
       " ['Claim',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Premise', 'Claim', 'Claim'],\n",
       " ['Claim',\n",
       "  'Claim',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Claim',\n",
       "  'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Claim', 'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Premise', 'Claim', 'Claim', 'Claim'],\n",
       " ['Claim', 'Premise', 'Premise', 'Premise', 'Premise', 'Claim', 'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Premise', 'Claim', 'Claim', 'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Premise', 'Premise', 'Claim', 'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Premise', 'Premise', 'Claim'],\n",
       " ['Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Claim',\n",
       "  'Claim']]"
      ]
     },
     "execution_count": 47,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "preds_l"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 48,
   "id": "d47ed2e4-a396-4a78-910c-ee7280032cfc",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "100"
      ]
     },
     "execution_count": 48,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "len(preds_l)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 49,
   "id": "88a7a3fa-3d00-46c0-a584-2256fa41e9bf",
   "metadata": {},
   "outputs": [],
   "source": [
    "grouped_df = neo_test_df[neo_test_df.aty != 'none'].groupby('doc_id', sort=False)['aty'].apply(list).reset_index()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 50,
   "id": "344bdc0e-6ce9-4ae4-963c-829ae14cb072",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>doc_id</th>\n",
       "      <th>aty</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>11346336</td>\n",
       "      <td>[Premise, Premise, Premise, Premise, Premise, ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>10210927</td>\n",
       "      <td>[Claim, Premise, Premise, Premise, Premise, Pr...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>12748244</td>\n",
       "      <td>[Premise, Premise, Premise, Premise, Premise, ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>24028441</td>\n",
       "      <td>[Claim, Premise, Premise, Premise, Premise, Cl...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>12004217</td>\n",
       "      <td>[Claim, Premise, Premise, Premise, Premise, Pr...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>95</th>\n",
       "      <td>20734132</td>\n",
       "      <td>[Premise, Premise, Premise, Claim]</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>96</th>\n",
       "      <td>23793805</td>\n",
       "      <td>[Premise, Premise, Premise, Premise, Claim, Cl...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>97</th>\n",
       "      <td>23816967</td>\n",
       "      <td>[Premise, Premise, Premise, Premise, Premise, ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>98</th>\n",
       "      <td>20680680</td>\n",
       "      <td>[Premise, Premise, Premise, Premise, Claim, Cl...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>99</th>\n",
       "      <td>20821047</td>\n",
       "      <td>[Premise, Premise, Premise, Premise, Premise, ...</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>100 rows × 2 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "      doc_id                                                aty\n",
       "0   11346336  [Premise, Premise, Premise, Premise, Premise, ...\n",
       "1   10210927  [Claim, Premise, Premise, Premise, Premise, Pr...\n",
       "2   12748244  [Premise, Premise, Premise, Premise, Premise, ...\n",
       "3   24028441  [Claim, Premise, Premise, Premise, Premise, Cl...\n",
       "4   12004217  [Claim, Premise, Premise, Premise, Premise, Pr...\n",
       "..       ...                                                ...\n",
       "95  20734132                 [Premise, Premise, Premise, Claim]\n",
       "96  23793805  [Premise, Premise, Premise, Premise, Claim, Cl...\n",
       "97  23816967  [Premise, Premise, Premise, Premise, Premise, ...\n",
       "98  20680680  [Premise, Premise, Premise, Premise, Claim, Cl...\n",
       "99  20821047  [Premise, Premise, Premise, Premise, Premise, ...\n",
       "\n",
       "[100 rows x 2 columns]"
      ]
     },
     "execution_count": 50,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "grouped_df"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 51,
   "id": "c3470e01-e402-4bf0-9009-5919e88bb48d",
   "metadata": {},
   "outputs": [],
   "source": [
    "grounds_l = grouped_df.aty.tolist()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 52,
   "id": "5bcbf083-a167-468f-b839-f5a34e41cd27",
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[['Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Claim',\n",
       "  'Claim'],\n",
       " ['Claim',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Claim',\n",
       "  'Claim'],\n",
       " ['Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Claim',\n",
       "  'Claim',\n",
       "  'Claim'],\n",
       " ['Claim', 'Premise', 'Premise', 'Premise', 'Premise', 'Claim', 'Claim'],\n",
       " ['Claim',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Claim',\n",
       "  'Claim',\n",
       "  'Premise',\n",
       "  'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Premise', 'Premise', 'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Premise', 'Claim', 'Claim', 'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Claim', 'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Claim', 'Claim'],\n",
       " ['Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Claim',\n",
       "  'Claim'],\n",
       " ['Claim', 'Premise', 'Premise', 'Premise', 'Premise', 'Claim', 'Claim'],\n",
       " ['Premise', 'Premise', 'Claim', 'Claim'],\n",
       " ['Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Claim',\n",
       "  'Claim',\n",
       "  'Premise'],\n",
       " ['Claim', 'Premise', 'Claim'],\n",
       " ['Premise', 'Premise', 'Claim', 'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Claim', 'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Premise', 'Claim', 'Claim'],\n",
       " ['Premise',\n",
       "  'Claim',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Claim',\n",
       "  'Claim'],\n",
       " ['Claim',\n",
       "  'Claim',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Claim',\n",
       "  'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Claim', 'Claim'],\n",
       " ['Premise', 'Premise', 'Claim', 'Claim', 'Claim', 'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Premise', 'Claim', 'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Premise', 'Premise', 'Claim'],\n",
       " ['Claim', 'Premise', 'Premise', 'Premise', 'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Claim', 'Claim'],\n",
       " ['Claim',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Claim',\n",
       "  'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Premise', 'Premise', 'Claim'],\n",
       " ['Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Claim',\n",
       "  'Premise',\n",
       "  'Claim',\n",
       "  'Claim'],\n",
       " ['Claim',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Claim',\n",
       "  'Claim',\n",
       "  'Claim',\n",
       "  'Claim'],\n",
       " ['Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Claim',\n",
       "  'Claim',\n",
       "  'Claim'],\n",
       " ['Claim',\n",
       "  'Claim',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Claim',\n",
       "  'Claim'],\n",
       " ['Claim',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Claim'],\n",
       " ['Claim',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Claim',\n",
       "  'Claim',\n",
       "  'Claim',\n",
       "  'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Claim'],\n",
       " ['Claim',\n",
       "  'Claim',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Claim',\n",
       "  'Claim'],\n",
       " ['Claim',\n",
       "  'Claim',\n",
       "  'Claim',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Claim',\n",
       "  'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Premise', 'Claim'],\n",
       " ['Premise', 'Premise', 'Claim', 'Premise', 'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Premise', 'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Premise', 'Claim', 'Claim'],\n",
       " ['Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Claim',\n",
       "  'Claim'],\n",
       " ['Premise', 'Premise', 'Claim'],\n",
       " ['Premise', 'Premise', 'Claim', 'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Claim', 'Premise', 'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Premise', 'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Premise', 'Claim', 'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Premise', 'Premise', 'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Claim', 'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Premise', 'Premise', 'Claim'],\n",
       " ['Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Claim',\n",
       "  'Claim'],\n",
       " ['Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Claim',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Claim',\n",
       "  'Claim'],\n",
       " ['Claim',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Claim',\n",
       "  'Claim'],\n",
       " ['Premise', 'Claim', 'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Premise', 'Premise', 'Claim', 'Claim'],\n",
       " ['Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Claim',\n",
       "  'Claim',\n",
       "  'Claim',\n",
       "  'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Premise', 'Premise', 'Claim', 'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Premise', 'Claim', 'Claim', 'Claim'],\n",
       " ['Claim', 'Premise', 'Premise', 'Claim', 'Claim'],\n",
       " ['Claim',\n",
       "  'Claim',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Claim',\n",
       "  'Claim',\n",
       "  'Premise',\n",
       "  'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Premise', 'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Claim', 'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Premise', 'Premise', 'Claim', 'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Premise', 'Claim'],\n",
       " ['Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Claim',\n",
       "  'Claim',\n",
       "  'Claim',\n",
       "  'Claim',\n",
       "  'Claim',\n",
       "  'Claim'],\n",
       " ['Claim', 'Premise', 'Premise', 'Premise', 'Premise', 'Claim', 'Claim'],\n",
       " ['Claim', 'Premise', 'Premise', 'Premise', 'Claim', 'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Claim'],\n",
       " ['Claim', 'Premise', 'Premise', 'Premise', 'Premise', 'Claim', 'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Premise', 'Premise', 'Claim', 'Claim'],\n",
       " ['Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Claim',\n",
       "  'Claim',\n",
       "  'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Premise', 'Premise', 'Premise', 'Claim'],\n",
       " ['Claim', 'Premise', 'Premise', 'Premise', 'Premise', 'Claim'],\n",
       " ['Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Claim',\n",
       "  'Claim'],\n",
       " ['Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Claim',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Claim',\n",
       "  'Claim',\n",
       "  'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Premise', 'Premise', 'Claim'],\n",
       " ['Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Claim',\n",
       "  'Claim',\n",
       "  'Claim',\n",
       "  'Claim',\n",
       "  'Claim'],\n",
       " ['Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Claim',\n",
       "  'Claim',\n",
       "  'Premise'],\n",
       " ['Claim',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Claim',\n",
       "  'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Premise', 'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Premise', 'Premise', 'Claim', 'Claim'],\n",
       " ['Claim',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Claim'],\n",
       " ['Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Claim',\n",
       "  'Premise',\n",
       "  'Claim',\n",
       "  'Claim',\n",
       "  'Claim'],\n",
       " ['Claim', 'Premise', 'Premise', 'Premise', 'Claim', 'Premise'],\n",
       " ['Claim',\n",
       "  'Claim',\n",
       "  'Claim',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Claim',\n",
       "  'Claim'],\n",
       " ['Claim',\n",
       "  'Claim',\n",
       "  'Claim',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Claim',\n",
       "  'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Premise', 'Claim', 'Claim', 'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Premise', 'Premise', 'Claim'],\n",
       " ['Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Claim',\n",
       "  'Premise',\n",
       "  'Claim'],\n",
       " ['Claim',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Claim',\n",
       "  'Claim'],\n",
       " ['Claim',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Premise', 'Claim', 'Claim'],\n",
       " ['Claim',\n",
       "  'Claim',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Claim',\n",
       "  'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Claim', 'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Premise', 'Claim', 'Claim', 'Claim'],\n",
       " ['Claim', 'Premise', 'Premise', 'Premise', 'Premise', 'Claim', 'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Premise', 'Claim', 'Claim', 'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Premise', 'Premise', 'Claim', 'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Premise', 'Claim', 'Claim'],\n",
       " ['Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Claim',\n",
       "  'Claim']]"
      ]
     },
     "execution_count": 52,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "grounds_l"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 53,
   "id": "d914eda2-15ac-4be9-9012-d47342851aa7",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "100"
      ]
     },
     "execution_count": 53,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "len(grounds_l)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 54,
   "id": "c78f7c4a-b6ad-4f4d-befb-e31acd74aad2",
   "metadata": {},
   "outputs": [],
   "source": [
    "preds_l = [item for sublist in preds_l for item in sublist]\n",
    "grounds_l = [item for sublist in grounds_l for item in sublist]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 55,
   "id": "773d50ad-e38a-4a8b-9d90-7f9c9806a55f",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "(691, 691)"
      ]
     },
     "execution_count": 55,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "len(preds_l), len(grounds_l)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 56,
   "id": "51e97e12-0813-4f01-a9b8-ea46790fe3e8",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "              precision    recall  f1-score   support\n",
      "\n",
      "       Claim     0.9220    0.8105    0.8627       248\n",
      "     Premise     0.9006    0.9616    0.9301       443\n",
      "\n",
      "    accuracy                         0.9074       691\n",
      "   macro avg     0.9113    0.8861    0.8964       691\n",
      "weighted avg     0.9083    0.9074    0.9059       691\n",
      "\n"
     ]
    }
   ],
   "source": [
    "print(classification_report(grounds_l, preds_l, digits=4))"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "eb131369-6667-4972-b076-e636faa514c4",
   "metadata": {},
   "source": [
    "### gla_test"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 57,
   "id": "7eb00080-c196-4aed-a2a5-ef321fa22da6",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "CPU times: user 25 s, sys: 37.8 ms, total: 25 s\n",
      "Wall time: 25.1 s\n"
     ]
    }
   ],
   "source": [
    "%%time\n",
    "\n",
    "#experiment_df = df[df.split == 'TEST']\n",
    "# experiment_df = neo_test_df\n",
    "experiment_df = gla_test_df\n",
    "# experiment_df = mix_test_df\n",
    "\n",
    "target_l = []\n",
    "\n",
    "# Pre-prepare all examples from each document\n",
    "title_l = []\n",
    "essay_l = []\n",
    "example_l = []\n",
    "buffer_l = []\n",
    "label_l = []\n",
    "for e in experiment_df.iterrows():\n",
    "\n",
    "    if e[1].span_pos == 1:\n",
    "    #if e[0] == 0:\n",
    "        essay_l.append(e[1].abstract_text)\n",
    "        title_l.append(e[1].abstract_title)\n",
    "    \n",
    "    if e[1].span_pos == 1 and len(buffer_l) > 0:\n",
    "    #if e[0] == 0 and len(buffer_l) > 0:\n",
    "        example_l.append(buffer_l)\n",
    "        target_l.append(label_l)\n",
    "        buffer_l = []\n",
    "        label_l = []\n",
    "    if e[1].aty != 'none':\n",
    "        buffer_l.append(e[1].text)\n",
    "        label_l.append(e[1].aty)\n",
    "\n",
    "# Flush the buffers\n",
    "example_l.append(buffer_l)\n",
    "target_l.append(label_l)\n",
    "\n",
    "\n",
    "sys_msg_l_by_seed_d = {}\n",
    "task_msg_l = []\n",
    "\n",
    "for i in range(len(example_l)):\n",
    "\n",
    "    # Prepare numbered list of ACs in this example\n",
    "    other_acs_prompt = ''\n",
    "    for j, s in enumerate(example_l[i]):\n",
    "        # other_acs_prompt += f'Argument {j + 1}={s}\\n'\n",
    "        other_acs_prompt += f'Argument {j + 1}={s}\\n'\n",
    "\n",
    "    for seed in [33, 34, 35, 36, 37]:\n",
    "        sys_msg = {\"role\":\"system\", \"content\": \"### Task description: You are an expert biomedical assistant that takes 1) an abstract text, 2) the list of all arguments from this abstract text, and must classify all arguments into one of two classes: Claim or Premise. \" + proportion_desc + \" You must absolutely not generate any text or explanation other than the following JSON format {\\\"Argument 1\\\": <predicted class for Argument 1 (str)>, ..., \\\"Argument n\\\": <predicted class for Argument n (str)>}\\n\\n### Class definitions:\" + \" Claim = \" + claim_fulldesc + \" Premise = \" + premise_fulldesc + \"\\n\\n### Examples:\\n\\n\" + prepare_similar_example_prompts(title_l[i], experiment_df, k=5, seed=seed)}  # Sample by similar title\n",
    "\n",
    "        try:\n",
    "            sys_msg_l_by_seed_d[seed].append(sys_msg)\n",
    "        except KeyError:\n",
    "            sys_msg_l_by_seed_d[seed] = [sys_msg]\n",
    "\n",
    "    task_msg = {\"role\":\"user\", \"content\": f\"# Abstract:\\n{essay_l[i]}\\n\\n# Arguments:\\n{other_acs_prompt}\\n\\n# Result:\\n\"}\n",
    "    \n",
    "    task_msg_l.append(task_msg)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 58,
   "id": "d181518c-41c1-4f5b-8a03-3d4839f173f3",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "100"
      ]
     },
     "execution_count": 58,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "len(sys_msg_l_by_seed_d[33])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 59,
   "id": "0a8f750d-bf0e-4b37-9d37-6fcd27a1ae8f",
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "### Task description: You are an expert biomedical assistant that takes 1) an abstract text, 2) the list of all arguments from this abstract text, and must classify all arguments into one of two classes: Claim or Premise. 68.0052% of examples are of type Premise and 31.9948% of type Claim. You must absolutely not generate any text or explanation other than the following JSON format {\"Argument 1\": <predicted class for Argument 1 (str)>, ..., \"Argument n\": <predicted class for Argument n (str)>}\n",
      "\n",
      "### Class definitions: Claim = A claim in the abstract of an RCT is a statement or conclusion about the findings of the study. Premise = A premise in the abstract of an RCT is a statement that provides an evidence or proof for a claim.\n",
      "\n",
      "### Examples:\n",
      "\n",
      "## Example 1\n",
      "# Abstract:\n",
      "Exercise for Health was a randomized, controlled trial designed to evaluate two modes of delivering (face-to-face [FtF] and over-the-telephone [Tel]) an 8-month translational exercise intervention, commencing 6-weeks post-breast cancer surgery (PS). Outcomes included quality of life (QoL), function (fitness and upper body) and treatment-related side effects (fatigue, lymphoedema, body mass index, menopausal symptoms, anxiety, depression and pain). Generalised estimating equation modelling determined time (baseline [5 weeks PS], mid-intervention [6 months PS], post-intervention [12 months PS]), group (FtF, Tel, Usual Care [UC]) and time-by-group effects. 194 women representative of the breast cancer population were randomised to the FtF (n = 67), Tel (n = 67) and UC (n = 60) groups. There were significant (p < 0.05) interaction effects on QoL, fitness and fatigue with differences being observed between the treatment groups and the UC group. Trends observed for the treatment groups were similar. The treatment groups reported improved QoL, fitness and fatigue over time and changes observed between baseline and post-intervention were clinically relevant. In contrast, the UC group experienced no change, or worsening QoL, fitness and fatigue, mid-intervention. Although improvements in the UC group occurred by 12-months post-surgery, the change did not meet the clinically relevant threshold. There were no differences in other treatment-related side effects between groups. This translational intervention trial, delivered either FtF or Tel, supports exercise as a form of adjuvant breast cancer therapy that can prevent declines in fitness and function during treatment and optimise recovery post-treatment.\n",
      "\n",
      "# Arguments:\n",
      "Argument 1=There were significant (p < 0.05) interaction effects on QoL, fitness and fatigue with differences being observed between the treatment groups and the UC group.\n",
      "Argument 2=Trends observed for the treatment groups were similar.\n",
      "Argument 3=The treatment groups reported improved QoL, fitness and fatigue over time and changes observed between baseline and post-intervention were clinically relevant.\n",
      "Argument 4=In contrast, the UC group experienced no change, or worsening QoL, fitness and fatigue, mid-intervention.\n",
      "Argument 5=Although improvements in the UC group occurred by 12-months post-surgery,\n",
      "Argument 6=the change did not meet the clinically relevant threshold.\n",
      "Argument 7=There were no differences in other treatment-related side effects between groups.\n",
      "Argument 8=This translational intervention trial, delivered either FtF or Tel, supports exercise as a form of adjuvant breast cancer therapy that can prevent declines in fitness and function during treatment and optimise recovery post-treatment.\n",
      "\n",
      "# Result:\n",
      "{\"Argument 1\": \"Premise\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Premise\", \"Argument 5\": \"Premise\", \"Argument 6\": \"Premise\", \"Argument 7\": \"Premise\", \"Argument 8\": \"Claim\"}\n",
      "\n",
      "## Example 2\n",
      "# Abstract:\n",
      "This study aimed to compare quality of life (QOL), functional outcome, body image, and cosmesis after hand-assisted laparoscopic (LRP) versus open restorative proctocolectomy (ORP). The potential long-term advantages of LRP over ORP remain to be determined. The most likely advantage of LRP is the superior cosmetic result. It is, however, unclear whether the size and location of incisions affect body image and QOL. In a previously conducted randomized trial comparing LRP with ORP, 60 patients were prospectively evaluated. The primary end points were body image and cosmesis. The secondary end points were morbidity, QOL, and functional outcome. A body image questionnaire was used to evaluate body image and cosmesis. The Short Form-36 Health Survey and the Gastrointestinal Quality of Life Inventory were used to assess QOL. Body image and QOL also were assessed preoperatively. A total of 53 patients completed the QOL and functional outcome questionnaires. There were no differences in functional outcome, morbidity, or QOL between LRP and ORP. At a median of 2.7 years after surgery, 46 patients returned the questionnaires regarding body image, cosmesis, and morbidity. The body image and cosmesis scores of female patients were significantly higher in the LRP group than in the ORP group (body image, 17.4 vs 14.9; cosmesis, 19.1 vs 13.0, respectively). The female patients in the ORP group had significantly lower body image scores than the male patients (14.9 vs 18.3). This study is the first to show that ORP has a negative impact on body image and cosmesis as compared with LRP. Functional outcome, QOL, and morbidity are similar for the two approaches. The advantages of a long-lasting improved body image and cosmesis for this relatively young patient population may compensate for the longer operating times and higher costs, particularly for women.\n",
      "\n",
      "# Arguments:\n",
      "Argument 1=There were no differences in functional outcome, morbidity, or QOL between LRP and ORP.\n",
      "Argument 2=The body image and cosmesis scores of female patients were significantly higher in the LRP group than in the ORP group (body image, 17.4 vs 14.9; cosmesis, 19.1 vs 13.0, respectively).\n",
      "Argument 3=The female patients in the ORP group had significantly lower body image scores than the male patients (14.9 vs 18.3).\n",
      "Argument 4=This study is the first to show that ORP has a negative impact on body image and cosmesis as compared with LRP.\n",
      "Argument 5=Functional outcome, QOL, and morbidity are similar for the two approaches.\n",
      "Argument 6=The advantages of a long-lasting improved body image and cosmesis for this relatively young patient population may compensate for the longer operating times and higher costs, particularly for women.\n",
      "\n",
      "# Result:\n",
      "{\"Argument 1\": \"Premise\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Claim\", \"Argument 5\": \"Claim\", \"Argument 6\": \"Claim\"}\n",
      "\n",
      "## Example 3\n",
      "# Abstract:\n",
      "We investigated the role of tamoxifen and radiotherapy (RT) for the prevention and treatment of gynecomastia and breast pain during adjuvant bicalutamide monotherapy after radical prostatectomy (RP) in patients with prostate cancer. Also, we evaluated their effects on patient hormonal status, quality of life (QOL), sexual function and prostate specific antigen relapse-free survival. This was a multicenter prospective trial. From January 2002 to February 2004, 102 patients who had undergone RP for localized or locally advanced prostate cancer were recruited and randomized into 3 groups, namely group 1-those receiving only 150 mg bicalutamide as adjuvant hormonal therapy, group 2-those receiving bicalutamide and 10 mg tamoxifen, and group 3-those receiving bicalutamide and RT. Patients in group 1 in whom gynecomastia or breast pain developed were subsequently randomized to receive tamoxifen or RT soon after symptoms started. Gynecomastia, breast pain, prostate specific antigen, QOL, sexual function and hormonal levels were assessed. Minimum followup was 12 months. Of group 1 patients 67% had gynecomastia compared with 8% in group 2 and 34% in group 3. Breast pain was more frequent in group 1 than in groups 2 and 3 (58% vs 7% and 30%, respectively). Differences were significant between groups 1 and 2 (OR 0.12 p <0.001), and groups 1 and 3 (OR 0.52 p < 0.01). In patients in group 1 who had gynecomastia or breast pain a significant decrease in symptoms was achieved in those receiving tamoxifen (p <0.05). Treatments were well tolerated in the 3 groups. No differences in QOL between groups 2 and 3 were found. At a median followup of 26 months we observed 12 biochemical relapses. Gynecomastia and breast pain induced by bicalutamide monotherapy after RP can be prevented and treated. Tamoxifen has been shown to be more effective and safe than RT in this setting. QOL and sexual function are not negatively influenced by these 2 treatment options .\n",
      "\n",
      "# Arguments:\n",
      "Argument 1=Of group 1 patients 67% had gynecomastia compared with 8% in group 2 and 34% in group 3.\n",
      "Argument 2=Breast pain was more frequent in group 1 than in groups 2 and 3 (58% vs 7% and 30%, respectively).\n",
      "Argument 3=Differences were significant between groups 1 and 2 (OR 0.12 p <0.001), and groups 1 and 3 (OR 0.52 p < 0.01).\n",
      "Argument 4=In patients in group 1 who had gynecomastia or breast pain a significant decrease in symptoms was achieved in those receiving tamoxifen (p <0.05).\n",
      "Argument 5=Treatments were well tolerated in the 3 groups.\n",
      "Argument 6=No differences in QOL between groups 2 and 3 were found.\n",
      "Argument 7=At a median followup of 26 months we observed 12 biochemical relapses.\n",
      "Argument 8=Gynecomastia and breast pain induced by bicalutamide monotherapy after RP can be prevented and treated.\n",
      "Argument 9=Tamoxifen has been shown to be more effective and safe than RT in this setting.\n",
      "Argument 10=QOL and sexual function are not negatively influenced by these 2 treatment options\n",
      "\n",
      "# Result:\n",
      "{\"Argument 1\": \"Premise\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Premise\", \"Argument 5\": \"Premise\", \"Argument 6\": \"Premise\", \"Argument 7\": \"Premise\", \"Argument 8\": \"Claim\", \"Argument 9\": \"Claim\", \"Argument 10\": \"Claim\"}\n",
      "\n",
      "## Example 4\n",
      "# Abstract:\n",
      "To assess the safety, tolerability and efficacy of abatacept in patients with rheumatoid arthritis (RA) who had failed anti-tumour necrosis factor (TNF) therapy and were switched to abatacept directly or after completing washout. In this international, 6-month, open-label trial, patients had active RA, an inadequate response to anti-TNF therapy for 3 months or longer and a disease activity score in 28 joints (DAS28 (C-reactive protein; CRP) of 5.1 or greater. \"Washout\" patients discontinued anti-TNF therapy 2 months or longer pre-screening; \"direct-switch\" patients began abatacept ( approximately 10 mg/kg) at their next scheduled anti-TNF therapy dose. 1046 patients were treated (449 washout, 597 direct-switch; baseline characteristics were similar between groups). At 6 months, adverse events (AE; 78.0% vs 79.2%), serious AE (11.1% vs 9.9%) and discontinuations due to AE (3.8% vs 4.0%) and serious AE (2.0% vs 1.3%) were comparable in washout versus direct-switch patients. At 6 months, adverse events (AE; 78.0% vs 79.2%), serious AE (11.1% vs 9.9%) and discontinuations due to AE (3.8% vs 4.0%) and serious AE (2.0% vs 1.3%) were comparable in washout versus direct-switch patients. There were no opportunistic infections. At 6 months, in washout versus direct-switch patients, similar clinically meaningful improvements were seen in DAS28 (CRP) (> or =1.2 unit improvement, 59.5% vs 53.6%, respectively; low disease activity state, 22.5% vs 22.3%; DAS28-defined remission, 12.0% vs 13.7%), physical function (health assessment questionnaire disability index > or =0.22 improvement; 46.3% vs 47.1%) and health-related quality of life (mean change in short-form 36 scores: physical component summary, 5.5 vs 6.1; mental component summary, 4.8 vs 5.4). At 6 months, in washout versus direct-switch patients, similar clinically meaningful improvements were seen in DAS28 (CRP) (> or =1.2 unit improvement, 59.5% vs 53.6%, respectively; low disease activity state, 22.5% vs 22.3%; DAS28-defined remission, 12.0% vs 13.7%), physical function (health assessment questionnaire disability index > or =0.22 improvement; 46.3% vs 47.1%) and health-related quality of life (mean change in short-form 36 scores: physical component summary, 5.5 vs 6.1; mental component summary, 4.8 vs 5.4). Abatacept demonstrated acceptable safety and tolerability and clinically meaningful efficacy over 6 months in patients with inadequate response to anti-TNF therapy. Results were comparable with or without a washout, supporting direct switching from anti-TNF therapy to abatacept as an option in clinical practice.\n",
      "\n",
      "# Arguments:\n",
      "Argument 1=At 6 months, adverse events (AE; 78.0% vs 79.2%), serious AE (11.1% vs 9.9%) and discontinuations due to AE (3.8% vs 4.0%) and serious AE (2.0% vs 1.3%) were comparable in washout versus direct-switch patients.\n",
      "Argument 2=At 6 months, adverse events (AE; 78.0% vs 79.2%), serious AE (11.1% vs 9.9%) and discontinuations due to AE (3.8% vs 4.0%) and serious AE (2.0% vs 1.3%) were comparable in washout versus direct-switch patients.\n",
      "Argument 3=There were no opportunistic infections.\n",
      "Argument 4=At 6 months, in washout versus direct-switch patients, similar clinically meaningful improvements were seen in DAS28 (CRP) (> or =1.2 unit improvement, 59.5% vs 53.6%, respectively; low disease activity state, 22.5% vs 22.3%; DAS28-defined remission, 12.0% vs 13.7%), physical function (health assessment questionnaire disability index > or =0.22 improvement; 46.3% vs 47.1%) and health-related quality of life (mean change in short-form 36 scores: physical component summary, 5.5 vs 6.1; mental component summary, 4.8 vs 5.4).\n",
      "Argument 5=At 6 months, in washout versus direct-switch patients, similar clinically meaningful improvements were seen in DAS28 (CRP) (> or =1.2 unit improvement, 59.5% vs 53.6%, respectively; low disease activity state, 22.5% vs 22.3%; DAS28-defined remission, 12.0% vs 13.7%), physical function (health assessment questionnaire disability index > or =0.22 improvement; 46.3% vs 47.1%) and health-related quality of life (mean change in short-form 36 scores: physical component summary, 5.5 vs 6.1; mental component summary, 4.8 vs 5.4).\n",
      "Argument 6=Abatacept demonstrated acceptable safety and tolerability and clinically meaningful efficacy over 6 months in patients with inadequate response to anti-TNF therapy.\n",
      "Argument 7=Results were comparable with or without a washout, supporting direct switching from anti-TNF therapy to abatacept as an option in clinical practice.\n",
      "\n",
      "# Result:\n",
      "{\"Argument 1\": \"Premise\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Premise\", \"Argument 5\": \"Premise\", \"Argument 6\": \"Claim\", \"Argument 7\": \"Claim\"}\n",
      "\n",
      "## Example 5\n",
      "# Abstract:\n",
      "The goal of this study was to assess the impact of neuronavigation on the cytoreductive treatment of solitary contrast-enhancing intracerebral tumors and outcomes of this treatment in cases in which neuronavigation was preoperatively judged to be redundant. The authors conducted a prospective randomized study in which 45 patients, each harboring a solitary contrast-enhancing intracerebral tumor, were randomized for surgery with or without neuronavigation. Peri- and postoperative parameters under investigation included the following: duration of the procedure; surgeon's estimate of the usefulness of neuronavigation; quantification of the extent of resection, determined using magnetic resonance imaging; and the postoperative course, as evaluated by neurological examinations, the patient's quality-of-life self-assessment, application of the Barthel index and the Karnofsky Performance Scale score, and the patient's time of death. The mean amount of residual tumor tissue was 28.9% for standard surgery (SS) and 13.8% for surgery involving neuronavigation (SN). The corresponding mean amounts of residual contrast-enhancing tumor tissue were 29.2 and 24.4%, respectively. These differences were not significant. Gross-total removal (GTR) was achieved in five patients who underwent SS and in three who underwent SN. Median survival was significantly shorter in the SN group (5.6 months compared with 9 months, unadjusted hazard ratio = 1.6); however, this difference may be attributable to the coincidental early death of three patients in the SN group. No discernible important effect on the patients' 3-month postoperative course was identified. There is no rationale for the routine use of neuronavigation to improve the extent of tumor resection and prognosis in patients harboring a solitary enhancing intracerebral lesion when neuronavigation is not already deemed advantageous because of the size or location of the lesion.\n",
      "\n",
      "# Arguments:\n",
      "Argument 1=The mean amount of residual tumor tissue was 28.9% for standard surgery (SS) and 13.8% for surgery involving neuronavigation (SN).\n",
      "Argument 2=The corresponding mean amounts of residual contrast-enhancing tumor tissue were 29.2 and 24.4%, respectively.\n",
      "Argument 3=These differences were not significant.\n",
      "Argument 4=Gross-total removal (GTR) was achieved in five patients who underwent SS and in three who underwent SN.\n",
      "Argument 5=Median survival was significantly shorter in the SN group (5.6 months compared with 9 months, unadjusted hazard ratio = 1.6);\n",
      "Argument 6=however, this difference may be attributable to the coincidental early death of three patients in the SN group.\n",
      "Argument 7=No discernible important effect on the patients' 3-month postoperative course was identified.\n",
      "Argument 8=There is no rationale for the routine use of neuronavigation to improve the extent of tumor resection and prognosis in patients harboring a solitary enhancing intracerebral lesion when neuronavigation is not already deemed advantageous because of the size or location of the lesion.\n",
      "\n",
      "# Result:\n",
      "{\"Argument 1\": \"Premise\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Premise\", \"Argument 5\": \"Premise\", \"Argument 6\": \"Premise\", \"Argument 7\": \"Premise\", \"Argument 8\": \"Claim\"}\n",
      "\n",
      "\n"
     ]
    }
   ],
   "source": [
    "print(sys_msg_l_by_seed_d[33][0]['content'])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 60,
   "id": "79ac3eea-b4f9-4670-8aea-2f9ba04eb35a",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "100"
      ]
     },
     "execution_count": 60,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "len(task_msg_l)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 61,
   "id": "d292eb10-9ac4-485f-8d84-a1e6f0001696",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "# Abstract:\n",
      "To compare the longitudinal effects of treatment on intraocular pressure (IOP) and visual field performance in Japanese normal-tension glaucoma (NTG) between latanoprost and timolol.\n",
      "This is an open-label, randomized, study. A total of 62 NTG patients were prospectively, consecutively enrolled. All study subjects were randomly assigned to 0.005% latanoprost instillation once daily in the morning or 0.5% timolol instillation twice daily for a prospective 3-year follow-up, and underwent a routine ocular examination every month. Automated perimetry was performed every 6 months using Humphrey field analysers. Stereophotographs of optic discs were also obtained every 6 months. Percentage of IOP reduction or the magnitude of IOP reduction showed no intergroup differences either at any time point (13-15%). In the visual field, the estimated rate of change in the MD value (dB/year) was -0.34+/-0.17 (SE) for the latanoprost group, and -0.10+/-0.18 (SE) for the timolol group. The estimated rate of change in MD showed no significant difference from zero in both groups, and there were no statistical intergroup differences. No changes in the optic nerve head topography in the vertical cup-to-disc ratio and rim area measured by image-analysis techniques were observed in either group. There were no patients who dropped out due to the side effects of treatment regimens. Both latanoprost and timolol single treatments reduced IOP by 13-15% at their trough effects for 3 years in Japanese NTG patients  both showed similar effects on visual field performance.\n",
      "\n",
      "# Arguments:\n",
      "Argument 1=Percentage of IOP reduction or the magnitude of IOP reduction showed no intergroup differences either at any time point (13-15%).\n",
      "Argument 2=In the visual field, the estimated rate of change in the MD value (dB/year) was -0.34+/-0.17 (SE) for the latanoprost group, and -0.10+/-0.18 (SE) for the timolol group.\n",
      "Argument 3=The estimated rate of change in MD showed no significant difference from zero in both groups, and there were no statistical intergroup differences.\n",
      "Argument 4=No changes in the optic nerve head topography in the vertical cup-to-disc ratio and rim area measured by image-analysis techniques were observed in either group.\n",
      "Argument 5=There were no patients who dropped out due to the side effects of treatment regimens.\n",
      "Argument 6=Both latanoprost and timolol single treatments reduced IOP by 13-15% at their trough effects for 3 years in Japanese NTG patients\n",
      "Argument 7=both showed similar effects on visual field performance.\n",
      "\n",
      "\n",
      "# Result:\n",
      "\n"
     ]
    }
   ],
   "source": [
    "print(task_msg_l[0]['content'])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 62,
   "id": "25b6fc7c-14de-43b8-9470-44157a8d739f",
   "metadata": {},
   "outputs": [],
   "source": [
    "prepared_sys_task_msg_l = []\n",
    "\n",
    "for i in range(len(sys_msg_l_by_seed_d[33])):\n",
    "    prepared_sys_task_msg_l.append([sys_msg_l_by_seed_d[33][i], task_msg_l[i]])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 63,
   "id": "d031baa1-3e2c-4d93-9117-b24764fc619a",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "100"
      ]
     },
     "execution_count": 63,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "len(prepared_sys_task_msg_l)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 64,
   "id": "3c681d2e-5c71-491f-b5f3-abacfd225f65",
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "[{'role': 'system', 'content': '### Task description: You are an expert biomedical assistant that takes 1) an abstract text, 2) the list of all arguments from this abstract text, and must classify all arguments into one of two classes: Claim or Premise. 68.0052% of examples are of type Premise and 31.9948% of type Claim. You must absolutely not generate any text or explanation other than the following JSON format {\"Argument 1\": <predicted class for Argument 1 (str)>, ..., \"Argument n\": <predicted class for Argument n (str)>}\\n\\n### Class definitions: Claim = A claim in the abstract of an RCT is a statement or conclusion about the findings of the study. Premise = A premise in the abstract of an RCT is a statement that provides an evidence or proof for a claim.\\n\\n### Examples:\\n\\n## Example 1\\n# Abstract:\\nExercise for Health was a randomized, controlled trial designed to evaluate two modes of delivering (face-to-face [FtF] and over-the-telephone [Tel]) an 8-month translational exercise intervention, commencing 6-weeks post-breast cancer surgery (PS). Outcomes included quality of life (QoL), function (fitness and upper body) and treatment-related side effects (fatigue, lymphoedema, body mass index, menopausal symptoms, anxiety, depression and pain). Generalised estimating equation modelling determined time (baseline [5 weeks PS], mid-intervention [6 months PS], post-intervention [12 months PS]), group (FtF, Tel, Usual Care [UC]) and time-by-group effects. 194 women representative of the breast cancer population were randomised to the FtF (n = 67), Tel (n = 67) and UC (n = 60) groups. There were significant (p < 0.05) interaction effects on QoL, fitness and fatigue with differences being observed between the treatment groups and the UC group. Trends observed for the treatment groups were similar. The treatment groups reported improved QoL, fitness and fatigue over time and changes observed between baseline and post-intervention were clinically relevant. In contrast, the UC group experienced no change, or worsening QoL, fitness and fatigue, mid-intervention. Although improvements in the UC group occurred by 12-months post-surgery, the change did not meet the clinically relevant threshold. There were no differences in other treatment-related side effects between groups. This translational intervention trial, delivered either FtF or Tel, supports exercise as a form of adjuvant breast cancer therapy that can prevent declines in fitness and function during treatment and optimise recovery post-treatment.\\n\\n# Arguments:\\nArgument 1=There were significant (p < 0.05) interaction effects on QoL, fitness and fatigue with differences being observed between the treatment groups and the UC group.\\nArgument 2=Trends observed for the treatment groups were similar.\\nArgument 3=The treatment groups reported improved QoL, fitness and fatigue over time and changes observed between baseline and post-intervention were clinically relevant.\\nArgument 4=In contrast, the UC group experienced no change, or worsening QoL, fitness and fatigue, mid-intervention.\\nArgument 5=Although improvements in the UC group occurred by 12-months post-surgery,\\nArgument 6=the change did not meet the clinically relevant threshold.\\nArgument 7=There were no differences in other treatment-related side effects between groups.\\nArgument 8=This translational intervention trial, delivered either FtF or Tel, supports exercise as a form of adjuvant breast cancer therapy that can prevent declines in fitness and function during treatment and optimise recovery post-treatment.\\n\\n# Result:\\n{\"Argument 1\": \"Premise\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Premise\", \"Argument 5\": \"Premise\", \"Argument 6\": \"Premise\", \"Argument 7\": \"Premise\", \"Argument 8\": \"Claim\"}\\n\\n## Example 2\\n# Abstract:\\nThis study aimed to compare quality of life (QOL), functional outcome, body image, and cosmesis after hand-assisted laparoscopic (LRP) versus open restorative proctocolectomy (ORP). The potential long-term advantages of LRP over ORP remain to be determined. The most likely advantage of LRP is the superior cosmetic result. It is, however, unclear whether the size and location of incisions affect body image and QOL. In a previously conducted randomized trial comparing LRP with ORP, 60 patients were prospectively evaluated. The primary end points were body image and cosmesis. The secondary end points were morbidity, QOL, and functional outcome. A body image questionnaire was used to evaluate body image and cosmesis. The Short Form-36 Health Survey and the Gastrointestinal Quality of Life Inventory were used to assess QOL. Body image and QOL also were assessed preoperatively. A total of 53 patients completed the QOL and functional outcome questionnaires. There were no differences in functional outcome, morbidity, or QOL between LRP and ORP. At a median of 2.7 years after surgery, 46 patients returned the questionnaires regarding body image, cosmesis, and morbidity. The body image and cosmesis scores of female patients were significantly higher in the LRP group than in the ORP group (body image, 17.4 vs 14.9; cosmesis, 19.1 vs 13.0, respectively). The female patients in the ORP group had significantly lower body image scores than the male patients (14.9 vs 18.3). This study is the first to show that ORP has a negative impact on body image and cosmesis as compared with LRP. Functional outcome, QOL, and morbidity are similar for the two approaches. The advantages of a long-lasting improved body image and cosmesis for this relatively young patient population may compensate for the longer operating times and higher costs, particularly for women.\\n\\n# Arguments:\\nArgument 1=There were no differences in functional outcome, morbidity, or QOL between LRP and ORP.\\nArgument 2=The body image and cosmesis scores of female patients were significantly higher in the LRP group than in the ORP group (body image, 17.4 vs 14.9; cosmesis, 19.1 vs 13.0, respectively).\\nArgument 3=The female patients in the ORP group had significantly lower body image scores than the male patients (14.9 vs 18.3).\\nArgument 4=This study is the first to show that ORP has a negative impact on body image and cosmesis as compared with LRP.\\nArgument 5=Functional outcome, QOL, and morbidity are similar for the two approaches.\\nArgument 6=The advantages of a long-lasting improved body image and cosmesis for this relatively young patient population may compensate for the longer operating times and higher costs, particularly for women.\\n\\n# Result:\\n{\"Argument 1\": \"Premise\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Claim\", \"Argument 5\": \"Claim\", \"Argument 6\": \"Claim\"}\\n\\n## Example 3\\n# Abstract:\\nWe investigated the role of tamoxifen and radiotherapy (RT) for the prevention and treatment of gynecomastia and breast pain during adjuvant bicalutamide monotherapy after radical prostatectomy (RP) in patients with prostate cancer. Also, we evaluated their effects on patient hormonal status, quality of life (QOL), sexual function and prostate specific antigen relapse-free survival. This was a multicenter prospective trial. From January 2002 to February 2004, 102 patients who had undergone RP for localized or locally advanced prostate cancer were recruited and randomized into 3 groups, namely group 1-those receiving only 150 mg bicalutamide as adjuvant hormonal therapy, group 2-those receiving bicalutamide and 10 mg tamoxifen, and group 3-those receiving bicalutamide and RT. Patients in group 1 in whom gynecomastia or breast pain developed were subsequently randomized to receive tamoxifen or RT soon after symptoms started. Gynecomastia, breast pain, prostate specific antigen, QOL, sexual function and hormonal levels were assessed. Minimum followup was 12 months. Of group 1 patients 67% had gynecomastia compared with 8% in group 2 and 34% in group 3. Breast pain was more frequent in group 1 than in groups 2 and 3 (58% vs 7% and 30%, respectively). Differences were significant between groups 1 and 2 (OR 0.12 p <0.001), and groups 1 and 3 (OR 0.52 p < 0.01). In patients in group 1 who had gynecomastia or breast pain a significant decrease in symptoms was achieved in those receiving tamoxifen (p <0.05). Treatments were well tolerated in the 3 groups. No differences in QOL between groups 2 and 3 were found. At a median followup of 26 months we observed 12 biochemical relapses. Gynecomastia and breast pain induced by bicalutamide monotherapy after RP can be prevented and treated. Tamoxifen has been shown to be more effective and safe than RT in this setting. QOL and sexual function are not negatively influenced by these 2 treatment options .\\n\\n# Arguments:\\nArgument 1=Of group 1 patients 67% had gynecomastia compared with 8% in group 2 and 34% in group 3.\\nArgument 2=Breast pain was more frequent in group 1 than in groups 2 and 3 (58% vs 7% and 30%, respectively).\\nArgument 3=Differences were significant between groups 1 and 2 (OR 0.12 p <0.001), and groups 1 and 3 (OR 0.52 p < 0.01).\\nArgument 4=In patients in group 1 who had gynecomastia or breast pain a significant decrease in symptoms was achieved in those receiving tamoxifen (p <0.05).\\nArgument 5=Treatments were well tolerated in the 3 groups.\\nArgument 6=No differences in QOL between groups 2 and 3 were found.\\nArgument 7=At a median followup of 26 months we observed 12 biochemical relapses.\\nArgument 8=Gynecomastia and breast pain induced by bicalutamide monotherapy after RP can be prevented and treated.\\nArgument 9=Tamoxifen has been shown to be more effective and safe than RT in this setting.\\nArgument 10=QOL and sexual function are not negatively influenced by these 2 treatment options\\n\\n# Result:\\n{\"Argument 1\": \"Premise\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Premise\", \"Argument 5\": \"Premise\", \"Argument 6\": \"Premise\", \"Argument 7\": \"Premise\", \"Argument 8\": \"Claim\", \"Argument 9\": \"Claim\", \"Argument 10\": \"Claim\"}\\n\\n## Example 4\\n# Abstract:\\nTo assess the safety, tolerability and efficacy of abatacept in patients with rheumatoid arthritis (RA) who had failed anti-tumour necrosis factor (TNF) therapy and were switched to abatacept directly or after completing washout. In this international, 6-month, open-label trial, patients had active RA, an inadequate response to anti-TNF therapy for 3 months or longer and a disease activity score in 28 joints (DAS28 (C-reactive protein; CRP) of 5.1 or greater. \"Washout\" patients discontinued anti-TNF therapy 2 months or longer pre-screening; \"direct-switch\" patients began abatacept ( approximately 10 mg/kg) at their next scheduled anti-TNF therapy dose. 1046 patients were treated (449 washout, 597 direct-switch; baseline characteristics were similar between groups). At 6 months, adverse events (AE; 78.0% vs 79.2%), serious AE (11.1% vs 9.9%) and discontinuations due to AE (3.8% vs 4.0%) and serious AE (2.0% vs 1.3%) were comparable in washout versus direct-switch patients. At 6 months, adverse events (AE; 78.0% vs 79.2%), serious AE (11.1% vs 9.9%) and discontinuations due to AE (3.8% vs 4.0%) and serious AE (2.0% vs 1.3%) were comparable in washout versus direct-switch patients. There were no opportunistic infections. At 6 months, in washout versus direct-switch patients, similar clinically meaningful improvements were seen in DAS28 (CRP) (> or =1.2 unit improvement, 59.5% vs 53.6%, respectively; low disease activity state, 22.5% vs 22.3%; DAS28-defined remission, 12.0% vs 13.7%), physical function (health assessment questionnaire disability index > or =0.22 improvement; 46.3% vs 47.1%) and health-related quality of life (mean change in short-form 36 scores: physical component summary, 5.5 vs 6.1; mental component summary, 4.8 vs 5.4). At 6 months, in washout versus direct-switch patients, similar clinically meaningful improvements were seen in DAS28 (CRP) (> or =1.2 unit improvement, 59.5% vs 53.6%, respectively; low disease activity state, 22.5% vs 22.3%; DAS28-defined remission, 12.0% vs 13.7%), physical function (health assessment questionnaire disability index > or =0.22 improvement; 46.3% vs 47.1%) and health-related quality of life (mean change in short-form 36 scores: physical component summary, 5.5 vs 6.1; mental component summary, 4.8 vs 5.4). Abatacept demonstrated acceptable safety and tolerability and clinically meaningful efficacy over 6 months in patients with inadequate response to anti-TNF therapy. Results were comparable with or without a washout, supporting direct switching from anti-TNF therapy to abatacept as an option in clinical practice.\\n\\n# Arguments:\\nArgument 1=At 6 months, adverse events (AE; 78.0% vs 79.2%), serious AE (11.1% vs 9.9%) and discontinuations due to AE (3.8% vs 4.0%) and serious AE (2.0% vs 1.3%) were comparable in washout versus direct-switch patients.\\nArgument 2=At 6 months, adverse events (AE; 78.0% vs 79.2%), serious AE (11.1% vs 9.9%) and discontinuations due to AE (3.8% vs 4.0%) and serious AE (2.0% vs 1.3%) were comparable in washout versus direct-switch patients.\\nArgument 3=There were no opportunistic infections.\\nArgument 4=At 6 months, in washout versus direct-switch patients, similar clinically meaningful improvements were seen in DAS28 (CRP) (> or =1.2 unit improvement, 59.5% vs 53.6%, respectively; low disease activity state, 22.5% vs 22.3%; DAS28-defined remission, 12.0% vs 13.7%), physical function (health assessment questionnaire disability index > or =0.22 improvement; 46.3% vs 47.1%) and health-related quality of life (mean change in short-form 36 scores: physical component summary, 5.5 vs 6.1; mental component summary, 4.8 vs 5.4).\\nArgument 5=At 6 months, in washout versus direct-switch patients, similar clinically meaningful improvements were seen in DAS28 (CRP) (> or =1.2 unit improvement, 59.5% vs 53.6%, respectively; low disease activity state, 22.5% vs 22.3%; DAS28-defined remission, 12.0% vs 13.7%), physical function (health assessment questionnaire disability index > or =0.22 improvement; 46.3% vs 47.1%) and health-related quality of life (mean change in short-form 36 scores: physical component summary, 5.5 vs 6.1; mental component summary, 4.8 vs 5.4).\\nArgument 6=Abatacept demonstrated acceptable safety and tolerability and clinically meaningful efficacy over 6 months in patients with inadequate response to anti-TNF therapy.\\nArgument 7=Results were comparable with or without a washout, supporting direct switching from anti-TNF therapy to abatacept as an option in clinical practice.\\n\\n# Result:\\n{\"Argument 1\": \"Premise\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Premise\", \"Argument 5\": \"Premise\", \"Argument 6\": \"Claim\", \"Argument 7\": \"Claim\"}\\n\\n## Example 5\\n# Abstract:\\nThe goal of this study was to assess the impact of neuronavigation on the cytoreductive treatment of solitary contrast-enhancing intracerebral tumors and outcomes of this treatment in cases in which neuronavigation was preoperatively judged to be redundant. The authors conducted a prospective randomized study in which 45 patients, each harboring a solitary contrast-enhancing intracerebral tumor, were randomized for surgery with or without neuronavigation. Peri- and postoperative parameters under investigation included the following: duration of the procedure; surgeon\\'s estimate of the usefulness of neuronavigation; quantification of the extent of resection, determined using magnetic resonance imaging; and the postoperative course, as evaluated by neurological examinations, the patient\\'s quality-of-life self-assessment, application of the Barthel index and the Karnofsky Performance Scale score, and the patient\\'s time of death. The mean amount of residual tumor tissue was 28.9% for standard surgery (SS) and 13.8% for surgery involving neuronavigation (SN). The corresponding mean amounts of residual contrast-enhancing tumor tissue were 29.2 and 24.4%, respectively. These differences were not significant. Gross-total removal (GTR) was achieved in five patients who underwent SS and in three who underwent SN. Median survival was significantly shorter in the SN group (5.6 months compared with 9 months, unadjusted hazard ratio = 1.6); however, this difference may be attributable to the coincidental early death of three patients in the SN group. No discernible important effect on the patients\\' 3-month postoperative course was identified. There is no rationale for the routine use of neuronavigation to improve the extent of tumor resection and prognosis in patients harboring a solitary enhancing intracerebral lesion when neuronavigation is not already deemed advantageous because of the size or location of the lesion.\\n\\n# Arguments:\\nArgument 1=The mean amount of residual tumor tissue was 28.9% for standard surgery (SS) and 13.8% for surgery involving neuronavigation (SN).\\nArgument 2=The corresponding mean amounts of residual contrast-enhancing tumor tissue were 29.2 and 24.4%, respectively.\\nArgument 3=These differences were not significant.\\nArgument 4=Gross-total removal (GTR) was achieved in five patients who underwent SS and in three who underwent SN.\\nArgument 5=Median survival was significantly shorter in the SN group (5.6 months compared with 9 months, unadjusted hazard ratio = 1.6);\\nArgument 6=however, this difference may be attributable to the coincidental early death of three patients in the SN group.\\nArgument 7=No discernible important effect on the patients\\' 3-month postoperative course was identified.\\nArgument 8=There is no rationale for the routine use of neuronavigation to improve the extent of tumor resection and prognosis in patients harboring a solitary enhancing intracerebral lesion when neuronavigation is not already deemed advantageous because of the size or location of the lesion.\\n\\n# Result:\\n{\"Argument 1\": \"Premise\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Premise\", \"Argument 5\": \"Premise\", \"Argument 6\": \"Premise\", \"Argument 7\": \"Premise\", \"Argument 8\": \"Claim\"}\\n\\n'}, {'role': 'user', 'content': '# Abstract:\\nTo compare the longitudinal effects of treatment on intraocular pressure (IOP) and visual field performance in Japanese normal-tension glaucoma (NTG) between latanoprost and timolol.\\nThis is an open-label, randomized, study. A total of 62 NTG patients were prospectively, consecutively enrolled. All study subjects were randomly assigned to 0.005% latanoprost instillation once daily in the morning or 0.5% timolol instillation twice daily for a prospective 3-year follow-up, and underwent a routine ocular examination every month. Automated perimetry was performed every 6 months using Humphrey field analysers. Stereophotographs of optic discs were also obtained every 6 months. Percentage of IOP reduction or the magnitude of IOP reduction showed no intergroup differences either at any time point (13-15%). In the visual field, the estimated rate of change in the MD value (dB/year) was -0.34+/-0.17 (SE) for the latanoprost group, and -0.10+/-0.18 (SE) for the timolol group. The estimated rate of change in MD showed no significant difference from zero in both groups, and there were no statistical intergroup differences. No changes in the optic nerve head topography in the vertical cup-to-disc ratio and rim area measured by image-analysis techniques were observed in either group. There were no patients who dropped out due to the side effects of treatment regimens. Both latanoprost and timolol single treatments reduced IOP by 13-15% at their trough effects for 3 years in Japanese NTG patients  both showed similar effects on visual field performance.\\n\\n# Arguments:\\nArgument 1=Percentage of IOP reduction or the magnitude of IOP reduction showed no intergroup differences either at any time point (13-15%).\\nArgument 2=In the visual field, the estimated rate of change in the MD value (dB/year) was -0.34+/-0.17 (SE) for the latanoprost group, and -0.10+/-0.18 (SE) for the timolol group.\\nArgument 3=The estimated rate of change in MD showed no significant difference from zero in both groups, and there were no statistical intergroup differences.\\nArgument 4=No changes in the optic nerve head topography in the vertical cup-to-disc ratio and rim area measured by image-analysis techniques were observed in either group.\\nArgument 5=There were no patients who dropped out due to the side effects of treatment regimens.\\nArgument 6=Both latanoprost and timolol single treatments reduced IOP by 13-15% at their trough effects for 3 years in Japanese NTG patients\\nArgument 7=both showed similar effects on visual field performance.\\n\\n\\n# Result:\\n'}]\n"
     ]
    }
   ],
   "source": [
    "print(prepared_sys_task_msg_l[0])"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "7c72e65f-09bc-483a-9f58-919d24a97a58",
   "metadata": {},
   "source": [
    "## Generate Predictions"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 65,
   "id": "52ffb891-0998-40f0-9c85-f613daed4964",
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "100%|██████████| 100/100 [13:12<00:00,  7.92s/it]\n"
     ]
    }
   ],
   "source": [
    "outputs_l = []\n",
    "\n",
    "for i in tqdm(range(len(prepared_sys_task_msg_l))):\n",
    "\n",
    "    messages = prepared_sys_task_msg_l[i]\n",
    "\n",
    "    input_ids = inference_tokenizer.apply_chat_template(\n",
    "    messages,\n",
    "    add_generation_prompt=True,\n",
    "    tokenize=True,\n",
    "    padding=True,\n",
    "    truncation=True,\n",
    "    return_tensors=\"pt\"\n",
    ").to(generation_model.device)\n",
    "\n",
    "    outputs = generation_model.generate(\n",
    "    input_ids = input_ids,\n",
    "    max_new_tokens=1024,\n",
    "    pad_token_id=inference_tokenizer.eos_token_id,\n",
    "    eos_token_id=terminators,\n",
    "    do_sample=True,\n",
    "    temperature=0.1,\n",
    "    top_p=0.9,\n",
    "    )\n",
    "    # inference_tokenizer.decode(outputs[0][input_ids.shape[-1]:], skip_special_tokens=True)\n",
    "    outputs_l.append(inference_tokenizer.decode(outputs[0][input_ids.shape[-1]:], skip_special_tokens=True))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 66,
   "id": "dd424ddd-7a99-4de8-b7c3-6e6fd30d5812",
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "['{\"Argument 1\": \"Premise\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Premise\", \"Argument 5\": \"Premise\", \"Argument 6\": \"Claim\", \"Argument 7\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Premise\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Premise\", \"Argument 5\": \"Premise\", \"Argument 6\": \"Premise\", \"Argument 7\": \"Claim\", \"Argument 8\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Premise\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Premise\", \"Argument 5\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Premise\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Premise\", \"Argument 5\": \"Premise\", \"Argument 6\": \"Claim\", \"Argument 7\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Premise\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Premise\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Premise\", \"Argument 5\": \"Claim\", \"Argument 6\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Premise\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Premise\", \"Argument 5\": \"Premise\", \"Argument 6\": \"Claim\", \"Argument 7\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Premise\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Premise\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Premise\", \"Argument 5\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Premise\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Premise\", \"Argument 5\": \"Premise\", \"Argument 6\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Premise\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\"}',\n",
       " '{\"Argument 1\": \"Premise\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Premise\", \"Argument 5\": \"Claim\", \"Argument 6\": \"Claim\", \"Argument 7\": \"Premise\", \"Argument 8\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Premise\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Premise\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Premise\", \"Argument 5\": \"Claim\", \"Argument 6\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Premise\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Premise\", \"Argument 5\": \"Premise\", \"Argument 6\": \"Premise\", \"Argument 7\": \"Premise\", \"Argument 8\": \"Premise\", \"Argument 9\": \"Premise\", \"Argument 10\": \"Premise\", \"Argument 11\": \"Premise\", \"Argument 12\": \"Premise\", \"Argument 13\": \"Claim\", \"Argument 14\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Premise\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Claim\", \"Argument 5\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Premise\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Premise\", \"Argument 5\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Premise\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Premise\", \"Argument 5\": \"Premise\", \"Argument 6\": \"Premise\", \"Argument 7\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Premise\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Premise\", \"Argument 5\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Premise\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Premise\", \"Argument 5\": \"Premise\", \"Argument 6\": \"Premise\", \"Argument 7\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Premise\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Claim\", \"Argument 5\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Premise\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Premise\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Premise\", \"Argument 5\": \"Premise\", \"Argument 6\": \"Claim\", \"Argument 7\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Premise\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Premise\", \"Argument 5\": \"Premise\", \"Argument 6\": \"Claim\", \"Argument 7\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Premise\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Premise\", \"Argument 5\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Premise\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Premise\", \"Argument 5\": \"Premise\", \"Argument 6\": \"Premise\", \"Argument 7\": \"Premise\", \"Argument 8\": \"Premise\", \"Argument 9\": \"Claim\", \"Argument 10\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Premise\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Premise\", \"Argument 5\": \"Premise\", \"Argument 6\": \"Premise\", \"Argument 7\": \"Premise\", \"Argument 8\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Premise\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Premise\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Premise\", \"Argument 5\": \"Claim\", \"Argument 6\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Premise\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Claim\", \"Argument 4\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Premise\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Premise\", \"Argument 5\": \"Premise\", \"Argument 6\": \"Premise\", \"Argument 7\": \"Premise\", \"Argument 8\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Premise\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Premise\", \"Argument 5\": \"Claim\", \"Argument 6\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Premise\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Premise\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Premise\", \"Argument 5\": \"Premise\", \"Argument 6\": \"Premise\", \"Argument 7\": \"Premise\", \"Argument 8\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Premise\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Premise\", \"Argument 5\": \"Premise\", \"Argument 6\": \"Premise\", \"Argument 7\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Premise\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Premise\", \"Argument 5\": \"Premise\", \"Argument 6\": \"Premise\", \"Argument 7\": \"Premise\", \"Argument 8\": \"Premise\", \"Argument 9\": \"Premise\", \"Argument 10\": \"Premise\", \"Argument 11\": \"Premise\", \"Argument 12\": \"Premise\", \"Argument 13\": \"Claim\", \"Argument 14\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Claim\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Premise\", \"Argument 5\": \"Premise\", \"Argument 6\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Premise\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Premise\", \"Argument 5\": \"Claim\", \"Argument 6\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Claim\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Premise\", \"Argument 5\": \"Claim\", \"Argument 6\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Premise\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Premise\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Premise\", \"Argument 5\": \"Premise\", \"Argument 6\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Premise\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Premise\", \"Argument 5\": \"Premise\", \"Argument 6\": \"Premise\", \"Argument 7\": \"Premise\", \"Argument 8\": \"Premise\", \"Argument 9\": \"Claim\", \"Argument 10\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Premise\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Premise\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Premise\", \"Argument 5\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Premise\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Premise\", \"Argument 5\": \"Premise\", \"Argument 6\": \"Claim\", \"Argument 7\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Premise\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Premise\", \"Argument 5\": \"Premise\", \"Argument 6\": \"Premise\", \"Argument 7\": \"Premise\", \"Argument 8\": \"Premise\", \"Argument 9\": \"Premise\", \"Argument 10\": \"Premise\", \"Argument 11\": \"Premise\", \"Argument 12\": \"Premise\", \"Argument 13\": \"Premise\", \"Argument 14\": \"Claim\", \"Argument 15\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Premise\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Claim\", \"Argument 4\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Claim\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Premise\", \"Argument 5\": \"Premise\", \"Argument 6\": \"Claim\", \"Argument 7\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Premise\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Premise\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Premise\", \"Argument 2\": \"Claim\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Premise\", \"Argument 5\": \"Premise\", \"Argument 6\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Premise\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Premise\", \"Argument 5\": \"Premise\", \"Argument 6\": \"Claim\", \"Argument 7\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Premise\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Premise\", \"Argument 5\": \"Claim\", \"Argument 6\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Premise\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Premise\", \"Argument 5\": \"Claim\", \"Argument 6\": \"Premise\", \"Argument 7\": \"Premise\", \"Argument 8\": \"Premise\", \"Argument 9\": \"Premise\", \"Argument 10\": \"Claim\", \"Argument 11\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Premise\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Premise\", \"Argument 5\": \"Premise\", \"Argument 6\": \"Premise\", \"Argument 7\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Premise\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Premise\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Premise\", \"Argument 5\": \"Claim\", \"Argument 6\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Premise\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Premise\", \"Argument 5\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Premise\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Premise\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Premise\", \"Argument 5\": \"Claim\", \"Argument 6\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Premise\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Premise\", \"Argument 5\": \"Claim\", \"Argument 6\": \"Premise\"}',\n",
       " '{\"Argument 1\": \"Premise\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Premise\", \"Argument 5\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Premise\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Premise\", \"Argument 5\": \"Claim\", \"Argument 6\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Premise\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Claim\", \"Argument 5\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Premise\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Premise\", \"Argument 5\": \"Premise\", \"Argument 6\": \"Claim\", \"Argument 7\": \"Premise\", \"Argument 8\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Premise\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Premise\", \"Argument 5\": \"Premise\", \"Argument 6\": \"Claim\", \"Argument 7\": \"Claim\", \"Argument 8\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Premise\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Claim\", \"Argument 5\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Premise\", \"Argument 2\": \"Claim\", \"Argument 3\": \"Claim\", \"Argument 4\": \"Premise\", \"Argument 5\": \"Premise\", \"Argument 6\": \"Premise\", \"Argument 7\": \"Premise\", \"Argument 8\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Premise\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Claim\", \"Argument 5\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Premise\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Claim\", \"Argument 4\": \"Premise\", \"Argument 5\": \"Premise\"}',\n",
       " '{\"Argument 1\": \"Premise\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Premise\", \"Argument 5\": \"Premise\", \"Argument 6\": \"Claim\", \"Argument 7\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Premise\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Claim\", \"Argument 5\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Premise\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Premise\", \"Argument 5\": \"Claim\", \"Argument 6\": \"Claim\", \"Argument 7\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Premise\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Premise\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Premise\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Claim\", \"Argument 5\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Premise\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Premise\", \"Argument 5\": \"Claim\", \"Argument 6\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Premise\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Premise\", \"Argument 5\": \"Claim\", \"Argument 6\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Premise\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Premise\", \"Argument 5\": \"Premise\", \"Argument 6\": \"Claim\", \"Argument 7\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Premise\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Claim\", \"Argument 5\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Premise\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Premise\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Premise\", \"Argument 5\": \"Premise\", \"Argument 6\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Premise\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Claim\", \"Argument 5\": \"Premise\", \"Argument 6\": \"Claim\", \"Argument 7\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Premise\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Premise\", \"Argument 5\": \"Claim\", \"Argument 6\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Premise\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Premise\", \"Argument 5\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Premise\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Premise\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Claim\", \"Argument 5\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Premise\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Claim\", \"Argument 4\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Premise\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Premise\", \"Argument 5\": \"Premise\", \"Argument 6\": \"Claim\", \"Argument 7\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Premise\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Premise\", \"Argument 5\": \"Premise\", \"Argument 6\": \"Premise\", \"Argument 7\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Claim\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Premise\", \"Argument 5\": \"Premise\", \"Argument 6\": \"Premise\", \"Argument 7\": \"Premise\", \"Argument 8\": \"Claim\", \"Argument 9\": \"Claim\", \"Argument 10\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Premise\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Premise\", \"Argument 5\": \"Premise\", \"Argument 6\": \"Premise\", \"Argument 7\": \"Premise\", \"Argument 8\": \"Claim\", \"Argument 9\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Premise\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Premise\", \"Argument 5\": \"Premise\", \"Argument 6\": \"Premise\", \"Argument 7\": \"Claim\", \"Argument 8\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Premise\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Claim\", \"Argument 5\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Premise\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Premise\", \"Argument 5\": \"Premise\", \"Argument 6\": \"Premise\", \"Argument 7\": \"Premise\", \"Argument 8\": \"Premise\", \"Argument 9\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Premise\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Premise\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Premise\", \"Argument 5\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Premise\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Premise\", \"Argument 5\": \"Claim\", \"Argument 6\": \"Premise\"}',\n",
       " '{\"Argument 1\": \"Premise\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Premise\", \"Argument 5\": \"Premise\", \"Argument 6\": \"Premise\", \"Argument 7\": \"Premise\", \"Argument 8\": \"Premise\", \"Argument 9\": \"Claim\", \"Argument 10\": \"Premise\", \"Argument 11\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Premise\", \"Argument 2\": \"Claim\"}']"
      ]
     },
     "execution_count": 66,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "outputs_l"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 67,
   "id": "195df323-c5f1-45d8-8cf0-25540ccd6f8c",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "100"
      ]
     },
     "execution_count": 67,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "len(outputs_l)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 68,
   "id": "9a80cb0f-4482-4be9-ae35-2c23f723890e",
   "metadata": {},
   "outputs": [],
   "source": [
    "outputs_l_cleaned = []\n",
    "\n",
    "for output in outputs_l:\n",
    "    new_output = output.replace(\"Here is the result in the required JSON format:\\n\\n\",\"\")\n",
    "    outputs_l_cleaned.append(new_output)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 69,
   "id": "2f2767c7-6060-404e-82b4-b4ddfbc521a3",
   "metadata": {},
   "outputs": [],
   "source": [
    "preds_l = [list(ast.literal_eval(output).values()) for output in outputs_l_cleaned]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 70,
   "id": "280c936b-b9dd-4d70-afb7-bd5fbb434c8f",
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[['Premise', 'Premise', 'Premise', 'Premise', 'Premise', 'Claim', 'Claim'],\n",
       " ['Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Claim',\n",
       "  'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Premise', 'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Premise', 'Premise', 'Claim', 'Claim'],\n",
       " ['Premise', 'Premise', 'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Premise', 'Claim', 'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Premise', 'Premise', 'Claim', 'Claim'],\n",
       " ['Premise', 'Premise', 'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Premise', 'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Premise', 'Premise', 'Claim'],\n",
       " ['Premise', 'Premise', 'Premise'],\n",
       " ['Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Claim',\n",
       "  'Claim',\n",
       "  'Premise',\n",
       "  'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Premise', 'Claim', 'Claim'],\n",
       " ['Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Claim',\n",
       "  'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Claim', 'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Premise', 'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Premise', 'Premise', 'Premise', 'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Premise', 'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Premise', 'Premise', 'Premise', 'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Claim', 'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Premise', 'Premise', 'Claim', 'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Premise', 'Premise', 'Claim', 'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Premise', 'Claim'],\n",
       " ['Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Claim',\n",
       "  'Claim'],\n",
       " ['Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Premise', 'Claim', 'Claim'],\n",
       " ['Premise', 'Premise', 'Claim', 'Claim'],\n",
       " ['Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Premise', 'Claim', 'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Claim'],\n",
       " ['Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Premise', 'Premise', 'Premise', 'Claim'],\n",
       " ['Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Claim',\n",
       "  'Claim'],\n",
       " ['Claim', 'Premise', 'Premise', 'Premise', 'Premise', 'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Premise', 'Claim', 'Claim'],\n",
       " ['Claim', 'Premise', 'Premise', 'Premise', 'Claim', 'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Premise', 'Premise', 'Claim'],\n",
       " ['Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Claim',\n",
       "  'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Premise', 'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Premise', 'Premise', 'Claim', 'Claim'],\n",
       " ['Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Claim',\n",
       "  'Claim'],\n",
       " ['Premise', 'Premise', 'Claim', 'Claim'],\n",
       " ['Claim', 'Premise', 'Premise', 'Premise', 'Premise', 'Claim', 'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Claim'],\n",
       " ['Premise', 'Claim', 'Premise', 'Premise', 'Premise', 'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Premise', 'Premise', 'Claim', 'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Premise', 'Claim', 'Claim'],\n",
       " ['Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Claim',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Claim',\n",
       "  'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Premise', 'Premise', 'Premise', 'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Premise', 'Claim', 'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Premise', 'Claim'],\n",
       " ['Premise', 'Premise', 'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Premise', 'Claim', 'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Premise', 'Claim', 'Premise'],\n",
       " ['Premise', 'Premise', 'Premise', 'Premise', 'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Premise', 'Claim', 'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Claim', 'Claim'],\n",
       " ['Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Claim',\n",
       "  'Premise',\n",
       "  'Claim'],\n",
       " ['Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Claim',\n",
       "  'Claim',\n",
       "  'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Claim', 'Claim'],\n",
       " ['Premise',\n",
       "  'Claim',\n",
       "  'Claim',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Claim', 'Claim'],\n",
       " ['Premise', 'Premise', 'Claim', 'Premise', 'Premise'],\n",
       " ['Premise', 'Premise', 'Premise', 'Premise', 'Premise', 'Claim', 'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Claim', 'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Premise', 'Claim', 'Claim', 'Claim'],\n",
       " ['Premise', 'Premise', 'Claim'],\n",
       " ['Premise', 'Premise', 'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Claim', 'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Premise', 'Claim', 'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Premise', 'Claim', 'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Premise', 'Premise', 'Claim', 'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Claim', 'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Premise', 'Premise', 'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Claim', 'Premise', 'Claim', 'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Premise', 'Claim', 'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Premise', 'Claim'],\n",
       " ['Premise', 'Premise', 'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Claim', 'Claim'],\n",
       " ['Premise', 'Premise', 'Claim', 'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Premise', 'Premise', 'Claim', 'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Premise', 'Premise', 'Premise', 'Claim'],\n",
       " ['Claim',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Claim',\n",
       "  'Claim',\n",
       "  'Claim'],\n",
       " ['Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Claim',\n",
       "  'Claim'],\n",
       " ['Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Claim',\n",
       "  'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Claim', 'Claim'],\n",
       " ['Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Premise', 'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Premise', 'Claim', 'Premise'],\n",
       " ['Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Claim',\n",
       "  'Premise',\n",
       "  'Claim'],\n",
       " ['Premise', 'Claim']]"
      ]
     },
     "execution_count": 70,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "preds_l"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 71,
   "id": "caa03c17-4b68-45c7-9ca4-0ef927c8ca2a",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "100"
      ]
     },
     "execution_count": 71,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "len(preds_l)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 72,
   "id": "628b3132-d134-4776-b804-7c41f774bf24",
   "metadata": {},
   "outputs": [],
   "source": [
    "grouped_df = gla_test_df[gla_test_df.aty != 'none'].groupby('doc_id', sort=False)['aty'].apply(list).reset_index()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 73,
   "id": "c08a5bb2-d284-427d-913a-46c15f30239b",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>doc_id</th>\n",
       "      <th>aty</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>15037889</td>\n",
       "      <td>[Premise, Premise, Premise, Premise, Premise, ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>11124286</td>\n",
       "      <td>[Premise, Premise, Premise, Premise, Premise, ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>19427617</td>\n",
       "      <td>[Claim, Premise, Premise, Premise, Claim]</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>11336940</td>\n",
       "      <td>[Premise, Premise, Premise, Premise, Premise, ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>17947826</td>\n",
       "      <td>[Premise, Premise, Claim]</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>95</th>\n",
       "      <td>20545217</td>\n",
       "      <td>[Premise, Premise, Premise, Claim]</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>96</th>\n",
       "      <td>20092592</td>\n",
       "      <td>[Premise, Premise, Premise, Premise, Claim]</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>97</th>\n",
       "      <td>22814041</td>\n",
       "      <td>[Premise, Premise, Premise, Premise, Claim, Cl...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>98</th>\n",
       "      <td>11813932</td>\n",
       "      <td>[Premise, Premise, Premise, Premise, Premise, ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>99</th>\n",
       "      <td>16899528</td>\n",
       "      <td>[Premise, Claim]</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>100 rows × 2 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "      doc_id                                                aty\n",
       "0   15037889  [Premise, Premise, Premise, Premise, Premise, ...\n",
       "1   11124286  [Premise, Premise, Premise, Premise, Premise, ...\n",
       "2   19427617          [Claim, Premise, Premise, Premise, Claim]\n",
       "3   11336940  [Premise, Premise, Premise, Premise, Premise, ...\n",
       "4   17947826                          [Premise, Premise, Claim]\n",
       "..       ...                                                ...\n",
       "95  20545217                 [Premise, Premise, Premise, Claim]\n",
       "96  20092592        [Premise, Premise, Premise, Premise, Claim]\n",
       "97  22814041  [Premise, Premise, Premise, Premise, Claim, Cl...\n",
       "98  11813932  [Premise, Premise, Premise, Premise, Premise, ...\n",
       "99  16899528                                   [Premise, Claim]\n",
       "\n",
       "[100 rows x 2 columns]"
      ]
     },
     "execution_count": 73,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "grouped_df"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 74,
   "id": "423f778a-18e1-499d-a347-8c232f529134",
   "metadata": {},
   "outputs": [],
   "source": [
    "grounds_l = grouped_df.aty.tolist()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 75,
   "id": "5c29ef46-37e8-43e5-9601-64fb01fc4cc9",
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[['Premise', 'Premise', 'Premise', 'Premise', 'Premise', 'Claim', 'Claim'],\n",
       " ['Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Claim'],\n",
       " ['Claim', 'Premise', 'Premise', 'Premise', 'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Premise', 'Premise', 'Claim', 'Claim'],\n",
       " ['Premise', 'Premise', 'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Premise', 'Claim', 'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Premise', 'Claim', 'Claim', 'Claim'],\n",
       " ['Premise', 'Premise', 'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Premise', 'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Premise', 'Premise', 'Claim'],\n",
       " ['Premise', 'Premise', 'Claim'],\n",
       " ['Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Claim',\n",
       "  'Claim',\n",
       "  'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Premise', 'Claim', 'Claim'],\n",
       " ['Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Claim',\n",
       "  'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Claim', 'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Claim', 'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Premise', 'Premise', 'Premise', 'Claim'],\n",
       " ['Premise', 'Premise', 'Claim', 'Premise', 'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Premise', 'Premise', 'Claim', 'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Claim', 'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Premise', 'Premise', 'Claim', 'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Premise', 'Premise', 'Claim', 'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Claim', 'Claim'],\n",
       " ['Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Claim',\n",
       "  'Claim'],\n",
       " ['Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Claim',\n",
       "  'Claim',\n",
       "  'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Claim', 'Claim', 'Claim'],\n",
       " ['Premise', 'Premise', 'Claim', 'Claim'],\n",
       " ['Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Claim',\n",
       "  'Premise',\n",
       "  'Claim',\n",
       "  'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Premise', 'Claim', 'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Claim'],\n",
       " ['Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Claim',\n",
       "  'Premise',\n",
       "  'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Premise', 'Premise', 'Premise', 'Claim'],\n",
       " ['Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Claim',\n",
       "  'Claim'],\n",
       " ['Claim', 'Premise', 'Premise', 'Claim', 'Premise', 'Claim'],\n",
       " ['Premise', 'Claim', 'Premise', 'Premise', 'Claim', 'Claim'],\n",
       " ['Claim', 'Premise', 'Premise', 'Premise', 'Claim', 'Claim'],\n",
       " ['Premise', 'Claim', 'Premise', 'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Premise', 'Premise', 'Claim'],\n",
       " ['Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Claim',\n",
       "  'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Claim'],\n",
       " ['Premise', 'Premise', 'Claim', 'Premise', 'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Premise', 'Premise', 'Claim', 'Claim'],\n",
       " ['Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Claim',\n",
       "  'Claim'],\n",
       " ['Premise', 'Premise', 'Claim', 'Claim'],\n",
       " ['Claim', 'Premise', 'Premise', 'Premise', 'Claim', 'Claim', 'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Claim'],\n",
       " ['Premise', 'Premise', 'Claim', 'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Premise', 'Claim', 'Claim'],\n",
       " ['Premise', 'Claim', 'Premise', 'Premise', 'Claim', 'Claim', 'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Premise', 'Claim', 'Claim'],\n",
       " ['Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Claim',\n",
       "  'Claim',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Claim',\n",
       "  'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Premise', 'Premise', 'Premise', 'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Premise', 'Claim', 'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Claim', 'Claim'],\n",
       " ['Premise', 'Premise', 'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Premise', 'Claim', 'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Premise', 'Claim', 'Premise'],\n",
       " ['Premise', 'Premise', 'Premise', 'Premise', 'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Premise', 'Claim', 'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Claim', 'Claim'],\n",
       " ['Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Claim',\n",
       "  'Premise',\n",
       "  'Claim',\n",
       "  'Claim',\n",
       "  'Claim'],\n",
       " ['Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Claim',\n",
       "  'Claim',\n",
       "  'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Claim', 'Claim'],\n",
       " ['Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Claim', 'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Claim', 'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Premise', 'Premise', 'Claim', 'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Claim', 'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Claim', 'Claim', 'Claim', 'Claim'],\n",
       " ['Premise', 'Premise', 'Claim'],\n",
       " ['Premise', 'Premise', 'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Claim', 'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Premise', 'Claim', 'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Claim', 'Claim', 'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Premise', 'Claim', 'Claim', 'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Claim', 'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Premise', 'Claim', 'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Premise', 'Premise', 'Claim', 'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Premise', 'Claim', 'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Premise', 'Claim'],\n",
       " ['Premise', 'Premise', 'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Claim', 'Claim'],\n",
       " ['Premise', 'Premise', 'Claim', 'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Claim', 'Claim', 'Claim', 'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Claim', 'Premise', 'Premise', 'Claim'],\n",
       " ['Claim',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Claim',\n",
       "  'Premise',\n",
       "  'Premise'],\n",
       " ['Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Claim',\n",
       "  'Claim'],\n",
       " ['Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise'],\n",
       " ['Premise', 'Premise', 'Premise', 'Claim', 'Claim'],\n",
       " ['Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Premise', 'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Premise', 'Claim', 'Claim'],\n",
       " ['Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Claim',\n",
       "  'Premise',\n",
       "  'Claim'],\n",
       " ['Premise', 'Claim']]"
      ]
     },
     "execution_count": 75,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "grounds_l"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 76,
   "id": "fde5ee17-2317-43bf-931b-1d33ad1f1fe8",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "100"
      ]
     },
     "execution_count": 76,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "len(grounds_l)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 77,
   "id": "dd16f2e7-c09c-4289-baa4-d87fab170f27",
   "metadata": {},
   "outputs": [],
   "source": [
    "preds_l = [item for sublist in preds_l for item in sublist]\n",
    "grounds_l = [item for sublist in grounds_l for item in sublist]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 78,
   "id": "477be3ad-bd41-4f53-a667-702b59503622",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "(615, 615)"
      ]
     },
     "execution_count": 78,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "len(preds_l), len(grounds_l)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 79,
   "id": "04e2d299-ca70-437b-b86c-9ca84bcd121b",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "              precision    recall  f1-score   support\n",
      "\n",
      "       Claim     0.9333    0.8063    0.8652       191\n",
      "     Premise     0.9178    0.9741    0.9451       424\n",
      "\n",
      "    accuracy                         0.9220       615\n",
      "   macro avg     0.9256    0.8902    0.9051       615\n",
      "weighted avg     0.9226    0.9220    0.9203       615\n",
      "\n"
     ]
    }
   ],
   "source": [
    "print(classification_report(grounds_l, preds_l, digits=4))"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "5897aa54-e83e-472b-83ff-e53cd5ca29b3",
   "metadata": {},
   "source": [
    "### mix_test"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 80,
   "id": "a9a68561-9b08-46ba-a519-6149356586e1",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "CPU times: user 24.9 s, sys: 31.6 ms, total: 24.9 s\n",
      "Wall time: 25.1 s\n"
     ]
    }
   ],
   "source": [
    "%%time\n",
    "\n",
    "#experiment_df = df[df.split == 'TEST']\n",
    "# experiment_df = neo_test_df\n",
    "# experiment_df = gla_test_df\n",
    "experiment_df = mix_test_df\n",
    "\n",
    "target_l = []\n",
    "\n",
    "# Pre-prepare all examples from each document\n",
    "title_l = []\n",
    "essay_l = []\n",
    "example_l = []\n",
    "buffer_l = []\n",
    "label_l = []\n",
    "for e in experiment_df.iterrows():\n",
    "\n",
    "    if e[1].span_pos == 1:\n",
    "    #if e[0] == 0:\n",
    "        essay_l.append(e[1].abstract_text)\n",
    "        title_l.append(e[1].abstract_title)\n",
    "    \n",
    "    if e[1].span_pos == 1 and len(buffer_l) > 0:\n",
    "    #if e[0] == 0 and len(buffer_l) > 0:\n",
    "        example_l.append(buffer_l)\n",
    "        target_l.append(label_l)\n",
    "        buffer_l = []\n",
    "        label_l = []\n",
    "    if e[1].aty != 'none':\n",
    "        buffer_l.append(e[1].text)\n",
    "        label_l.append(e[1].aty)\n",
    "\n",
    "# Flush the buffers\n",
    "example_l.append(buffer_l)\n",
    "target_l.append(label_l)\n",
    "\n",
    "\n",
    "sys_msg_l_by_seed_d = {}\n",
    "task_msg_l = []\n",
    "\n",
    "for i in range(len(example_l)):\n",
    "\n",
    "    # Prepare numbered list of ACs in this example\n",
    "    other_acs_prompt = ''\n",
    "    for j, s in enumerate(example_l[i]):\n",
    "        # other_acs_prompt += f'Argument {j + 1}={s}\\n'\n",
    "        other_acs_prompt += f'Argument {j + 1}={s}\\n'\n",
    "\n",
    "    for seed in [33, 34, 35, 36, 37]:\n",
    "        sys_msg = {\"role\":\"system\", \"content\": \"### Task description: You are an expert biomedical assistant that takes 1) an abstract text, 2) the list of all arguments from this abstract text, and must classify all arguments into one of two classes: Claim or Premise. \" + proportion_desc + \" You must absolutely not generate any text or explanation other than the following JSON format {\\\"Argument 1\\\": <predicted class for Argument 1 (str)>, ..., \\\"Argument n\\\": <predicted class for Argument n (str)>}\\n\\n### Class definitions:\" + \" Claim = \" + claim_fulldesc + \" Premise = \" + premise_fulldesc + \"\\n\\n### Examples:\\n\\n\" + prepare_similar_example_prompts(title_l[i], experiment_df, k=5, seed=seed)}  # Sample by similar title\n",
    "\n",
    "        try:\n",
    "            sys_msg_l_by_seed_d[seed].append(sys_msg)\n",
    "        except KeyError:\n",
    "            sys_msg_l_by_seed_d[seed] = [sys_msg]\n",
    "\n",
    "    task_msg = {\"role\":\"user\", \"content\": f\"# Abstract:\\n{essay_l[i]}\\n\\n# Arguments:\\n{other_acs_prompt}\\n\\n# Result:\\n\"}\n",
    "    \n",
    "    task_msg_l.append(task_msg)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 81,
   "id": "20703b15-c441-41d1-bf70-3303fba3c743",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "100"
      ]
     },
     "execution_count": 81,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "len(sys_msg_l_by_seed_d[33])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 82,
   "id": "94741037-dd30-4cca-97c1-d77a4644ab3f",
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "### Task description: You are an expert biomedical assistant that takes 1) an abstract text, 2) the list of all arguments from this abstract text, and must classify all arguments into one of two classes: Claim or Premise. 68.0052% of examples are of type Premise and 31.9948% of type Claim. You must absolutely not generate any text or explanation other than the following JSON format {\"Argument 1\": <predicted class for Argument 1 (str)>, ..., \"Argument n\": <predicted class for Argument n (str)>}\n",
      "\n",
      "### Class definitions: Claim = A claim in the abstract of an RCT is a statement or conclusion about the findings of the study. Premise = A premise in the abstract of an RCT is a statement that provides an evidence or proof for a claim.\n",
      "\n",
      "### Examples:\n",
      "\n",
      "## Example 1\n",
      "# Abstract:\n",
      "Malignant pleural effusion (MPE) is a common complication of advanced non-small cell lung cancer (NSCLC). Bevacizumab, a humanized monoclonal antibody against vascular endothelial growth factor (VEGF), has been shown to be efficient in suppressing the accumulation of pleural fluid. However, whether intrapleural delivery of bevacizumab can be used to treat MPE remains unknown. The aim of the present study was to evaluate the efficacy and safety of combined intrapleural therapy with bevacizumab and cisplatin, an antineoplastic agent, in controlling MPE. A total of 72 NSCLC study subjects with MPE were randomly assigned to one of two groups. The first group received intrapleural bevacizumab (300 mg) with cisplatin (30 mg) therapy and the second group received intrapleural cisplatin (30 mg) therapy alone. Pleural fluid was collected from both groups prior to and following treatment. The levels of VEGF and carcinoembryonic antigen (CEA) in the pleural fluid were determined by ELISA. In 70 evaluable study subjects, the curative efficacy in the bevacizumab group was significantly higher than that found in the cisplatin group (83.33 vs. 50.00%, respectively; p<0.05). Therapy with combined bevacizumab plus cisplatin significantly reduced VEGF levels in the pleural fluid (p<0.01). In the bevacizumab group, the levels of VEGF in the pleural fluid were significantly lower compared to those of the cisplatin group after treatment, which showed greater efficacy (p<0.01). In addition, combination therapy showed greater efficacy in the patients with high levels of VEGF expression (p<0.01). There was no significant difference in grade III/IV adverse events between the two groups. All procedures were well tolerated by the patients. Combined intrapleural therapy with bevacizumab and cisplatin was effective and safe in managing NSCLC-mediated MPE. We propose that VEGF expression levels in MPE could serve as a prognostic marker for bevacizumab therapy.\n",
      "\n",
      "# Arguments:\n",
      "Argument 1=Malignant pleural effusion (MPE) is a common complication of advanced non-small cell lung cancer (NSCLC).\n",
      "Argument 2=Bevacizumab, a humanized monoclonal antibody against vascular endothelial growth factor (VEGF), has been shown to be efficient in suppressing the accumulation of pleural fluid.\n",
      "Argument 3=In 70 evaluable study subjects, the curative efficacy in the bevacizumab group was significantly higher than that found in the cisplatin group (83.33 vs. 50.00%, respectively; p<0.05).\n",
      "Argument 4=Therapy with combined bevacizumab plus cisplatin significantly reduced VEGF levels in the pleural fluid (p<0.01).\n",
      "Argument 5=In the bevacizumab group, the levels of VEGF in the pleural fluid were significantly lower compared to those of the cisplatin group after treatment, which showed greater efficacy (p<0.01).\n",
      "Argument 6=In addition, combination therapy showed greater efficacy in the patients with high levels of VEGF expression (p<0.01).\n",
      "Argument 7=There was no significant difference in grade III/IV adverse events between the two groups.\n",
      "Argument 8=All procedures were well tolerated by the patients.\n",
      "Argument 9=Combined intrapleural therapy with bevacizumab and cisplatin was effective and safe in managing NSCLC-mediated MPE.\n",
      "Argument 10=We propose that VEGF expression levels in MPE could serve as a prognostic marker for bevacizumab therapy.\n",
      "\n",
      "# Result:\n",
      "{\"Argument 1\": \"Claim\", \"Argument 2\": \"Claim\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Premise\", \"Argument 5\": \"Premise\", \"Argument 6\": \"Premise\", \"Argument 7\": \"Premise\", \"Argument 8\": \"Premise\", \"Argument 9\": \"Claim\", \"Argument 10\": \"Claim\"}\n",
      "\n",
      "## Example 2\n",
      "# Abstract:\n",
      "Therapy of patients with advanced gastric or gastroesophageal junction cancer should provide symptom relief and improve quality of life (QOL) because most patients are symptomatic at baseline. Using validated instruments, we prospectively assessed QOL (even after completion of protocol treatment) as one of the secondary end points of the V325 phase III trial. Four hundred forty-five patients randomly received either docetaxel 75 mg/m(2) and cisplatin 75 mg/m(2) each on day 1 plus fluorouracil 750 mg/m(2)/d continuous infusion on days 1 to 5 every 3 weeks (DCF) or cisplatin 100 mg/m(2) on day 1 plus fluorouracil 1,000 mg/m(2)/d continuous infusion on days 1 to 5 every 4 weeks (CF). The European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC QLQ-C30) and, where available, the EuroQOL EQ-5D questionnaire were administered every 8 weeks from baseline until progression and then every 3 months. Time to definitive deterioration of QOL parameters was analyzed. The proportions of patients having assessable EORTC QLQ-C30 and EQ-5D questionnaires at baseline were 86.0% and 78.7% with DCF, respectively, and 89.7% and 92.8% with CF, respectively. Time to 5% deterioration of global health status (primary end point) significantly favored DCF over CF (log-rank test, P = .01). QOL was preserved longer for patients on DCF than those on CF for all time to deterioration analyses, demonstrating the statistical superiority of DCF compared with CF. V325 represents the largest trial with the longest prospectively controlled evaluations of QOL during protocol chemotherapy and follow-up in patients with advanced gastric or gastroesophageal junction cancer. In V325, advanced gastric or gastroesophageal junction cancer patients receiving DCF not only had statistically improved overall survival and time to tumor-progression, but they also had better preservation of QOL compared with patients receiving CF.\n",
      "\n",
      "# Arguments:\n",
      "Argument 1=Therapy of patients with advanced gastric or gastroesophageal junction cancer should provide symptom relief and improve quality of life (QOL) because most patients are symptomatic at baseline.\n",
      "Argument 2=Time to 5% deterioration of global health status (primary end point) significantly favored DCF over CF (log-rank test, P = .01).\n",
      "Argument 3=QOL was preserved longer for patients on DCF than those on CF for all time to deterioration analyses, demonstrating the statistical superiority of DCF compared with CF.\n",
      "Argument 4=In V325, advanced gastric or gastroesophageal junction cancer patients receiving DCF not only had statistically improved overall survival and time to tumor-progression, but they also had better preservation of QOL compared with patients receiving CF.\n",
      "\n",
      "# Result:\n",
      "{\"Argument 1\": \"Claim\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Claim\"}\n",
      "\n",
      "## Example 3\n",
      "# Abstract:\n",
      "Anaemia is common in patients receiving chemotherapy, causing symptoms that have a major impact on quality of life (QoL). Epoetin beta rapidly increases haemoglobin (Hb) levels and improves QoL in anaemic patients with a variety of tumours. This was a randomized, double-blind, parallel-group, dose-finding study assessing the efficacy and safety of once-weekly epoetin beta in patients with solid tumours receiving chemotherapy. Adult patients with anaemia (Hb < 11 g/dL) were randomized to receive epoetin beta 30,000 IU or 20,000 IU once weekly for 12 weeks. All patients received oral iron supplementation. Haemoglobin levels, transfusion need and QoL [Functional Assessment of Cancer Therapy-fatigue (FACT-F) subscale score] were assessed at regular intervals. Fifty patients were randomized; 30 patients received epoetin beta 30,000 IU once weekly and 20 received 20,000 IU once weekly. Mean (+/- SD) increase in Hb from baseline to week 12 was 1.75 +/- 2.15 g/dL in the 30,000 IU group (P = 0.008 vs. baseline) and 1.04 +/- 1.75 g/dL in the 20,000 IU group (non-significant). Haemoglobin response (increase in Hb >or=2 g/dL from baseline) was observed in 78.3% of patients receiving epoetin beta 30,000 IU and 66.7% receiving epoetin beta 20,000 IU. Improvements in FACT-F subscale score were significantly (P < 0.001) correlated with increases in Hb level. Transfusion use was low during the study in both groups. Both epoetin beta regiments were well tolerated and there were no dose-dependent adverse events. Epoetin beta 30,000 IU once weekly is an effective and well-tolerated treatment of anaemia in patients with solid tumours.\n",
      "\n",
      "# Arguments:\n",
      "Argument 1=Mean (+/- SD) increase in Hb from baseline to week 12 was 1.75 +/- 2.15 g/dL in the 30,000 IU group (P = 0.008 vs. baseline) and 1.04 +/- 1.75 g/dL in the 20,000 IU group (non-significant).\n",
      "Argument 2=Haemoglobin response (increase in Hb >or=2 g/dL from baseline) was observed in 78.3% of patients receiving epoetin beta 30,000 IU and 66.7% receiving epoetin beta 20,000 IU.\n",
      "Argument 3=Both epoetin beta regiments were well tolerated and there were no dose-dependent adverse events.\n",
      "Argument 4=Epoetin beta 30,000 IU once weekly is an effective and well-tolerated treatment of anaemia in patients with solid tumours.\n",
      "\n",
      "# Result:\n",
      "{\"Argument 1\": \"Premise\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Claim\"}\n",
      "\n",
      "## Example 4\n",
      "# Abstract:\n",
      "Treatment with cisplatin-based chemotherapy provides a modest survival advantage over supportive care alone in advanced non-small-cell lung cancer (NSCLC). To determine whether a new agent, paclitaxel, would further improve survival in NSCLC, the Eastern Cooperative Oncology Group conducted a randomized trial comparing paclitaxel plus cisplatin to a standard chemotherapy regimen consisting of cisplatin and etoposide. The study was carried out by a multi-institutional cooperative group in chemotherapy-naive stage IIIB to IV NSCLC patients randomized to receive paclitaxel plus cisplatin or etoposide plus cisplatin. Paclitaxel was administered at two different dose levels (135 mg/m(2) and 250 mg/m(2)), and etoposide was given at a dose of 100 mg/m(2) daily on days 1 to 3. Each regimen was repeated every 21 days and each included cisplatin (75 mg/m(2)). The characteristics of the 599 patients were well-balanced across the three treatment groups. Superior survival was observed with the combined paclitaxel regimens (median survival time, 9.9 months; 1-year survival rate, 38.9%) compared with etoposide plus cisplatin (median survival time, 7.6 months; 1-year survival rate, 31.8%; P =. 048). Comparing survival for the two dose levels of paclitaxel revealed no significant difference. The median survival duration for the stage IIIB subgroup was 7.9 months for etoposide plus cisplatin patients versus 13.1 months for all paclitaxel patients (P =.152). For the stage IV subgroup, the median survival time for etoposide plus cisplatin was 7.6 months compared with 8.9 months for paclitaxel (P =.246). With the exceptions of increased granulocytopenia on the low-dose paclitaxel regimen and increased myalgias, neurotoxicity, and, possibly, increased treatment-related cardiac events with high-dose paclitaxel, toxicity was similar across all three arms. Quality of life (QOL) declined significantly over the 6 months. However, QOL scores were not significantly different among the regimens. As a result of these observations, paclitaxel (135 mg/m(2)) combined with cisplatin has replaced etoposide plus cisplatin as the reference regimen in our recently completed phase III trial.\n",
      "\n",
      "# Arguments:\n",
      "Argument 1=Treatment with cisplatin-based chemotherapy provides a modest survival advantage over supportive care alone in advanced non-small-cell lung cancer (NSCLC).\n",
      "Argument 2=Superior survival was observed with the combined paclitaxel regimens (median survival time, 9.9 months; 1-year survival rate, 38.9%) compared with etoposide plus cisplatin (median survival time, 7.6 months; 1-year survival rate, 31.8%; P =. 048).\n",
      "Argument 3=Comparing survival for the two dose levels of paclitaxel revealed no significant difference.\n",
      "Argument 4=The median survival duration for the stage IIIB subgroup was 7.9 months for etoposide plus cisplatin patients versus 13.1 months for all paclitaxel patients (P =.152).\n",
      "Argument 5=For the stage IV subgroup, the median survival time for etoposide plus cisplatin was 7.6 months compared with 8.9 months for paclitaxel (P =.246).\n",
      "Argument 6=With the exceptions of increased granulocytopenia on the low-dose paclitaxel regimen and increased myalgias, neurotoxicity, and, possibly, increased treatment-related cardiac events with high-dose paclitaxel, toxicity was similar across all three arms.\n",
      "Argument 7=Quality of life (QOL) declined significantly over the 6 months.\n",
      "Argument 8=QOL scores were not significantly different among the regimens.\n",
      "Argument 9=paclitaxel (135 mg/m(2)) combined with cisplatin has replaced etoposide plus cisplatin as the reference regimen in our recently completed phase III trial.\n",
      "\n",
      "# Result:\n",
      "{\"Argument 1\": \"Claim\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Premise\", \"Argument 5\": \"Premise\", \"Argument 6\": \"Premise\", \"Argument 7\": \"Premise\", \"Argument 8\": \"Claim\", \"Argument 9\": \"Claim\"}\n",
      "\n",
      "## Example 5\n",
      "# Abstract:\n",
      "Adjuvant chemotherapy for early stage non-small-cell lung cancer (NSCLC) is now the standard of care, but there is little information regarding its impact on quality of life (QOL). We report the QOL results of JBR.10, a North American, intergroup, randomized trial of adjuvant cisplatin and vinorelbine compared with observation in patients who have completely resected, stages IB to II NSCLC. QOL was assessed with the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire C30 and a trial-specific checklist at baseline and at weeks 5 and 9 for those who received chemotherapy and at follow-up months 3, 6, 9, 12, 18, 24, 30 and 36. A 10-point change in QOL scores from baseline was considered clinically significant. Four hundred eighty-two patients were randomly assigned on JBR.10. A total of 173 patients (82% of the expected) in the observation arm and 186 (85% of expected) in the chemotherapy arm completed baseline QOL assessments. The two groups were comparable, with low global QOL scores and significant symptom burden, especially pain and fatigue, after thoracotomy. Changes in QOL during chemotherapy were relatively modest; fatigue, nausea, and vomiting worsened, but there was a reduction in pain and no change in global QOL. Patients in the observation arm showed considerable improvements in QOL by 3 months. QOL, except for symptoms of sensory neuropathy and hearing loss, in those treated with chemotherapy returned to baseline by 9 months. The findings of this trial indicate that the negative effects of adjuvant chemotherapy on QOL appear to be temporary, and that improvements (with a return to baseline function) are likely in most patients.\n",
      "\n",
      "# Arguments:\n",
      "Argument 1=The two groups were comparable, with low global QOL scores and significant symptom burden, especially pain and fatigue, after thoracotomy.\n",
      "Argument 2=fatigue, nausea, and vomiting worsened,\n",
      "Argument 3=but there was a reduction in pain and no change in global QOL.\n",
      "Argument 4=Patients in the observation arm showed considerable improvements in QOL by 3 months.\n",
      "Argument 5=QOL, except for symptoms of sensory neuropathy and hearing loss, in those treated with chemotherapy returned to baseline by 9 months.\n",
      "Argument 6=The findings of this trial indicate that the negative effects of adjuvant chemotherapy on QOL appear to be temporary, and that improvements (with a return to baseline function) are likely in most patients.\n",
      "\n",
      "# Result:\n",
      "{\"Argument 1\": \"Premise\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Premise\", \"Argument 5\": \"Premise\", \"Argument 6\": \"Claim\"}\n",
      "\n",
      "\n"
     ]
    }
   ],
   "source": [
    "print(sys_msg_l_by_seed_d[33][0]['content'])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 83,
   "id": "0a4e8133-a4b3-4bda-a5a4-b70c95de75f4",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "100"
      ]
     },
     "execution_count": 83,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "len(task_msg_l)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 84,
   "id": "2161b770-91f0-4aba-bdb2-e96eedfc8444",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "# Abstract:\n",
      "Few controlled clinical trials exist to support oral combination therapy in pulmonary arterial hypertension (PAH). Patients with PAH (idiopathic [IPAH] or associated with connective tissue disease [APAH-CTD]) taking bosentan (62.5 or 125 mg twice daily at a stable dose for ≥3 months) were randomized (1:1) to sildenafil (20 mg, 3 times daily; n = 50) or placebo (n = 53). The primary endpoint was change from baseline in 6-min walk distance (6MWD) at week 12, assessed using analysis of covariance. Patients could continue in a 52-week extension study. An analysis of covariance main-effects model was used, which included categorical terms for treatment, baseline 6MWD (<325 m; ≥325 m), and baseline aetiology; sensitivity analyses were subsequently performed. In sildenafil versus placebo arms, week-12 6MWD increases were similar (least squares mean difference [sildenafil-placebo], -2.4 m [90% CI: -21.8 to 17.1 m]; P = 0.6); mean ± SD changes from baseline were 26.4 ± 45.7 versus 11.8 ± 57.4 m, respectively, in IPAH (65% of population) and -18.3 ± 82.0 versus 17.5 ± 59.1 m in APAH-CTD (35% of population). One-year survival was 96%; patients maintained modest 6MWD improvements. Changes in WHO functional class and Borg dyspnoea score and incidence of clinical worsening did not differ. Headache, diarrhoea, and flushing were more common with sildenafil. Sildenafil, in addition to stable (≥3 months) bosentan therapy, had no benefit over placebo for 12-week change from baseline in 6MWD. The influence of PAH aetiology warrants future study.\n",
      "\n",
      "# Arguments:\n",
      "Argument 1=In sildenafil versus placebo arms, week-12 6MWD increases were similar (least squares mean difference [sildenafil-placebo], -2.4 m [90% CI: -21.8 to 17.1 m]; P = 0.6); mean ± SD changes from baseline were 26.4 ± 45.7 versus 11.8 ± 57.4 m, respectively, in IPAH (65% of population) and -18.3 ± 82.0 versus 17.5 ± 59.1 m in APAH-CTD (35% of population).\n",
      "Argument 2=Changes in WHO functional class and Borg dyspnoea score and incidence of clinical worsening did not differ.\n",
      "Argument 3=Headache, diarrhoea, and flushing were more common with sildenafil.\n",
      "Argument 4=Sildenafil, in addition to stable (≥3 months) bosentan therapy, had no benefit over placebo for 12-week change from baseline in 6MWD.\n",
      "\n",
      "\n",
      "# Result:\n",
      "\n"
     ]
    }
   ],
   "source": [
    "print(task_msg_l[0]['content'])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 85,
   "id": "973d0ffd-3e63-40e0-9653-cab05ce1acfe",
   "metadata": {},
   "outputs": [],
   "source": [
    "prepared_sys_task_msg_l = []\n",
    "\n",
    "for i in range(len(sys_msg_l_by_seed_d[33])):\n",
    "    prepared_sys_task_msg_l.append([sys_msg_l_by_seed_d[33][i], task_msg_l[i]])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 86,
   "id": "ae69c157-2538-4f97-ab4d-29a5c02a8d8d",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "100"
      ]
     },
     "execution_count": 86,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "len(prepared_sys_task_msg_l)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 87,
   "id": "ec917057-42ce-4434-af89-b6b52775fd3a",
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "[{'role': 'system', 'content': '### Task description: You are an expert biomedical assistant that takes 1) an abstract text, 2) the list of all arguments from this abstract text, and must classify all arguments into one of two classes: Claim or Premise. 68.0052% of examples are of type Premise and 31.9948% of type Claim. You must absolutely not generate any text or explanation other than the following JSON format {\"Argument 1\": <predicted class for Argument 1 (str)>, ..., \"Argument n\": <predicted class for Argument n (str)>}\\n\\n### Class definitions: Claim = A claim in the abstract of an RCT is a statement or conclusion about the findings of the study. Premise = A premise in the abstract of an RCT is a statement that provides an evidence or proof for a claim.\\n\\n### Examples:\\n\\n## Example 1\\n# Abstract:\\nMalignant pleural effusion (MPE) is a common complication of advanced non-small cell lung cancer (NSCLC). Bevacizumab, a humanized monoclonal antibody against vascular endothelial growth factor (VEGF), has been shown to be efficient in suppressing the accumulation of pleural fluid. However, whether intrapleural delivery of bevacizumab can be used to treat MPE remains unknown. The aim of the present study was to evaluate the efficacy and safety of combined intrapleural therapy with bevacizumab and cisplatin, an antineoplastic agent, in controlling MPE. A total of 72 NSCLC study subjects with MPE were randomly assigned to one of two groups. The first group received intrapleural bevacizumab (300\\xa0mg) with cisplatin (30\\xa0mg) therapy and the second group received intrapleural cisplatin (30\\xa0mg) therapy alone. Pleural fluid was collected from both groups prior to and following treatment. The levels of VEGF and carcinoembryonic antigen (CEA) in the pleural fluid were determined by ELISA. In 70 evaluable study subjects, the curative efficacy in the bevacizumab group was significantly higher than that found in the cisplatin group (83.33 vs. 50.00%, respectively; p<0.05). Therapy with combined bevacizumab plus cisplatin significantly reduced VEGF levels in the pleural fluid (p<0.01). In the bevacizumab group, the levels of VEGF in the pleural fluid were significantly lower compared to those of the cisplatin group after treatment, which showed greater efficacy (p<0.01). In addition, combination therapy showed greater efficacy in the patients with high levels of VEGF expression (p<0.01). There was no significant difference in grade III/IV adverse events between the two groups. All procedures were well tolerated by the patients. Combined intrapleural therapy with bevacizumab and cisplatin was effective and safe in managing NSCLC-mediated MPE. We propose that VEGF expression levels in MPE could serve as a prognostic marker for bevacizumab therapy.\\n\\n# Arguments:\\nArgument 1=Malignant pleural effusion (MPE) is a common complication of advanced non-small cell lung cancer (NSCLC).\\nArgument 2=Bevacizumab, a humanized monoclonal antibody against vascular endothelial growth factor (VEGF), has been shown to be efficient in suppressing the accumulation of pleural fluid.\\nArgument 3=In 70 evaluable study subjects, the curative efficacy in the bevacizumab group was significantly higher than that found in the cisplatin group (83.33 vs. 50.00%, respectively; p<0.05).\\nArgument 4=Therapy with combined bevacizumab plus cisplatin significantly reduced VEGF levels in the pleural fluid (p<0.01).\\nArgument 5=In the bevacizumab group, the levels of VEGF in the pleural fluid were significantly lower compared to those of the cisplatin group after treatment, which showed greater efficacy (p<0.01).\\nArgument 6=In addition, combination therapy showed greater efficacy in the patients with high levels of VEGF expression (p<0.01).\\nArgument 7=There was no significant difference in grade III/IV adverse events between the two groups.\\nArgument 8=All procedures were well tolerated by the patients.\\nArgument 9=Combined intrapleural therapy with bevacizumab and cisplatin was effective and safe in managing NSCLC-mediated MPE.\\nArgument 10=We propose that VEGF expression levels in MPE could serve as a prognostic marker for bevacizumab therapy.\\n\\n# Result:\\n{\"Argument 1\": \"Claim\", \"Argument 2\": \"Claim\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Premise\", \"Argument 5\": \"Premise\", \"Argument 6\": \"Premise\", \"Argument 7\": \"Premise\", \"Argument 8\": \"Premise\", \"Argument 9\": \"Claim\", \"Argument 10\": \"Claim\"}\\n\\n## Example 2\\n# Abstract:\\nTherapy of patients with advanced gastric or gastroesophageal junction cancer should provide symptom relief and improve quality of life (QOL) because most patients are symptomatic at baseline. Using validated instruments, we prospectively assessed QOL (even after completion of protocol treatment) as one of the secondary end points of the V325 phase III trial. Four hundred forty-five patients randomly received either docetaxel 75 mg/m(2) and cisplatin 75 mg/m(2) each on day 1 plus fluorouracil 750 mg/m(2)/d continuous infusion on days 1 to 5 every 3 weeks (DCF) or cisplatin 100 mg/m(2) on day 1 plus fluorouracil 1,000 mg/m(2)/d continuous infusion on days 1 to 5 every 4 weeks (CF). The European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC QLQ-C30) and, where available, the EuroQOL EQ-5D questionnaire were administered every 8 weeks from baseline until progression and then every 3 months. Time to definitive deterioration of QOL parameters was analyzed. The proportions of patients having assessable EORTC QLQ-C30 and EQ-5D questionnaires at baseline were 86.0% and 78.7% with DCF, respectively, and 89.7% and 92.8% with CF, respectively. Time to 5% deterioration of global health status (primary end point) significantly favored DCF over CF (log-rank test, P = .01). QOL was preserved longer for patients on DCF than those on CF for all time to deterioration analyses, demonstrating the statistical superiority of DCF compared with CF. V325 represents the largest trial with the longest prospectively controlled evaluations of QOL during protocol chemotherapy and follow-up in patients with advanced gastric or gastroesophageal junction cancer. In V325, advanced gastric or gastroesophageal junction cancer patients receiving DCF not only had statistically improved overall survival and time to tumor-progression, but they also had better preservation of QOL compared with patients receiving CF.\\n\\n# Arguments:\\nArgument 1=Therapy of patients with advanced gastric or gastroesophageal junction cancer should provide symptom relief and improve quality of life (QOL) because most patients are symptomatic at baseline.\\nArgument 2=Time to 5% deterioration of global health status (primary end point) significantly favored DCF over CF (log-rank test, P = .01).\\nArgument 3=QOL was preserved longer for patients on DCF than those on CF for all time to deterioration analyses, demonstrating the statistical superiority of DCF compared with CF.\\nArgument 4=In V325, advanced gastric or gastroesophageal junction cancer patients receiving DCF not only had statistically improved overall survival and time to tumor-progression, but they also had better preservation of QOL compared with patients receiving CF.\\n\\n# Result:\\n{\"Argument 1\": \"Claim\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Claim\"}\\n\\n## Example 3\\n# Abstract:\\nAnaemia is common in patients receiving chemotherapy, causing symptoms that have a major impact on quality of life (QoL). Epoetin beta rapidly increases haemoglobin (Hb) levels and improves QoL in anaemic patients with a variety of tumours. This was a randomized, double-blind, parallel-group, dose-finding study assessing the efficacy and safety of once-weekly epoetin beta in patients with solid tumours receiving chemotherapy. Adult patients with anaemia (Hb < 11 g/dL) were randomized to receive epoetin beta 30,000 IU or 20,000 IU once weekly for 12 weeks. All patients received oral iron supplementation. Haemoglobin levels, transfusion need and QoL [Functional Assessment of Cancer Therapy-fatigue (FACT-F) subscale score] were assessed at regular intervals. Fifty patients were randomized; 30 patients received epoetin beta 30,000 IU once weekly and 20 received 20,000 IU once weekly. Mean (+/- SD) increase in Hb from baseline to week 12 was 1.75 +/- 2.15 g/dL in the 30,000 IU group (P = 0.008 vs. baseline) and 1.04 +/- 1.75 g/dL in the 20,000 IU group (non-significant). Haemoglobin response (increase in Hb >or=2 g/dL from baseline) was observed in 78.3% of patients receiving epoetin beta 30,000 IU and 66.7% receiving epoetin beta 20,000 IU. Improvements in FACT-F subscale score were significantly (P < 0.001) correlated with increases in Hb level. Transfusion use was low during the study in both groups. Both epoetin beta regiments were well tolerated and there were no dose-dependent adverse events. Epoetin beta 30,000 IU once weekly is an effective and well-tolerated treatment of anaemia in patients with solid tumours.\\n\\n# Arguments:\\nArgument 1=Mean (+/- SD) increase in Hb from baseline to week 12 was 1.75 +/- 2.15 g/dL in the 30,000 IU group (P = 0.008 vs. baseline) and 1.04 +/- 1.75 g/dL in the 20,000 IU group (non-significant).\\nArgument 2=Haemoglobin response (increase in Hb >or=2 g/dL from baseline) was observed in 78.3% of patients receiving epoetin beta 30,000 IU and 66.7% receiving epoetin beta 20,000 IU.\\nArgument 3=Both epoetin beta regiments were well tolerated and there were no dose-dependent adverse events.\\nArgument 4=Epoetin beta 30,000 IU once weekly is an effective and well-tolerated treatment of anaemia in patients with solid tumours.\\n\\n# Result:\\n{\"Argument 1\": \"Premise\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Claim\"}\\n\\n## Example 4\\n# Abstract:\\nTreatment with cisplatin-based chemotherapy provides a modest survival advantage over supportive care alone in advanced non-small-cell lung cancer (NSCLC). To determine whether a new agent, paclitaxel, would further improve survival in NSCLC, the Eastern Cooperative Oncology Group conducted a randomized trial comparing paclitaxel plus cisplatin to a standard chemotherapy regimen consisting of cisplatin and etoposide. The study was carried out by a multi-institutional cooperative group in chemotherapy-naive stage IIIB to IV NSCLC patients randomized to receive paclitaxel plus cisplatin or etoposide plus cisplatin. Paclitaxel was administered at two different dose levels (135 mg/m(2) and 250 mg/m(2)), and etoposide was given at a dose of 100 mg/m(2) daily on days 1 to 3. Each regimen was repeated every 21 days and each included cisplatin (75 mg/m(2)). The characteristics of the 599 patients were well-balanced across the three treatment groups. Superior survival was observed with the combined paclitaxel regimens (median survival time, 9.9 months; 1-year survival rate, 38.9%) compared with etoposide plus cisplatin (median survival time, 7.6 months; 1-year survival rate, 31.8%; P =. 048). Comparing survival for the two dose levels of paclitaxel revealed no significant difference. The median survival duration for the stage IIIB subgroup was 7.9 months for etoposide plus cisplatin patients versus 13.1 months for all paclitaxel patients (P =.152). For the stage IV subgroup, the median survival time for etoposide plus cisplatin was 7.6 months compared with 8.9 months for paclitaxel (P =.246). With the exceptions of increased granulocytopenia on the low-dose paclitaxel regimen and increased myalgias, neurotoxicity, and, possibly, increased treatment-related cardiac events with high-dose paclitaxel, toxicity was similar across all three arms. Quality of life (QOL) declined significantly over the 6 months. However, QOL scores were not significantly different among the regimens. As a result of these observations, paclitaxel (135 mg/m(2)) combined with cisplatin has replaced etoposide plus cisplatin as the reference regimen in our recently completed phase III trial.\\n\\n# Arguments:\\nArgument 1=Treatment with cisplatin-based chemotherapy provides a modest survival advantage over supportive care alone in advanced non-small-cell lung cancer (NSCLC).\\nArgument 2=Superior survival was observed with the combined paclitaxel regimens (median survival time, 9.9 months; 1-year survival rate, 38.9%) compared with etoposide plus cisplatin (median survival time, 7.6 months; 1-year survival rate, 31.8%; P =. 048).\\nArgument 3=Comparing survival for the two dose levels of paclitaxel revealed no significant difference.\\nArgument 4=The median survival duration for the stage IIIB subgroup was 7.9 months for etoposide plus cisplatin patients versus 13.1 months for all paclitaxel patients (P =.152).\\nArgument 5=For the stage IV subgroup, the median survival time for etoposide plus cisplatin was 7.6 months compared with 8.9 months for paclitaxel (P =.246).\\nArgument 6=With the exceptions of increased granulocytopenia on the low-dose paclitaxel regimen and increased myalgias, neurotoxicity, and, possibly, increased treatment-related cardiac events with high-dose paclitaxel, toxicity was similar across all three arms.\\nArgument 7=Quality of life (QOL) declined significantly over the 6 months.\\nArgument 8=QOL scores were not significantly different among the regimens.\\nArgument 9=paclitaxel (135 mg/m(2)) combined with cisplatin has replaced etoposide plus cisplatin as the reference regimen in our recently completed phase III trial.\\n\\n# Result:\\n{\"Argument 1\": \"Claim\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Premise\", \"Argument 5\": \"Premise\", \"Argument 6\": \"Premise\", \"Argument 7\": \"Premise\", \"Argument 8\": \"Claim\", \"Argument 9\": \"Claim\"}\\n\\n## Example 5\\n# Abstract:\\nAdjuvant chemotherapy for early stage non-small-cell lung cancer (NSCLC) is now the standard of care, but there is little information regarding its impact on quality of life (QOL). We report the QOL results of JBR.10, a North American, intergroup, randomized trial of adjuvant cisplatin and vinorelbine compared with observation in patients who have completely resected, stages IB to II NSCLC. QOL was assessed with the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire C30 and a trial-specific checklist at baseline and at weeks 5 and 9 for those who received chemotherapy and at follow-up months 3, 6, 9, 12, 18, 24, 30 and 36. A 10-point change in QOL scores from baseline was considered clinically significant. Four hundred eighty-two patients were randomly assigned on JBR.10. A total of 173 patients (82% of the expected) in the observation arm and 186 (85% of expected) in the chemotherapy arm completed baseline QOL assessments. The two groups were comparable, with low global QOL scores and significant symptom burden, especially pain and fatigue, after thoracotomy. Changes in QOL during chemotherapy were relatively modest; fatigue, nausea, and vomiting worsened, but there was a reduction in pain and no change in global QOL. Patients in the observation arm showed considerable improvements in QOL by 3 months. QOL, except for symptoms of sensory neuropathy and hearing loss, in those treated with chemotherapy returned to baseline by 9 months. The findings of this trial indicate that the negative effects of adjuvant chemotherapy on QOL appear to be temporary, and that improvements (with a return to baseline function) are likely in most patients.\\n\\n# Arguments:\\nArgument 1=The two groups were comparable, with low global QOL scores and significant symptom burden, especially pain and fatigue, after thoracotomy.\\nArgument 2=fatigue, nausea, and vomiting worsened,\\nArgument 3=but there was a reduction in pain and no change in global QOL.\\nArgument 4=Patients in the observation arm showed considerable improvements in QOL by 3 months.\\nArgument 5=QOL, except for symptoms of sensory neuropathy and hearing loss, in those treated with chemotherapy returned to baseline by 9 months.\\nArgument 6=The findings of this trial indicate that the negative effects of adjuvant chemotherapy on QOL appear to be temporary, and that improvements (with a return to baseline function) are likely in most patients.\\n\\n# Result:\\n{\"Argument 1\": \"Premise\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Premise\", \"Argument 5\": \"Premise\", \"Argument 6\": \"Claim\"}\\n\\n'}, {'role': 'user', 'content': '# Abstract:\\nFew controlled clinical trials exist to support oral combination therapy in pulmonary arterial hypertension (PAH). Patients with PAH (idiopathic [IPAH] or associated with connective tissue disease [APAH-CTD]) taking bosentan (62.5 or 125 mg twice daily at a stable dose for ≥3 months) were randomized (1:1) to sildenafil (20 mg, 3 times daily; n = 50) or placebo (n = 53). The primary endpoint was change from baseline in 6-min walk distance (6MWD) at week 12, assessed using analysis of covariance. Patients could continue in a 52-week extension study. An analysis of covariance main-effects model was used, which included categorical terms for treatment, baseline 6MWD (<325 m; ≥325 m), and baseline aetiology; sensitivity analyses were subsequently performed. In sildenafil versus placebo arms, week-12 6MWD increases were similar (least squares mean difference [sildenafil-placebo], -2.4 m [90% CI: -21.8 to 17.1 m]; P = 0.6); mean ± SD changes from baseline were 26.4 ± 45.7 versus 11.8 ± 57.4 m, respectively, in IPAH (65% of population) and -18.3 ± 82.0 versus 17.5 ± 59.1 m in APAH-CTD (35% of population). One-year survival was 96%; patients maintained modest 6MWD improvements. Changes in WHO functional class and Borg dyspnoea score and incidence of clinical worsening did not differ. Headache, diarrhoea, and flushing were more common with sildenafil. Sildenafil, in addition to stable (≥3 months) bosentan therapy, had no benefit over placebo for 12-week change from baseline in 6MWD. The influence of PAH aetiology warrants future study.\\n\\n# Arguments:\\nArgument 1=In sildenafil versus placebo arms, week-12 6MWD increases were similar (least squares mean difference [sildenafil-placebo], -2.4 m [90% CI: -21.8 to 17.1 m]; P = 0.6); mean ± SD changes from baseline were 26.4 ± 45.7 versus 11.8 ± 57.4 m, respectively, in IPAH (65% of population) and -18.3 ± 82.0 versus 17.5 ± 59.1 m in APAH-CTD (35% of population).\\nArgument 2=Changes in WHO functional class and Borg dyspnoea score and incidence of clinical worsening did not differ.\\nArgument 3=Headache, diarrhoea, and flushing were more common with sildenafil.\\nArgument 4=Sildenafil, in addition to stable (≥3 months) bosentan therapy, had no benefit over placebo for 12-week change from baseline in 6MWD.\\n\\n\\n# Result:\\n'}]\n"
     ]
    }
   ],
   "source": [
    "print(prepared_sys_task_msg_l[0])"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "34918b15-da1e-440d-8892-5d263e09775d",
   "metadata": {},
   "source": [
    "## Generate Predictions"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 88,
   "id": "a74d6573-674a-4a56-9667-fbdd6070f552",
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "100%|██████████| 100/100 [13:01<00:00,  7.82s/it]\n"
     ]
    }
   ],
   "source": [
    "outputs_l = []\n",
    "\n",
    "for i in tqdm(range(len(prepared_sys_task_msg_l))):\n",
    "\n",
    "    messages = prepared_sys_task_msg_l[i]\n",
    "\n",
    "    input_ids = inference_tokenizer.apply_chat_template(\n",
    "    messages,\n",
    "    add_generation_prompt=True,\n",
    "    tokenize=True,\n",
    "    padding=True,\n",
    "    truncation=True,\n",
    "    return_tensors=\"pt\"\n",
    ").to(generation_model.device)\n",
    "\n",
    "    outputs = generation_model.generate(\n",
    "    input_ids = input_ids,\n",
    "    max_new_tokens=1024,\n",
    "    pad_token_id=inference_tokenizer.eos_token_id,\n",
    "    eos_token_id=terminators,\n",
    "    do_sample=True,\n",
    "    temperature=0.1,\n",
    "    top_p=0.9,\n",
    "    )\n",
    "    # inference_tokenizer.decode(outputs[0][input_ids.shape[-1]:], skip_special_tokens=True)\n",
    "    outputs_l.append(inference_tokenizer.decode(outputs[0][input_ids.shape[-1]:], skip_special_tokens=True))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 89,
   "id": "f2c55d76-ec20-4806-857a-c7aa538ad4a0",
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "['{\"Argument 1\": \"Premise\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Premise\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Premise\", \"Argument 5\": \"Premise\", \"Argument 6\": \"Premise\", \"Argument 7\": \"Premise\", \"Argument 8\": \"Claim\", \"Argument 9\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Premise\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Premise\", \"Argument 5\": \"Premise\", \"Argument 6\": \"Premise\", \"Argument 7\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Premise\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Premise\", \"Argument 5\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Claim\", \"Argument 2\": \"Claim\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Premise\", \"Argument 5\": \"Premise\", \"Argument 6\": \"Claim\", \"Argument 7\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Claim\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Claim\", \"Argument 5\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Premise\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Premise\", \"Argument 5\": \"Premise\", \"Argument 6\": \"Premise\", \"Argument 7\": \"Claim\", \"Argument 8\": \"Premise\", \"Argument 9\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Premise\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Premise\", \"Argument 5\": \"Premise\", \"Argument 6\": \"Claim\", \"Argument 7\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Claim\", \"Argument 2\": \"Claim\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Premise\", \"Argument 5\": \"Premise\", \"Argument 6\": \"Claim\", \"Argument 7\": \"Claim\", \"Argument 8\": \"Premise\", \"Argument 9\": \"Premise\", \"Argument 10\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Premise\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Premise\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Premise\", \"Argument 5\": \"Claim\", \"Argument 6\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Premise\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Premise\", \"Argument 5\": \"Claim\", \"Argument 6\": \"Claim\", \"Argument 7\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Claim\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Premise\", \"Argument 5\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Premise\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Premise\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Premise\", \"Argument 5\": \"Claim\", \"Argument 6\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Premise\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Premise\", \"Argument 5\": \"Claim\", \"Argument 6\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Premise\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Premise\", \"Argument 2\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Claim\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Premise\", \"Argument 5\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Premise\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Premise\", \"Argument 5\": \"Premise\", \"Argument 6\": \"Claim\", \"Argument 7\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Premise\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Premise\", \"Argument 5\": \"Premise\", \"Argument 6\": \"Premise\", \"Argument 7\": \"Claim\", \"Argument 8\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Premise\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Premise\", \"Argument 5\": \"Premise\", \"Argument 6\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Premise\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Premise\", \"Argument 5\": \"Premise\", \"Argument 6\": \"Premise\", \"Argument 7\": \"Premise\", \"Argument 8\": \"Premise\", \"Argument 9\": \"Premise\", \"Argument 10\": \"Premise\", \"Argument 11\": \"Claim\", \"Argument 12\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Premise\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Premise\", \"Argument 5\": \"Premise\", \"Argument 6\": \"Claim\", \"Argument 7\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Claim\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Premise\", \"Argument 5\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Premise\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Premise\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Premise\", \"Argument 5\": \"Premise\", \"Argument 6\": \"Premise\", \"Argument 7\": \"Claim\", \"Argument 8\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Premise\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Premise\", \"Argument 5\": \"Claim\", \"Argument 6\": \"Claim\", \"Argument 7\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Claim\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Claim\", \"Argument 2\": \"Claim\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Premise\", \"Argument 5\": \"Premise\", \"Argument 6\": \"Premise\", \"Argument 7\": \"Premise\", \"Argument 8\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Claim\", \"Argument 2\": \"Claim\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Premise\", \"Argument 5\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Claim\", \"Argument 2\": \"Claim\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Premise\", \"Argument 5\": \"Premise\", \"Argument 6\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Premise\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Claim\", \"Argument 5\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Premise\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Premise\", \"Argument 5\": \"Premise\", \"Argument 6\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Claim\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Premise\", \"Argument 5\": \"Premise\", \"Argument 6\": \"Premise\", \"Argument 7\": \"Premise\", \"Argument 8\": \"Claim\", \"Argument 9\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Claim\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Premise\", \"Argument 5\": \"Claim\", \"Argument 6\": \"Premise\", \"Argument 7\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Premise\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Claim\", \"Argument 4\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Premise\", \"Argument 2\": \"Claim\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Premise\", \"Argument 5\": \"Premise\", \"Argument 6\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Premise\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Premise\", \"Argument 5\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Premise\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Premise\", \"Argument 5\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Premise\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Premise\", \"Argument 5\": \"Premise\", \"Argument 6\": \"Premise\", \"Argument 7\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Premise\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Premise\", \"Argument 5\": \"Premise\", \"Argument 6\": \"Claim\", \"Argument 7\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Premise\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Premise\", \"Argument 5\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Premise\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Premise\", \"Argument 5\": \"Claim\", \"Argument 6\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Premise\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Premise\", \"Argument 5\": \"Premise\", \"Argument 6\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Premise\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Claim\", \"Argument 4\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Premise\", \"Argument 2\": \"Claim\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Premise\", \"Argument 5\": \"Claim\", \"Argument 6\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Premise\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Premise\", \"Argument 5\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Premise\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Claim\", \"Argument 5\": \"Premise\", \"Argument 6\": \"Premise\", \"Argument 7\": \"Claim\", \"Argument 8\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Premise\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Premise\", \"Argument 5\": \"Claim\", \"Argument 6\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Premise\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Premise\", \"Argument 5\": \"Claim\", \"Argument 6\": \"Premise\", \"Argument 7\": \"Premise\", \"Argument 8\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Premise\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Premise\", \"Argument 5\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Premise\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Premise\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Premise\", \"Argument 5\": \"Claim\", \"Argument 6\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Premise\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Premise\", \"Argument 5\": \"Premise\", \"Argument 6\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Premise\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Premise\", \"Argument 5\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Premise\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Claim\", \"Argument 4\": \"Premise\", \"Argument 5\": \"Claim\", \"Argument 6\": \"Claim\", \"Argument 7\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Premise\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Claim\", \"Argument 5\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Premise\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Premise\", \"Argument 5\": \"Claim\", \"Argument 6\": \"Claim\", \"Argument 7\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Claim\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Premise\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Claim\", \"Argument 4\": \"Premise\", \"Argument 5\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Premise\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Premise\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Premise\", \"Argument 5\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Premise\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Claim\", \"Argument 4\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Claim\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Premise\", \"Argument 5\": \"Premise\", \"Argument 6\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Claim\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Premise\", \"Argument 5\": \"Premise\", \"Argument 6\": \"Claim\", \"Argument 7\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Claim\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Claim\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Premise\", \"Argument 5\": \"Premise\", \"Argument 6\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Premise\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Premise\", \"Argument 5\": \"Claim\", \"Argument 6\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Premise\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Claim\", \"Argument 5\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Premise\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Claim\", \"Argument 5\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Premise\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Premise\", \"Argument 5\": \"Premise\", \"Argument 6\": \"Premise\", \"Argument 7\": \"Premise\", \"Argument 8\": \"Claim\", \"Argument 9\": \"Claim\", \"Argument 10\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Claim\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Premise\", \"Argument 5\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Premise\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Premise\", \"Argument 5\": \"Premise\", \"Argument 6\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Premise\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Claim\", \"Argument 5\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Premise\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Premise\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Premise\", \"Argument 5\": \"Claim\", \"Argument 6\": \"Claim\", \"Argument 7\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Premise\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Premise\", \"Argument 5\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Premise\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Premise\", \"Argument 5\": \"Premise\", \"Argument 6\": \"Claim\", \"Argument 7\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Claim\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Premise\", \"Argument 5\": \"Premise\", \"Argument 6\": \"Premise\", \"Argument 7\": \"Claim\", \"Argument 8\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Claim\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Premise\", \"Argument 5\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Premise\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Premise\", \"Argument 5\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Premise\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Premise\", \"Argument 5\": \"Premise\", \"Argument 6\": \"Premise\", \"Argument 7\": \"Premise\", \"Argument 8\": \"Premise\", \"Argument 9\": \"Claim\", \"Argument 10\": \"Claim\", \"Argument 11\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Claim\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Premise\", \"Argument 5\": \"Premise\", \"Argument 6\": \"Premise\", \"Argument 7\": \"Claim\", \"Argument 8\": \"Claim\", \"Argument 9\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Claim\", \"Argument 2\": \"Claim\", \"Argument 3\": \"Claim\", \"Argument 4\": \"Premise\", \"Argument 5\": \"Premise\", \"Argument 6\": \"Premise\", \"Argument 7\": \"Claim\", \"Argument 8\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Premise\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Claim\", \"Argument 5\": \"Premise\", \"Argument 6\": \"Claim\", \"Argument 7\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Premise\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Premise\", \"Argument 5\": \"Premise\", \"Argument 6\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Premise\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Premise\", \"Argument 2\": \"Claim\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Premise\", \"Argument 5\": \"Premise\", \"Argument 6\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Premise\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Premise\", \"Argument 5\": \"Premise\", \"Argument 6\": \"Premise\", \"Argument 7\": \"Premise\", \"Argument 8\": \"Claim\", \"Argument 9\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Premise\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Premise\", \"Argument 5\": \"Premise\", \"Argument 6\": \"Claim\", \"Argument 7\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Claim\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Premise\", \"Argument 5\": \"Premise\", \"Argument 6\": \"Claim\", \"Argument 7\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Premise\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Premise\", \"Argument 5\": \"Claim\", \"Argument 6\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Premise\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Claim\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Premise\", \"Argument 5\": \"Premise\", \"Argument 6\": \"Premise\", \"Argument 7\": \"Premise\", \"Argument 8\": \"Premise\", \"Argument 9\": \"Claim\", \"Argument 10\": \"Premise\", \"Argument 11\": \"Premise\", \"Argument 12\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Premise\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Premise\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Claim\", \"Argument 5\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Premise\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Premise\", \"Argument 5\": \"Claim\", \"Argument 6\": \"Premise\"}',\n",
       " '{\"Argument 1\": \"Claim\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Premise\", \"Argument 5\": \"Premise\", \"Argument 6\": \"Claim\", \"Argument 7\": \"Claim\"}',\n",
       " '{\"Argument 1\": \"Premise\", \"Argument 2\": \"Premise\", \"Argument 3\": \"Premise\", \"Argument 4\": \"Premise\", \"Argument 5\": \"Claim\", \"Argument 6\": \"Premise\", \"Argument 7\": \"Premise\", \"Argument 8\": \"Claim\"}']"
      ]
     },
     "execution_count": 89,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "outputs_l"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 90,
   "id": "e3426c8b-4e37-46b8-92d8-360c7ce86c09",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "100"
      ]
     },
     "execution_count": 90,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "len(outputs_l)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 91,
   "id": "0979e3b5-e762-46ee-baf6-fc706f241dcc",
   "metadata": {},
   "outputs": [],
   "source": [
    "preds_l = [list(ast.literal_eval(output).values()) for output in outputs_l]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 92,
   "id": "b50807c7-424b-404d-8d88-dfaebc086601",
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[['Premise', 'Premise', 'Premise', 'Claim'],\n",
       " ['Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Claim',\n",
       "  'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Premise', 'Premise', 'Premise', 'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Premise', 'Claim'],\n",
       " ['Claim', 'Claim', 'Premise', 'Premise', 'Premise', 'Claim', 'Claim'],\n",
       " ['Claim', 'Premise', 'Premise', 'Claim', 'Claim'],\n",
       " ['Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Claim',\n",
       "  'Premise',\n",
       "  'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Premise', 'Premise', 'Claim', 'Claim'],\n",
       " ['Claim',\n",
       "  'Claim',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Claim',\n",
       "  'Claim',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Premise', 'Claim', 'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Premise', 'Claim', 'Claim', 'Claim'],\n",
       " ['Claim', 'Premise', 'Premise', 'Premise', 'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Premise', 'Claim', 'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Premise', 'Claim', 'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Claim'],\n",
       " ['Premise', 'Claim'],\n",
       " ['Claim', 'Premise', 'Premise', 'Premise', 'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Premise', 'Premise', 'Claim', 'Claim'],\n",
       " ['Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Claim',\n",
       "  'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Premise', 'Premise', 'Claim'],\n",
       " ['Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Claim',\n",
       "  'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Premise', 'Premise', 'Claim', 'Claim'],\n",
       " ['Claim', 'Premise', 'Premise', 'Premise', 'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Claim'],\n",
       " ['Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Claim',\n",
       "  'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Premise', 'Claim', 'Claim', 'Claim'],\n",
       " ['Claim', 'Premise', 'Premise', 'Claim'],\n",
       " ['Claim',\n",
       "  'Claim',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Claim'],\n",
       " ['Claim', 'Claim', 'Premise', 'Premise', 'Claim'],\n",
       " ['Claim', 'Claim', 'Premise', 'Premise', 'Premise', 'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Claim', 'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Premise', 'Premise', 'Claim'],\n",
       " ['Claim',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Claim',\n",
       "  'Claim'],\n",
       " ['Claim', 'Premise', 'Premise', 'Premise', 'Claim', 'Premise', 'Claim'],\n",
       " ['Premise', 'Premise', 'Claim', 'Claim'],\n",
       " ['Premise', 'Claim', 'Premise', 'Premise', 'Premise', 'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Premise', 'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Premise', 'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Premise', 'Premise', 'Premise', 'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Premise', 'Premise', 'Claim', 'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Premise', 'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Premise', 'Claim', 'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Premise', 'Premise', 'Claim'],\n",
       " ['Premise', 'Premise', 'Claim', 'Claim'],\n",
       " ['Premise', 'Claim', 'Premise', 'Premise', 'Claim', 'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Premise', 'Claim'],\n",
       " ['Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Claim',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Claim',\n",
       "  'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Premise', 'Claim', 'Claim'],\n",
       " ['Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Claim',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Premise', 'Claim'],\n",
       " ['Premise', 'Premise', 'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Premise', 'Claim', 'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Premise', 'Premise', 'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Premise', 'Claim'],\n",
       " ['Premise', 'Premise', 'Claim', 'Premise', 'Claim', 'Claim', 'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Claim', 'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Premise', 'Claim', 'Claim', 'Claim'],\n",
       " ['Claim', 'Premise', 'Premise', 'Claim'],\n",
       " ['Premise', 'Premise', 'Claim', 'Premise', 'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Premise', 'Claim'],\n",
       " ['Premise', 'Premise', 'Claim', 'Claim'],\n",
       " ['Claim', 'Premise', 'Premise', 'Premise', 'Premise', 'Claim'],\n",
       " ['Claim', 'Premise', 'Premise', 'Premise', 'Premise', 'Claim', 'Claim'],\n",
       " ['Claim', 'Premise', 'Claim'],\n",
       " ['Claim', 'Premise', 'Premise', 'Premise', 'Premise', 'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Premise', 'Claim', 'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Claim', 'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Claim', 'Claim'],\n",
       " ['Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Claim',\n",
       "  'Claim',\n",
       "  'Claim'],\n",
       " ['Claim', 'Premise', 'Premise', 'Premise', 'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Premise', 'Premise', 'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Claim', 'Claim'],\n",
       " ['Premise', 'Premise', 'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Premise', 'Claim', 'Claim', 'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Premise', 'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Premise', 'Premise', 'Claim', 'Claim'],\n",
       " ['Claim',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Claim',\n",
       "  'Claim'],\n",
       " ['Claim', 'Premise', 'Premise', 'Premise', 'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Premise', 'Claim'],\n",
       " ['Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Claim',\n",
       "  'Claim',\n",
       "  'Claim'],\n",
       " ['Claim',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Claim',\n",
       "  'Claim',\n",
       "  'Claim'],\n",
       " ['Claim',\n",
       "  'Claim',\n",
       "  'Claim',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Claim',\n",
       "  'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Claim', 'Premise', 'Claim', 'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Premise', 'Premise', 'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Claim'],\n",
       " ['Premise', 'Claim', 'Premise', 'Premise', 'Premise', 'Claim'],\n",
       " ['Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Claim',\n",
       "  'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Premise', 'Premise', 'Claim', 'Claim'],\n",
       " ['Claim', 'Premise', 'Premise', 'Premise', 'Premise', 'Claim', 'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Premise', 'Claim', 'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Claim'],\n",
       " ['Claim',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Claim',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Claim'],\n",
       " ['Premise', 'Premise', 'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Claim', 'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Premise', 'Claim', 'Premise'],\n",
       " ['Claim', 'Premise', 'Premise', 'Premise', 'Premise', 'Claim', 'Claim'],\n",
       " ['Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Claim',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Claim']]"
      ]
     },
     "execution_count": 92,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "preds_l"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 93,
   "id": "875f7341-3d49-4a52-89db-cddca4294ca9",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "100"
      ]
     },
     "execution_count": 93,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "len(preds_l)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 94,
   "id": "9593694a-c26f-411d-a991-ef78911bd812",
   "metadata": {},
   "outputs": [],
   "source": [
    "grouped_df = mix_test_df[mix_test_df.aty != 'none'].groupby('doc_id', sort=False)['aty'].apply(list).reset_index()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 95,
   "id": "96f52f99-5063-4b8e-9001-03bed9b3d175",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>doc_id</th>\n",
       "      <th>aty</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>28874133</td>\n",
       "      <td>[Premise, Premise, Premise, Claim]</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>11346336</td>\n",
       "      <td>[Premise, Premise, Premise, Premise, Premise, ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>28370419</td>\n",
       "      <td>[Premise, Premise, Premise, Premise, Premise, ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>29596950</td>\n",
       "      <td>[Premise, Premise, Premise, Premise, Claim]</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>29633159</td>\n",
       "      <td>[Claim, Claim, Premise, Premise, Premise, Clai...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>95</th>\n",
       "      <td>29625440</td>\n",
       "      <td>[Premise, Premise, Claim]</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>96</th>\n",
       "      <td>23285843</td>\n",
       "      <td>[Premise, Premise, Premise, Claim, Claim]</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>97</th>\n",
       "      <td>22814041</td>\n",
       "      <td>[Premise, Premise, Premise, Premise, Claim, Cl...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>98</th>\n",
       "      <td>29329305</td>\n",
       "      <td>[Claim, Premise, Premise, Premise, Premise, Cl...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>99</th>\n",
       "      <td>28371482</td>\n",
       "      <td>[Premise, Premise, Premise, Premise, Claim, Cl...</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>100 rows × 2 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "      doc_id                                                aty\n",
       "0   28874133                 [Premise, Premise, Premise, Claim]\n",
       "1   11346336  [Premise, Premise, Premise, Premise, Premise, ...\n",
       "2   28370419  [Premise, Premise, Premise, Premise, Premise, ...\n",
       "3   29596950        [Premise, Premise, Premise, Premise, Claim]\n",
       "4   29633159  [Claim, Claim, Premise, Premise, Premise, Clai...\n",
       "..       ...                                                ...\n",
       "95  29625440                          [Premise, Premise, Claim]\n",
       "96  23285843          [Premise, Premise, Premise, Claim, Claim]\n",
       "97  22814041  [Premise, Premise, Premise, Premise, Claim, Cl...\n",
       "98  29329305  [Claim, Premise, Premise, Premise, Premise, Cl...\n",
       "99  28371482  [Premise, Premise, Premise, Premise, Claim, Cl...\n",
       "\n",
       "[100 rows x 2 columns]"
      ]
     },
     "execution_count": 95,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "grouped_df"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 96,
   "id": "5edd7eab-0622-487d-a01a-463eb9218f40",
   "metadata": {},
   "outputs": [],
   "source": [
    "grounds_l = grouped_df.aty.tolist()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 97,
   "id": "7298a4c2-169c-44fb-b58d-1696cc847ed9",
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[['Premise', 'Premise', 'Premise', 'Claim'],\n",
       " ['Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Claim',\n",
       "  'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Premise', 'Premise', 'Premise', 'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Premise', 'Claim'],\n",
       " ['Claim', 'Claim', 'Premise', 'Premise', 'Premise', 'Claim', 'Claim'],\n",
       " ['Claim', 'Premise', 'Premise', 'Claim', 'Claim'],\n",
       " ['Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Claim',\n",
       "  'Claim',\n",
       "  'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Premise', 'Premise', 'Claim', 'Claim'],\n",
       " ['Claim',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Claim',\n",
       "  'Claim',\n",
       "  'Premise',\n",
       "  'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Premise', 'Claim', 'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Premise', 'Claim', 'Claim', 'Claim'],\n",
       " ['Claim', 'Premise', 'Premise', 'Premise', 'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Premise', 'Claim', 'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Premise', 'Claim', 'Claim'],\n",
       " ['Premise', 'Premise', 'Claim', 'Claim'],\n",
       " ['Premise', 'Claim'],\n",
       " ['Claim', 'Premise', 'Premise', 'Premise', 'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Premise', 'Premise', 'Claim', 'Claim'],\n",
       " ['Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Claim',\n",
       "  'Claim',\n",
       "  'Premise'],\n",
       " ['Premise', 'Premise', 'Claim', 'Premise', 'Premise', 'Claim'],\n",
       " ['Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Claim',\n",
       "  'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Premise', 'Premise', 'Claim', 'Claim'],\n",
       " ['Claim', 'Premise', 'Premise', 'Premise', 'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Claim'],\n",
       " ['Claim',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Claim',\n",
       "  'Claim',\n",
       "  'Claim',\n",
       "  'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Premise', 'Claim', 'Claim', 'Claim'],\n",
       " ['Claim', 'Premise', 'Premise', 'Claim'],\n",
       " ['Claim',\n",
       "  'Claim',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Claim',\n",
       "  'Claim'],\n",
       " ['Claim', 'Claim', 'Premise', 'Premise', 'Claim'],\n",
       " ['Claim', 'Claim', 'Premise', 'Premise', 'Premise', 'Premise'],\n",
       " ['Premise', 'Premise', 'Premise', 'Claim', 'Premise'],\n",
       " ['Premise', 'Claim', 'Premise', 'Premise', 'Claim', 'Claim'],\n",
       " ['Claim',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Claim',\n",
       "  'Claim'],\n",
       " ['Claim', 'Premise', 'Premise', 'Premise', 'Claim', 'Claim', 'Claim'],\n",
       " ['Premise', 'Premise', 'Claim', 'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Premise', 'Premise', 'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Premise', 'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Premise', 'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Premise', 'Premise', 'Premise', 'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Premise', 'Premise', 'Claim', 'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Premise', 'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Premise', 'Claim', 'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Premise', 'Premise', 'Claim'],\n",
       " ['Premise', 'Premise', 'Claim', 'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Premise', 'Claim', 'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Premise', 'Claim'],\n",
       " ['Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Claim',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Claim',\n",
       "  'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Premise', 'Claim', 'Claim'],\n",
       " ['Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Claim',\n",
       "  'Claim',\n",
       "  'Claim',\n",
       "  'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Premise', 'Claim'],\n",
       " ['Premise', 'Premise', 'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Premise', 'Claim', 'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Premise', 'Premise', 'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Premise', 'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Premise', 'Claim', 'Claim', 'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Claim', 'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Premise', 'Premise', 'Claim', 'Claim'],\n",
       " ['Claim', 'Premise', 'Premise', 'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Premise', 'Claim'],\n",
       " ['Premise', 'Premise', 'Claim', 'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Premise', 'Claim'],\n",
       " ['Premise', 'Premise', 'Claim', 'Claim'],\n",
       " ['Claim', 'Premise', 'Premise', 'Premise', 'Claim', 'Claim'],\n",
       " ['Claim', 'Premise', 'Premise', 'Premise', 'Premise', 'Claim', 'Claim'],\n",
       " ['Claim', 'Premise', 'Claim'],\n",
       " ['Claim', 'Premise', 'Premise', 'Premise', 'Claim', 'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Premise', 'Claim', 'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Claim', 'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Claim', 'Claim'],\n",
       " ['Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Claim',\n",
       "  'Claim',\n",
       "  'Claim'],\n",
       " ['Claim', 'Premise', 'Premise', 'Premise', 'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Premise', 'Premise', 'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Claim', 'Claim'],\n",
       " ['Premise', 'Premise', 'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Premise', 'Claim', 'Claim', 'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Premise', 'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Premise', 'Premise', 'Claim', 'Claim'],\n",
       " ['Claim',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Claim',\n",
       "  'Claim'],\n",
       " ['Claim', 'Premise', 'Premise', 'Claim', 'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Premise', 'Claim'],\n",
       " ['Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Claim',\n",
       "  'Premise',\n",
       "  'Claim',\n",
       "  'Claim',\n",
       "  'Claim'],\n",
       " ['Claim',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Claim',\n",
       "  'Claim',\n",
       "  'Claim'],\n",
       " ['Claim',\n",
       "  'Claim',\n",
       "  'Claim',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Claim',\n",
       "  'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Premise', 'Premise', 'Claim', 'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Premise', 'Premise', 'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Premise', 'Premise', 'Claim'],\n",
       " ['Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Claim',\n",
       "  'Premise',\n",
       "  'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Claim', 'Claim', 'Claim', 'Claim'],\n",
       " ['Claim', 'Premise', 'Premise', 'Premise', 'Premise', 'Claim', 'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Premise', 'Claim', 'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Premise'],\n",
       " ['Claim',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Claim',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Claim'],\n",
       " ['Premise', 'Premise', 'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Claim', 'Claim'],\n",
       " ['Premise', 'Premise', 'Premise', 'Premise', 'Claim', 'Claim'],\n",
       " ['Claim', 'Premise', 'Premise', 'Premise', 'Premise', 'Claim', 'Claim'],\n",
       " ['Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Premise',\n",
       "  'Claim',\n",
       "  'Claim',\n",
       "  'Claim',\n",
       "  'Claim']]"
      ]
     },
     "execution_count": 97,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "grounds_l"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 98,
   "id": "8930d426-0fe7-4f18-b94b-d813293ed753",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "100"
      ]
     },
     "execution_count": 98,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "len(grounds_l)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 99,
   "id": "863899d6-3269-4ce3-b13e-7b115d7345f4",
   "metadata": {},
   "outputs": [],
   "source": [
    "preds_l = [item for sublist in preds_l for item in sublist]\n",
    "grounds_l = [item for sublist in grounds_l for item in sublist]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 100,
   "id": "813e1923-aa3c-4949-923f-818bc37934c9",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "(609, 609)"
      ]
     },
     "execution_count": 100,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "len(preds_l), len(grounds_l)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 101,
   "id": "564927a1-2e67-446e-848d-08cb958e9cfa",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "              precision    recall  f1-score   support\n",
      "\n",
      "       Claim     0.9303    0.8821    0.9056       212\n",
      "     Premise     0.9387    0.9647    0.9516       397\n",
      "\n",
      "    accuracy                         0.9360       609\n",
      "   macro avg     0.9345    0.9234    0.9286       609\n",
      "weighted avg     0.9358    0.9360    0.9355       609\n",
      "\n"
     ]
    }
   ],
   "source": [
    "print(classification_report(grounds_l, preds_l, digits=4))"
   ]
  },
  {
   "cell_type": "raw",
   "id": "7830ba48-e1db-4b4f-974b-f778a968f487",
   "metadata": {},
   "source": [
    "Results: 8B-Instruct, K=5, N=1\n",
    "\n",
    "neo_test\n",
    "\n",
    "precision    recall  f1-score   support\n",
    "\n",
    "       Claim     0.8519    0.8347    0.8432       248\n",
    "     Premise     0.9085    0.9187    0.9136       443\n",
    "\n",
    "    accuracy                         0.8886       691\n",
    "   macro avg     0.8802    0.8767    0.8784       691\n",
    "weighted avg     0.8882    0.8886    0.8883       691\n",
    "\n",
    "gla_test\n",
    "\n",
    "precision    recall  f1-score   support\n",
    "\n",
    "       Claim     0.8299    0.8429    0.8364       191\n",
    "     Premise     0.9287    0.9222    0.9254       424\n",
    "\n",
    "    accuracy                         0.8976       615\n",
    "   macro avg     0.8793    0.8826    0.8809       615\n",
    "weighted avg     0.8980    0.8976    0.8978       615\n",
    "\n",
    "mix_test\n",
    "\n",
    "precision    recall  f1-score   support\n",
    "\n",
    "       Claim     0.8818    0.9151    0.8981       212\n",
    "     Premise     0.9537    0.9345    0.9440       397\n",
    "\n",
    "    accuracy                         0.9278       609\n",
    "   macro avg     0.9178    0.9248    0.9211       609\n",
    "weighted avg     0.9287    0.9278    0.9281       609\n"
   ]
  },
  {
   "cell_type": "raw",
   "id": "ad0d9a66-1209-4f56-9e3d-d913e0ea1928",
   "metadata": {},
   "source": [
    "Results: 8B-Instruct-4bit, K=5, N=1\n",
    "\n",
    "neo_test\n",
    "\n",
    "precision    recall  f1-score   support\n",
    "\n",
    "       Claim     0.7823    0.8548    0.8170       248\n",
    "     Premise     0.9143    0.8668    0.8899       443\n",
    "\n",
    "    accuracy                         0.8625       691\n",
    "   macro avg     0.8483    0.8608    0.8534       691\n",
    "weighted avg     0.8669    0.8625    0.8637       691\n",
    "\n",
    "gla_test\n",
    "\n",
    "precision    recall  f1-score   support\n",
    "\n",
    "       Claim     0.8093    0.8220    0.8156       191\n",
    "     Premise     0.9192    0.9127    0.9160       424\n",
    "\n",
    "    accuracy                         0.8846       615\n",
    "   macro avg     0.8643    0.8674    0.8658       615\n",
    "weighted avg     0.8851    0.8846    0.8848       615\n",
    "\n",
    "mix_test\n",
    "\n",
    "precision    recall  f1-score   support\n",
    "\n",
    "       Claim     0.8248    0.9104    0.8655       212\n",
    "     Premise     0.9493    0.8967    0.9223       397\n",
    "\n",
    "    accuracy                         0.9015       609\n",
    "   macro avg     0.8871    0.9036    0.8939       609\n",
    "weighted avg     0.9060    0.9015    0.9025       609\n"
   ]
  },
  {
   "cell_type": "raw",
   "id": "2d58d081-9f73-488a-880a-7c67c913568d",
   "metadata": {},
   "source": [
    "Results: 70B-Instruct-4bit, K=5, N=1\n",
    "\n",
    "neo_test\n",
    "\n",
    "precision    recall  f1-score   support\n",
    "\n",
    "       Claim     0.9220    0.8105    0.8627       248\n",
    "     Premise     0.9006    0.9616    0.9301       443\n",
    "\n",
    "    accuracy                         0.9074       691\n",
    "   macro avg     0.9113    0.8861    0.8964       691\n",
    "weighted avg     0.9083    0.9074    0.9059       691\n",
    "\n",
    "gla_test\n",
    "\n",
    "precision    recall  f1-score   support\n",
    "\n",
    "       Claim     0.9333    0.8063    0.8652       191\n",
    "     Premise     0.9178    0.9741    0.9451       424\n",
    "\n",
    "    accuracy                         0.9220       615\n",
    "   macro avg     0.9256    0.8902    0.9051       615\n",
    "weighted avg     0.9226    0.9220    0.9203       615\n",
    "\n",
    "mix_test\n",
    "\n",
    "precision    recall  f1-score   support\n",
    "\n",
    "       Claim     0.9303    0.8821    0.9056       212\n",
    "     Premise     0.9387    0.9647    0.9516       397\n",
    "\n",
    "    accuracy                         0.9360       609\n",
    "   macro avg     0.9345    0.9234    0.9286       609\n",
    "weighted avg     0.9358    0.9360    0.9355       609"
   ]
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 3 (ipykernel)",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.11.9"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 5
}
